WO2016008433A1 - Substituted urea derivatives and pharmaceutical uses thereof - Google Patents
Substituted urea derivatives and pharmaceutical uses thereof Download PDFInfo
- Publication number
- WO2016008433A1 WO2016008433A1 PCT/CN2015/084253 CN2015084253W WO2016008433A1 WO 2016008433 A1 WO2016008433 A1 WO 2016008433A1 CN 2015084253 W CN2015084253 W CN 2015084253W WO 2016008433 A1 WO2016008433 A1 WO 2016008433A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- cancer
- alkoxy
- independently
- fused
- Prior art date
Links
- 150000003672 ureas Chemical class 0.000 title abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 355
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 91
- 201000010099 disease Diseases 0.000 claims abstract description 75
- 239000008194 pharmaceutical composition Chemical class 0.000 claims abstract description 60
- 230000002062 proliferating effect Effects 0.000 claims abstract description 24
- -1 cyano, nitro, hydroxy, mercapto, amino, carboxy Chemical group 0.000 claims description 354
- 125000000217 alkyl group Chemical group 0.000 claims description 79
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 73
- 125000000623 heterocyclic group Chemical group 0.000 claims description 72
- 150000003839 salts Chemical class 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 66
- 125000003282 alkyl amino group Chemical group 0.000 claims description 64
- 239000003112 inhibitor Substances 0.000 claims description 58
- 125000003545 alkoxy group Chemical group 0.000 claims description 57
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 55
- 125000003003 spiro group Chemical group 0.000 claims description 54
- 229940002612 prodrug Drugs 0.000 claims description 53
- 239000000651 prodrug Substances 0.000 claims description 53
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 50
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 50
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 50
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 50
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 47
- 125000003118 aryl group Chemical group 0.000 claims description 47
- 150000001204 N-oxides Chemical class 0.000 claims description 45
- 150000002148 esters Chemical class 0.000 claims description 44
- 125000001072 heteroaryl group Chemical group 0.000 claims description 44
- 239000012453 solvate Substances 0.000 claims description 43
- 239000002207 metabolite Substances 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 38
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 36
- 229910052794 bromium Inorganic materials 0.000 claims description 36
- 229910052801 chlorine Inorganic materials 0.000 claims description 36
- 229910052731 fluorine Inorganic materials 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 125000004414 alkyl thio group Chemical group 0.000 claims description 32
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 30
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 28
- 230000035772 mutation Effects 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 27
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 26
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 208000023275 Autoimmune disease Diseases 0.000 claims description 24
- 125000004104 aryloxy group Chemical group 0.000 claims description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 24
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 23
- 206010009944 Colon cancer Diseases 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 22
- 208000027866 inflammatory disease Diseases 0.000 claims description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 21
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 21
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 21
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 21
- 208000032839 leukemia Diseases 0.000 claims description 21
- 230000001404 mediated effect Effects 0.000 claims description 21
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 20
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 19
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 19
- 210000003169 central nervous system Anatomy 0.000 claims description 19
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 19
- 206010025323 Lymphomas Diseases 0.000 claims description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 18
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 18
- 125000001425 triazolyl group Chemical group 0.000 claims description 18
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 17
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims description 16
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 16
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims description 16
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 16
- 125000001188 haloalkyl group Chemical group 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 15
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 15
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 15
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 14
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 14
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 14
- 229910052740 iodine Inorganic materials 0.000 claims description 14
- 206010025135 lupus erythematosus Diseases 0.000 claims description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 14
- 125000002431 aminoalkoxy group Chemical group 0.000 claims description 13
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 13
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 13
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 13
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 13
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 13
- 229940043355 kinase inhibitor Drugs 0.000 claims description 13
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 13
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 12
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims description 12
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 12
- 208000006454 hepatitis Diseases 0.000 claims description 12
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 12
- 108091008605 VEGF receptors Proteins 0.000 claims description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 11
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 10
- 125000003418 alkyl amino alkoxy group Chemical group 0.000 claims description 10
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 10
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 9
- 208000017604 Hodgkin disease Diseases 0.000 claims description 9
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 9
- 210000000988 bone and bone Anatomy 0.000 claims description 9
- 201000010881 cervical cancer Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 206010008583 Chloroma Diseases 0.000 claims description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 8
- 230000001028 anti-proliverative effect Effects 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 201000005987 myeloid sarcoma Diseases 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 201000000306 sarcoidosis Diseases 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 230000009885 systemic effect Effects 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 206010018338 Glioma Diseases 0.000 claims description 7
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 206010029260 Neuroblastoma Diseases 0.000 claims description 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 7
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000000890 drug combination Substances 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 7
- 201000002510 thyroid cancer Diseases 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- 206010046766 uterine cancer Diseases 0.000 claims description 7
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 claims description 6
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 6
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 6
- 208000006820 Arthralgia Diseases 0.000 claims description 6
- 206010006002 Bone pain Diseases 0.000 claims description 6
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 208000002291 Histiocytic Sarcoma Diseases 0.000 claims description 6
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 6
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims description 6
- 206010024305 Leukaemia monocytic Diseases 0.000 claims description 6
- 206010024328 Leukaemoid reaction Diseases 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 claims description 6
- 208000024556 Mendelian disease Diseases 0.000 claims description 6
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 claims description 6
- 208000003076 Osteolysis Diseases 0.000 claims description 6
- 206010033645 Pancreatitis Diseases 0.000 claims description 6
- 208000007452 Plasmacytoma Diseases 0.000 claims description 6
- 206010037549 Purpura Diseases 0.000 claims description 6
- 241001672981 Purpura Species 0.000 claims description 6
- 201000000582 Retinoblastoma Diseases 0.000 claims description 6
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 6
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 6
- 239000003719 aurora kinase inhibitor Substances 0.000 claims description 6
- 231100001025 bone marrow hyperplasia Toxicity 0.000 claims description 6
- 229960001292 cabozantinib Drugs 0.000 claims description 6
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 6
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 claims description 6
- 201000001352 cholecystitis Diseases 0.000 claims description 6
- 208000037976 chronic inflammation Diseases 0.000 claims description 6
- 230000006020 chronic inflammation Effects 0.000 claims description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 206010009887 colitis Diseases 0.000 claims description 6
- DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 claims description 6
- 229950009240 crenolanib Drugs 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 6
- 230000001079 digestive effect Effects 0.000 claims description 6
- 208000007784 diverticulitis Diseases 0.000 claims description 6
- 229950005778 dovitinib Drugs 0.000 claims description 6
- 201000008825 fibrosarcoma of bone Diseases 0.000 claims description 6
- 208000017750 granulocytic sarcoma Diseases 0.000 claims description 6
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 208000029824 high grade glioma Diseases 0.000 claims description 6
- 201000008298 histiocytosis Diseases 0.000 claims description 6
- 230000003308 immunostimulating effect Effects 0.000 claims description 6
- 239000003018 immunosuppressive agent Substances 0.000 claims description 6
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 6
- 201000002529 islet cell tumor Diseases 0.000 claims description 6
- 208000017830 lymphoblastoma Diseases 0.000 claims description 6
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 6
- 201000000564 macroglobulinemia Diseases 0.000 claims description 6
- 201000011614 malignant glioma Diseases 0.000 claims description 6
- 201000006812 malignant histiocytosis Diseases 0.000 claims description 6
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 6
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 6
- 229960000485 methotrexate Drugs 0.000 claims description 6
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims description 6
- 201000006894 monocytic leukemia Diseases 0.000 claims description 6
- 208000025189 neoplasm of testis Diseases 0.000 claims description 6
- 210000004412 neuroendocrine cell Anatomy 0.000 claims description 6
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims description 6
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 6
- 229960001131 ponatinib Drugs 0.000 claims description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 claims description 6
- 229950001626 quizartinib Drugs 0.000 claims description 6
- 201000003120 testicular cancer Diseases 0.000 claims description 6
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims description 6
- 206010043778 thyroiditis Diseases 0.000 claims description 6
- 229960001350 tofacitinib Drugs 0.000 claims description 6
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 6
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims description 5
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 5
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims description 5
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 5
- 108010092160 Dactinomycin Proteins 0.000 claims description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 5
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims description 5
- 229960000975 daunorubicin Drugs 0.000 claims description 5
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- 229960002949 fluorouracil Drugs 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 229960004857 mitomycin Drugs 0.000 claims description 5
- 229960001052 streptozocin Drugs 0.000 claims description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 5
- UELYDGOOJPRWGF-SRQXXRKNSA-N (2r,3r)-3-[2-[4-(cyclopropylsulfonimidoyl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]oxybutan-2-ol Chemical compound C1=C(C(F)(F)F)C(O[C@H](C)[C@H](O)C)=NC(NC=2C=CC(=CC=2)[S@](=N)(=O)C2CC2)=N1 UELYDGOOJPRWGF-SRQXXRKNSA-N 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 claims description 4
- OVPNQJVDAFNBDN-UHFFFAOYSA-N 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 OVPNQJVDAFNBDN-UHFFFAOYSA-N 0.000 claims description 4
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- 102000006992 Interferon-alpha Human genes 0.000 claims description 4
- 108010047761 Interferon-alpha Proteins 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims description 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 4
- 229950001573 abemaciclib Drugs 0.000 claims description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229950010817 alvocidib Drugs 0.000 claims description 4
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 claims description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 229960005243 carmustine Drugs 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229960000640 dactinomycin Drugs 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960000390 fludarabine Drugs 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- 229960001924 melphalan Drugs 0.000 claims description 4
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims description 4
- 229960001756 oxaliplatin Drugs 0.000 claims description 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 229960004390 palbociclib Drugs 0.000 claims description 4
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 4
- 229960004618 prednisone Drugs 0.000 claims description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
- 229950003687 ribociclib Drugs 0.000 claims description 4
- VLQLUZFVFXYXQE-USRGLUTNSA-M rigosertib sodium Chemical compound [Na+].COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC([O-])=O)=C1 VLQLUZFVFXYXQE-USRGLUTNSA-M 0.000 claims description 4
- 229950002433 roniciclib Drugs 0.000 claims description 4
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims description 4
- 229950000055 seliciclib Drugs 0.000 claims description 4
- 229950010613 selinexor Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 229960003048 vinblastine Drugs 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- WCWUXEGQKLTGDX-LLVKDONJSA-N (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 WCWUXEGQKLTGDX-LLVKDONJSA-N 0.000 claims description 3
- KGWWHPZQLVVAPT-STTJLUEPSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(e)-2-phenylethenyl]pyrimidin-4-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(\C=C\C=2C=CC=CC=2)=N1 KGWWHPZQLVVAPT-STTJLUEPSA-N 0.000 claims description 3
- MWTUOSWPJOUADP-XDJHFCHBSA-N (5z)-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-(1-methylindol-5-yl)-1,2,4-triazolidin-3-one Chemical compound O=C1C=C(O)C(C(C)C)=C\C1=C\1N(C=2C=C3C=CN(C)C3=CC=2)C(=O)NN/1 MWTUOSWPJOUADP-XDJHFCHBSA-N 0.000 claims description 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 3
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 3
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 claims description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 3
- JLRIJKVMMZEKDF-UHFFFAOYSA-N 3-n-(1h-indol-5-yl)-5-pyridin-4-ylpyrazine-2,3-diamine Chemical compound N1=C(NC=2C=C3C=CNC3=CC=2)C(N)=NC=C1C1=CC=NC=C1 JLRIJKVMMZEKDF-UHFFFAOYSA-N 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims description 3
- QFCXANHHBCGMAS-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(COC=2C=3OC=CC=3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 QFCXANHHBCGMAS-UHFFFAOYSA-N 0.000 claims description 3
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 claims description 3
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims description 3
- GKEYKDOLBLYGRB-LGMDPLHJSA-N 5-[2-(diethylamino)ethyl]-2-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-3-methyl-6,7-dihydro-1h-pyrrolo[3,2-c]pyridin-4-one Chemical compound O=C\1NC2=CC=C(F)C=C2C/1=C/C(N1)=C(C)C2=C1CCN(CCN(CC)CC)C2=O GKEYKDOLBLYGRB-LGMDPLHJSA-N 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 3
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 3
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 3
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 3
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 3
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 3
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 3
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 3
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 3
- 239000002139 L01XE22 - Masitinib Substances 0.000 claims description 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 3
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 claims description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 3
- FOFDIMHVKGYHRU-UHFFFAOYSA-N N-(1,3-benzodioxol-5-ylmethyl)-4-(4-benzofuro[3,2-d]pyrimidinyl)-1-piperazinecarbothioamide Chemical compound C12=CC=CC=C2OC2=C1N=CN=C2N(CC1)CCN1C(=S)NCC1=CC=C(OCO2)C2=C1 FOFDIMHVKGYHRU-UHFFFAOYSA-N 0.000 claims description 3
- XKFTZKGMDDZMJI-HSZRJFAPSA-N N-[5-[(2R)-2-methoxy-1-oxo-2-phenylethyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XKFTZKGMDDZMJI-HSZRJFAPSA-N 0.000 claims description 3
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 claims description 3
- 108010064641 ONX 0912 Proteins 0.000 claims description 3
- HZLFFNCLTRVYJG-WWGOJCOQSA-N Patidegib Chemical compound C([C@@]1(CC(C)=C2C3)O[C@@H]4C[C@H](C)CN[C@H]4[C@H]1C)C[C@H]2[C@H]1[C@H]3[C@@]2(C)CC[C@@H](NS(C)(=O)=O)C[C@H]2CC1 HZLFFNCLTRVYJG-WWGOJCOQSA-N 0.000 claims description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 3
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 3
- 239000004012 Tofacitinib Substances 0.000 claims description 3
- 229960001686 afatinib Drugs 0.000 claims description 3
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 3
- 229960000548 alemtuzumab Drugs 0.000 claims description 3
- 229950009447 alisertib Drugs 0.000 claims description 3
- 229950009545 amuvatinib Drugs 0.000 claims description 3
- 229960003982 apatinib Drugs 0.000 claims description 3
- 229960003005 axitinib Drugs 0.000 claims description 3
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 3
- 229960001467 bortezomib Drugs 0.000 claims description 3
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 3
- 229960003736 bosutinib Drugs 0.000 claims description 3
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 229960000419 catumaxomab Drugs 0.000 claims description 3
- 229960002412 cediranib Drugs 0.000 claims description 3
- 229960005395 cetuximab Drugs 0.000 claims description 3
- LOLPPWBBNUVNQZ-UHFFFAOYSA-N chembl495727 Chemical compound C=1NN=C(C=2NC3=CC=C(CN4CCOCC4)C=C3N=2)C=1NC(=O)NC1CC1 LOLPPWBBNUVNQZ-UHFFFAOYSA-N 0.000 claims description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical group OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004630 chlorambucil Drugs 0.000 claims description 3
- 229960005061 crizotinib Drugs 0.000 claims description 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 229960002465 dabrafenib Drugs 0.000 claims description 3
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 3
- 229960003901 dacarbazine Drugs 0.000 claims description 3
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims description 3
- 229950002205 dacomitinib Drugs 0.000 claims description 3
- 229950002966 danusertib Drugs 0.000 claims description 3
- 229960002448 dasatinib Drugs 0.000 claims description 3
- 229960001251 denosumab Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 229960001433 erlotinib Drugs 0.000 claims description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 3
- 229960005167 everolimus Drugs 0.000 claims description 3
- 229940125199 famitinib Drugs 0.000 claims description 3
- 229960002074 flutamide Drugs 0.000 claims description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 3
- 229950008692 foretinib Drugs 0.000 claims description 3
- 229950004161 ganetespib Drugs 0.000 claims description 3
- 229960002584 gefitinib Drugs 0.000 claims description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- 229960000578 gemtuzumab Drugs 0.000 claims description 3
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 claims description 3
- 229950006304 gilteritinib Drugs 0.000 claims description 3
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 3
- 229960001507 ibrutinib Drugs 0.000 claims description 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 3
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 claims description 3
- 229950007440 icotinib Drugs 0.000 claims description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001101 ifosfamide Drugs 0.000 claims description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002411 imatinib Drugs 0.000 claims description 3
- 229950002133 iniparib Drugs 0.000 claims description 3
- 229960005386 ipilimumab Drugs 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- 229960002014 ixabepilone Drugs 0.000 claims description 3
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims description 3
- 229960004891 lapatinib Drugs 0.000 claims description 3
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims description 3
- 229960003784 lenvatinib Drugs 0.000 claims description 3
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims description 3
- 229950002216 linifanib Drugs 0.000 claims description 3
- 229950001762 linsitinib Drugs 0.000 claims description 3
- PKCDDUHJAFVJJB-VLZXCDOPSA-N linsitinib Chemical compound C1[C@](C)(O)C[C@@H]1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N PKCDDUHJAFVJJB-VLZXCDOPSA-N 0.000 claims description 3
- 229960002247 lomustine Drugs 0.000 claims description 3
- 229960004655 masitinib Drugs 0.000 claims description 3
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 claims description 3
- 229960001786 megestrol Drugs 0.000 claims description 3
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 3
- 229960001428 mercaptopurine Drugs 0.000 claims description 3
- 229960004584 methylprednisolone Drugs 0.000 claims description 3
- 229950010895 midostaurin Drugs 0.000 claims description 3
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 claims description 3
- 229950008814 momelotinib Drugs 0.000 claims description 3
- 229950003968 motesanib Drugs 0.000 claims description 3
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 claims description 3
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 claims description 3
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims description 3
- 229950008835 neratinib Drugs 0.000 claims description 3
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims description 3
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001346 nilotinib Drugs 0.000 claims description 3
- 229950010203 nimotuzumab Drugs 0.000 claims description 3
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 3
- 229950011068 niraparib Drugs 0.000 claims description 3
- 229960002450 ofatumumab Drugs 0.000 claims description 3
- 229960000572 olaparib Drugs 0.000 claims description 3
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229950005750 oprozomib Drugs 0.000 claims description 3
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 claims description 3
- 229950011410 pacritinib Drugs 0.000 claims description 3
- 229960001972 panitumumab Drugs 0.000 claims description 3
- 229960000639 pazopanib Drugs 0.000 claims description 3
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 3
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 claims description 3
- 229950004941 pictilisib Drugs 0.000 claims description 3
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000624 procarbazine Drugs 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- 229960004836 regorafenib Drugs 0.000 claims description 3
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 3
- OWBFCJROIKNMGD-BQYQJAHWSA-N rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 claims description 3
- 229950006764 rigosertib Drugs 0.000 claims description 3
- 229960004641 rituximab Drugs 0.000 claims description 3
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229950004707 rucaparib Drugs 0.000 claims description 3
- 229960000215 ruxolitinib Drugs 0.000 claims description 3
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 3
- 229950009919 saracatinib Drugs 0.000 claims description 3
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 claims description 3
- 229960005569 saridegib Drugs 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229960003787 sorafenib Drugs 0.000 claims description 3
- 229960001796 sunitinib Drugs 0.000 claims description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- 229950004186 telatinib Drugs 0.000 claims description 3
- 229960004964 temozolomide Drugs 0.000 claims description 3
- 229960000235 temsirolimus Drugs 0.000 claims description 3
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 3
- 229960003433 thalidomide Drugs 0.000 claims description 3
- 229950005976 tivantinib Drugs 0.000 claims description 3
- 229960000940 tivozanib Drugs 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 229960005267 tositumomab Drugs 0.000 claims description 3
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims description 3
- 229960000977 trabectedin Drugs 0.000 claims description 3
- 229960004066 trametinib Drugs 0.000 claims description 3
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960000575 trastuzumab Drugs 0.000 claims description 3
- 229960000241 vandetanib Drugs 0.000 claims description 3
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 3
- 229950011257 veliparib Drugs 0.000 claims description 3
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims description 3
- 229960003862 vemurafenib Drugs 0.000 claims description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 3
- 229960002066 vinorelbine Drugs 0.000 claims description 3
- 229960004449 vismodegib Drugs 0.000 claims description 3
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 claims description 3
- 229950003081 volasertib Drugs 0.000 claims description 3
- SXNJFOWDRLKDSF-STROYTFGSA-N volasertib Chemical compound C1CN([C@H]2CC[C@@H](CC2)NC(=O)C2=CC=C(C(=C2)OC)NC=2N=C3N(C(C)C)[C@@H](C(N(C)C3=CN=2)=O)CC)CCN1CC1CC1 SXNJFOWDRLKDSF-STROYTFGSA-N 0.000 claims description 3
- 235000008207 calcium folinate Nutrition 0.000 claims description 2
- 239000011687 calcium folinate Substances 0.000 claims description 2
- 229960002293 leucovorin calcium Drugs 0.000 claims description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 5
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 5
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 108060006633 protein kinase Proteins 0.000 abstract description 7
- 102000001253 Protein Kinase Human genes 0.000 abstract description 6
- 230000000670 limiting effect Effects 0.000 description 75
- 239000000203 mixture Substances 0.000 description 68
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 239000000460 chlorine Substances 0.000 description 36
- 125000001424 substituent group Chemical group 0.000 description 36
- 239000000543 intermediate Substances 0.000 description 34
- 238000003786 synthesis reaction Methods 0.000 description 34
- 230000015572 biosynthetic process Effects 0.000 description 32
- 239000002585 base Substances 0.000 description 30
- 125000004432 carbon atom Chemical group C* 0.000 description 29
- 230000008569 process Effects 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 25
- 239000007787 solid Substances 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 125000004122 cyclic group Chemical group 0.000 description 21
- 239000000126 substance Substances 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 150000002500 ions Chemical class 0.000 description 16
- 125000004430 oxygen atom Chemical group O* 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 239000003054 catalyst Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 238000004611 spectroscopical analysis Methods 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- 125000002619 bicyclic group Chemical group 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 229910052717 sulfur Inorganic materials 0.000 description 13
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 13
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- 229910052698 phosphorus Inorganic materials 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 10
- 125000001246 bromo group Chemical group Br* 0.000 description 10
- 125000001589 carboacyl group Chemical group 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 125000001309 chloro group Chemical group Cl* 0.000 description 10
- 125000001153 fluoro group Chemical group F* 0.000 description 10
- 125000002346 iodo group Chemical group I* 0.000 description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000004452 carbocyclyl group Chemical group 0.000 description 9
- 125000005518 carboxamido group Chemical group 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 description 9
- 125000003396 thiol group Chemical class [H]S* 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 7
- 229910002666 PdCl2 Inorganic materials 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 150000002430 hydrocarbons Chemical group 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 7
- JXYITCJMBRETQX-UHFFFAOYSA-N 4-ethynylaniline Chemical compound NC1=CC=C(C#C)C=C1 JXYITCJMBRETQX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- PIAZYBLGBSMNLX-UHFFFAOYSA-N 4-(3-chloropropyl)morpholine Chemical compound ClCCCN1CCOCC1 PIAZYBLGBSMNLX-UHFFFAOYSA-N 0.000 description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 201000005787 hematologic cancer Diseases 0.000 description 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- FGUDMROYDQCCNY-UHFFFAOYSA-N phenyl n-(5-tert-butyl-1,2-oxazol-3-yl)carbamate Chemical compound O1C(C(C)(C)C)=CC(NC(=O)OC=2C=CC=CC=2)=N1 FGUDMROYDQCCNY-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000003419 tautomerization reaction Methods 0.000 description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102100027907 Cytoplasmic tyrosine-protein kinase BMX Human genes 0.000 description 4
- 101000935548 Homo sapiens Cytoplasmic tyrosine-protein kinase BMX Proteins 0.000 description 4
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 4
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000007080 aromatic substitution reaction Methods 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 201000009277 hairy cell leukemia Diseases 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- HOFQVRTUGATRFI-XQKSVPLYSA-N vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- RWVOECKRIYILLY-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-[2-chloro-4-(3-morpholin-4-ylpropoxy)phenyl]ethynyl]phenyl]urea Chemical compound C(C)(C)(C)C1=CC(=NO1)NC(=O)NC1=CC=C(C=C1)C#CC1=C(C=C(C=C1)OCCCN1CCOCC1)Cl RWVOECKRIYILLY-UHFFFAOYSA-N 0.000 description 2
- IRUNPQDXIONCKN-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-[3-chloro-4-(3-morpholin-4-ylpropoxy)phenyl]ethynyl]phenyl]urea Chemical compound C(C)(C)(C)C1=CC(=NO1)NC(=O)NC1=CC=C(C=C1)C#CC1=CC(=C(C=C1)OCCCN1CCOCC1)Cl IRUNPQDXIONCKN-UHFFFAOYSA-N 0.000 description 2
- ZLSQMOUPLPXKLG-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-[4-(3-morpholin-4-ylpropoxy)-3-(trifluoromethyl)phenyl]ethynyl]phenyl]urea Chemical compound C(C)(C)(C)C1=CC(=NO1)NC(=O)NC1=CC=C(C=C1)C#CC1=CC(=C(C=C1)OCCCN1CCOCC1)C(F)(F)F ZLSQMOUPLPXKLG-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- UQZPGHOJMQTOHB-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)-n-ethylethanamine Chemical compound ClCCN(CC)CCCl UQZPGHOJMQTOHB-UHFFFAOYSA-N 0.000 description 2
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 2
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 2
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 2
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 2
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HCZGDQIAYVXPTI-UHFFFAOYSA-N 4-[2-[2-chloro-4-(3-morpholin-4-ylpropoxy)phenyl]ethynyl]aniline Chemical compound ClC1=C(C=CC(=C1)OCCCN1CCOCC1)C#CC1=CC=C(N)C=C1 HCZGDQIAYVXPTI-UHFFFAOYSA-N 0.000 description 2
- JUYSRHHOPJWKTL-UHFFFAOYSA-N 4-[2-[2-fluoro-4-(3-morpholin-4-ylpropoxy)phenyl]ethynyl]aniline Chemical compound FC1=C(C=CC(=C1)OCCCN1CCOCC1)C#CC1=CC=C(N)C=C1 JUYSRHHOPJWKTL-UHFFFAOYSA-N 0.000 description 2
- ZNBSABZTKVEXDP-UHFFFAOYSA-N 4-[2-[3-chloro-4-(3-morpholin-4-ylpropoxy)phenyl]ethynyl]aniline Chemical compound ClC=1C=C(C=CC=1OCCCN1CCOCC1)C#CC1=CC=C(N)C=C1 ZNBSABZTKVEXDP-UHFFFAOYSA-N 0.000 description 2
- LXSGGGDZDXQLOS-UHFFFAOYSA-N 4-[2-[3-fluoro-4-(3-morpholin-4-ylpropoxy)phenyl]ethynyl]aniline Chemical compound FC=1C=C(C=CC=1OCCCN1CCOCC1)C#CC1=CC=C(N)C=C1 LXSGGGDZDXQLOS-UHFFFAOYSA-N 0.000 description 2
- AOGFBHJCSWBBHX-UHFFFAOYSA-N 4-[2-[4-(3-morpholin-4-ylpropoxy)-3-(trifluoromethyl)phenyl]ethynyl]aniline Chemical compound O1CCN(CC1)CCCOC1=C(C=C(C=C1)C#CC1=CC=C(N)C=C1)C(F)(F)F AOGFBHJCSWBBHX-UHFFFAOYSA-N 0.000 description 2
- JTALUCVMLWUGRJ-UHFFFAOYSA-N 4-[3-(2-chloro-4-iodophenoxy)propyl]morpholine Chemical compound ClC1=C(OCCCN2CCOCC2)C=CC(=C1)I JTALUCVMLWUGRJ-UHFFFAOYSA-N 0.000 description 2
- UYIGEKAMHQFHAR-UHFFFAOYSA-N 4-[3-(2-fluoro-4-iodophenoxy)propyl]morpholine Chemical compound FC1=C(OCCCN2CCOCC2)C=CC(=C1)I UYIGEKAMHQFHAR-UHFFFAOYSA-N 0.000 description 2
- VDNCDUPTKGBINC-UHFFFAOYSA-N 4-[3-(3-chloro-4-iodophenoxy)propyl]morpholine Chemical compound ClC=1C=C(OCCCN2CCOCC2)C=CC=1I VDNCDUPTKGBINC-UHFFFAOYSA-N 0.000 description 2
- RSWOPTWQDXECBQ-UHFFFAOYSA-N 4-[3-(3-fluoro-4-iodophenoxy)propyl]morpholine Chemical compound FC=1C=C(OCCCN2CCOCC2)C=CC=1I RSWOPTWQDXECBQ-UHFFFAOYSA-N 0.000 description 2
- MFBKOWJWBYYUQD-UHFFFAOYSA-N 4-[3-[4-iodo-2-(trifluoromethyl)phenoxy]propyl]morpholine Chemical compound IC1=CC(=C(OCCCN2CCOCC2)C=C1)C(F)(F)F MFBKOWJWBYYUQD-UHFFFAOYSA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- 208000007743 Acute Abdomen Diseases 0.000 description 2
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010013082 Discomfort Diseases 0.000 description 2
- 206010014418 Electrolyte imbalance Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000009693 Gingival Hyperplasia Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101000938351 Homo sapiens Ephrin type-A receptor 3 Proteins 0.000 description 2
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
- 101000606067 Homo sapiens Tyrosine-protein kinase TXK Proteins 0.000 description 2
- 101000889732 Homo sapiens Tyrosine-protein kinase Tec Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010024652 Liver abscess Diseases 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 201000010183 Papilledema Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 208000005228 Pericardial Effusion Diseases 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000006311 Pyoderma Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 108091005682 Receptor kinases Proteins 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000010265 Sweet syndrome Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 2
- 102100039079 Tyrosine-protein kinase TXK Human genes 0.000 description 2
- 102100040177 Tyrosine-protein kinase Tec Human genes 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 2
- 208000034700 Vitreous opacities Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 125000005228 aryl sulfonate group Chemical group 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 2
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 description 2
- 229960001489 deferasirox Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010064 diabetes insipidus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 208000001936 exophthalmos Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 125000005549 heteroarylene group Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 201000009285 hypopyon Diseases 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000005945 imidazopyridyl group Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000009854 mucosal lesion Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 208000025303 orbit neoplasm Diseases 0.000 description 2
- 201000000890 orbital cancer Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 2
- 125000004624 phenarsazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3[As]=C12)* 0.000 description 2
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960004694 prednimustine Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004590 pyridopyridyl group Chemical group N1=C(C=CC2=C1C=CC=N2)* 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 208000026426 spleen abscess Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 239000006208 topical dosage form Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- FKBHRUQOROFRGD-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2[C]3C=CC=CC3=NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC FKBHRUQOROFRGD-IELIFDKJSA-N 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- PKEKLMATCFGDSL-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-[2-fluoro-4-(3-morpholin-4-ylpropoxy)phenyl]ethynyl]phenyl]urea Chemical compound C(C)(C)(C)C1=CC(=NO1)NC(=O)NC1=CC=C(C=C1)C#CC1=C(C=C(C=C1)OCCCN1CCOCC1)F PKEKLMATCFGDSL-UHFFFAOYSA-N 0.000 description 1
- YXQGJGKFASWRSC-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-[3-fluoro-4-(3-morpholin-4-ylpropoxy)phenyl]ethynyl]phenyl]urea Chemical compound C(C)(C)(C)C1=CC(=NO1)NC(=O)NC1=CC=C(C=C1)C#CC1=CC(=C(C=C1)OCCCN1CCOCC1)F YXQGJGKFASWRSC-UHFFFAOYSA-N 0.000 description 1
- GCDFZCHJVHNDQL-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-[5-(3-morpholin-4-ylpropoxy)pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]phenyl]urea Chemical compound C(C)(C)(C)C1=CC(=NO1)NC(=O)NC1=CC=C(C=C1)C#CC=1C=NN2C=1N=C(C=C2)OCCCN1CCOCC1 GCDFZCHJVHNDQL-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- VBRBDNRMJPYZTD-UHFFFAOYSA-N 1-[5-(1-hydroxy-2-methylpropan-2-yl)-1,2-oxazol-3-yl]-3-[4-[2-[4-[3-(4-oxidomorpholin-4-ium-4-yl)propoxy]phenyl]ethynyl]phenyl]urea Chemical compound OCC(C)(C)C1=CC(=NO1)NC(NC1=CC=C(C=C1)C#CC1=CC=C(OCCC[N+]2(CCOCC2)[O-])C=C1)=O VBRBDNRMJPYZTD-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- DVVGIUUJYPYENY-UHFFFAOYSA-N 1-methylpyridin-2-one Chemical compound CN1C=CC=CC1=O DVVGIUUJYPYENY-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- OZCYPGKPOUZZSO-UHFFFAOYSA-N 2-chloro-4-iodophenol Chemical compound OC1=CC=C(I)C=C1Cl OZCYPGKPOUZZSO-UHFFFAOYSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- FDOQGGGFQVVOBN-UHFFFAOYSA-N 2-fluoro-4-iodophenol Chemical compound OC1=CC=C(I)C=C1F FDOQGGGFQVVOBN-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- DIBGHLUZOSSRIT-UHFFFAOYSA-N 3-chloro-4-iodophenol Chemical compound OC1=CC=C(I)C(Cl)=C1 DIBGHLUZOSSRIT-UHFFFAOYSA-N 0.000 description 1
- ZJQWXXSZXSTKHW-UHFFFAOYSA-N 3-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1.OOC(=O)C1=CC=CC(Cl)=C1 ZJQWXXSZXSTKHW-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- CSQWLXZVUXRZFL-UHFFFAOYSA-N 3-fluoro-4-iodophenol Chemical compound OC1=CC=C(I)C(F)=C1 CSQWLXZVUXRZFL-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- GEANIDGUCIEWGJ-UHFFFAOYSA-N 4-[2-(5-chloropyrazolo[1,5-a]pyrimidin-3-yl)ethynyl]aniline Chemical compound ClC1=NC=2N(C=C1)N=CC=2C#CC1=CC=C(N)C=C1 GEANIDGUCIEWGJ-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- MHXCSGNJJHAYTN-UHFFFAOYSA-N 4-iodo-2-(trifluoromethyl)phenol Chemical compound OC1=CC=C(I)C=C1C(F)(F)F MHXCSGNJJHAYTN-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- OPASGSRWIMSJGT-UHFFFAOYSA-N 5-chloro-3-iodopyrazolo[1,5-a]pyrimidine Chemical compound N1=C(Cl)C=CN2N=CC(I)=C21 OPASGSRWIMSJGT-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000010581 Acute myeloid leukemia with minimal differentiation Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 206010071973 C-kit gene mutation Diseases 0.000 description 1
- 102000038625 CMGCs Human genes 0.000 description 1
- 108091007913 CMGCs Proteins 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 101100335080 Homo sapiens FLT3 gene Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010055046 Lichen myxoedematosus Diseases 0.000 description 1
- 208000022435 Light chain deposition disease Diseases 0.000 description 1
- 208000020647 Light chain disease Diseases 0.000 description 1
- 208000016426 Localized lichen myxedematosus Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000001941 Scleromyxedema Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000012082 adaptor molecule Substances 0.000 description 1
- 239000002318 adhesion promoter Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940044684 anti-microtubule agent Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 108010044481 calcineurin phosphatase Proteins 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001723 carbon free-radicals Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229940060038 chlorine Drugs 0.000 description 1
- 229950008249 chlornaphazine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- WQPDQJCBHQPNCZ-UHFFFAOYSA-N cyclohexa-2,4-dien-1-one Chemical compound O=C1CC=CC=C1 WQPDQJCBHQPNCZ-UHFFFAOYSA-N 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 125000004987 dibenzofuryl group Chemical group C1(=CC=CC=2OC3=C(C21)C=CC=C3)* 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960000533 dornase alfa Drugs 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000005994 isobenzotetrahydrofuranyl group Chemical group 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- CPTIBDHUFVHUJK-NZYDNVMFSA-N mitopodozide Chemical compound C1([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(=O)NNCC)=CC(OC)=C(OC)C(OC)=C1 CPTIBDHUFVHUJK-NZYDNVMFSA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229950005848 olivomycin Drugs 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- MQDVUDAZJMZQMF-UHFFFAOYSA-N pyridin-2-ylurea Chemical compound NC(=O)NC1=CC=CC=N1 MQDVUDAZJMZQMF-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005996 thiadiazolopyrimidinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000005503 thioxanyl group Chemical group 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- MHNHYTDAOYJUEZ-UHFFFAOYSA-N triphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MHNHYTDAOYJUEZ-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 229960005088 urethane Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention belongs to the pharmaceutical field, and it relates to novel substituted urea derivatives, pharmaceutical compositions thereof and uses thereof for the treatment of FLT3-mediated or FLT3-ITD-induced diseases.
- novel substituted urea derivatives and pharmaceutical compositions are useful in treating, ameliorating or preventing a tyrosine kinase activity related disease, or one or more symptoms thereof.
- RPTK receptor protein tyrosine kinase
- FLT3 plays an important role in the proliferation and differentiation of hematopoietic stem cells, and activating mutation or overexpression of this receptor is found in AML (acute myeloid leukemia) (See, Heinrich, Mini-Reviews in Medicinal Chemistry, 2004, 4 (3) : 255-271, and Kiyoi et al., Int J Hematol., 2005, 82: 85-92, incorporated herein by reference) .
- AML acute myeloid leukemia
- FLT3 inhibtor CEP-701 may be effective in reducing myelin loss in experimental autoimmune encephalomyelitis (EAE) , a mouse model for multiple sclerosis (See, Whartenby et al., PNAS, 2005, 102: 16741-16746, incorporated herein by reference) .
- EAE experimental autoimmune encephalomyelitis
- a high level of the FLT3 ligand is found in the serum of patients with Langerhans cell histiocytosis and systemic lupus erythematosus, that further means FLT3 signal transduction is implicated in the dysregulation of dendritic cell progenitors in those autoimmune diseases (See, Rolland et al., J. Immunol., 2005, 174: 3067-3071, incorporated herein by reference) .
- FLT3-ITD Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approximately 20%of acute myeloid leukemia patients and are associated with a poor prognosis.
- FLT3-ITD can represent a driver lesion, which has causative role in malignancy pathogenesis, and valid therapeutic target in human AML (See, Catherine et al., Nature, 2012, 485: 260-263, incorporated herein by reference) .
- Mutation of FLT3 gene is a frequent event in AML and usually involves internal tandem duplication (ITD) of the juxtamembrane domain coding region or point mutations of the tyrosine kinase domain (TKD) .
- FLT3-ITD and FLT3-TKD mutations result in ligand-independent proliferation due to constitutive dimerisation and activation of the FLT3 receptor.
- High mutant-to-wild type allelic ratios of FLT3-ITD are associated with a very poor prognosis in both adults and children (See, AS Moore et al., Leukemia, 2012, 26: 1462-1470, incorporated herein by reference) .
- bcr-Abl is a tyrosine kinase which inhibits cellular cancerization and immortalization of pH-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) .
- bcr-Abl protein is the constitutively active, cytoplasmic tyrosine kinase existing in 90%of the patients of chronic myeloid leukemia and 15-30%of the adult patients of acute lymphoblastic leukemia. Many studies have shown that bcr-Abl activation is the need of carcinogenic ability of said chimeric protein.
- c-Kit gene a member of type III receptor tyrosine kinase family in AML. It was found that mutations of c-KIT gene will cause the activation of c-Kit without receptor-ligand binding, thereby the abnormal proliferation of cells occurs, leading to cancer.
- c-KIT gene mutation in leukemia cell is closely associated with the occurrence of leukemia and the prognosis of therapeutic agent.
- c-Kit receptor also can be constitutively activated by mutation, leading to abnormal cell proliferation and development, such as mastocytosis (D816V mutation) and other diseases, and various cancers, such as GIST (c-kit ⁇ 27, juxtamembrane deletion) .
- the present invention provides a novel substituted urea compounds useful for treating, ameliorating or preventing a disease or symptom associated with tyrosine kinase activity, particularly the disease or complications thereof mediated by c-KIT mutation, RET, PDGFR, Bcr-ABL, FLT3 orinduced by FLT3-ITD, and for treating a proliferative disease, particularly blood cancer, especially for treating AML and related complications.
- substituted urea derivatives and pharmaceutical compositions thereof used for drug therapy and a series of substituted urea compounds used for adjusting Abl and FLT3 kinase activities and inhibiting FLT3-ITD, and the uses thereof as therapeutic agents for the treatment of diseases mediated by c-KIT mutation, RET, PDGFR, Bcr-ABL, FLT3 orinduced by FLT3-ITD.
- the compounds of the present invention show better inhibition activities against the proferation of MV4-11cell which contains the FLT3/ITD mutation.
- substituted urea derivatives having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each of ring A and ring E is independently C 6-10 aryl or C 1-12 heteroaryl;
- each J is -G- (CH 2 ) n -R 2 ;
- each R 3 and R 3a is independently C 1-4 alkyl, C 3-10 cycloalkyl, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl;
- each R 4 is independently H, C 1-4 alkyl, C 3-10 cycloalkyl, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl;
- ring K is 5-to 6-membered heteroaryl
- each a and e is independently 0, 1, 2, 3 or 4;
- each n, d and b is independently 1, 2, 3 or 4;
- each t is independently 0, 1 or 2;
- each R 3b and R 3c is independently H, F, Cl, Br, cyano, nitro, hydroxy, mercapto, amino, carboxy, C 1-4 alkyl, C 1-4 haloalkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl.
- urea derivatives having Formula (IIa) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- R 0 is C 2-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl
- each ring A, ring E, R 1 , R 1a , e, b, a and J is as defined herein.
- urea derivatives having Formula (II) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each ring A, ring E, R 1 , R 1a , e, b, a and J is as defined herein.
- urea derivatives having Formula (I) , Formula (IIa) or Formula (II) , or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each ring A and ring E is independently one of the following sub-formulae:
- each X, Y, Z, Z 1 , Z 2 , Z 3 and Z 4 is independently N or CH;
- each T, T 1 and T 2 is independently -O-, -S-, -N (R 4 ) -or -CH 2 -;
- each R 1 and R 1a is independently H, F, Cl, Br, cyano, nitro, hydroxy, mercapto, amino, carboxy, C 1-4 alkyl, C 1-4 haloalkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 1-4 alkylamino, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl; and
- each R 4 is as defined herein.
- urea derivatives having Formula (I) , Formula (IIa) or Formula (II) , or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each ring A and ring E is independently one of the following sub-formulae:
- each R 1 and R 1a is independently H, F, Cl, Br, trifluoromethyl, chloroethyl, trifluoroethyl, methyl, ethyl, propyl, isopropyl, dimethylamino, methylamino, diethylamino, ethylamino, hydroxy, cyano, nitro, methoxy, ethoxy, propoxy, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl.
- urea derivatives having Formula (I) , Formula (IIa) or Formula (II) , or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each R 3 and R 3a is independently C 1-4 alkyl, C 3-10 cycloalkyl, C 2-10 heterocycloalkyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl;
- each R 2a is as defined herein.
- urea derivatives having Formula (I) , Formula (IIa) or Formula (II) , or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each R 2 is independently -NR 3 R 3a , C 1-4 alkoxy-C 1-4 -alkyl, C 1-4 alkyl or C 1-4 hydroxyalkyl, or each R 2 is independently one of the following sub-formulae:
- each X 6 , X 7 , X 8 and X 9 is independently N or CH;
- each q, m, p and r is independently 0, 1, 2, 3 or 4;
- each t is independently 0, 1 or 2;
- each R 2 is independently substituted with one or more R 2a which are the same or different;
- each R 4a is independently H, C 1-4 alkyl, C 3-10 cycloalkyl, C 2-10 heterocycloalkyl, C 1-6 alkoxy-C 1-6 -alkyl, or C 1-4 hydroxyalkyl;
- R 3 , R 3a , R 3b , R 3c , and R 2a is as defined herein.
- urea derivatives having Formula (I) , Formula (IIa) or Formula (II) , or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each R 2 is independently one of the following sub-formulae:
- each R 3 and R 3a is independently methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, C 2-10 heterocycloalkyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl;
- each R 4 and R 4a is independently H, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, C 2-10 heterocycloalkyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl;
- each sub-formula represented by R 2 is independently substituted with one or more R 2a which are the same or different;
- urea derivatives having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- the substituted urea derivativesprovided herein having Formula (IIIa) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- R 0 is C 2-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl
- each R 1a , R 1 , J, e, a and b is as defined herein.
- the substituted urea derivativesprovided herein having Formula (III) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each R 1a , R 1 , J, e, a and b is as defined herein.
- the substituted urea derivativesprovided herein having Formula (IV) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each R 1a , R 1 , J, e, a and b is as defined herein.
- the substituted urea derivativesprovided herein having Formula (V) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each R 1a , R 1 , J, e, a and b is as defined herein;
- each of X, Y, Z, Z 1 , Z 3 and Z 4 is independently N or CH.
- the substituted urea derivativesprovided herein having Formula (VI) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each ring A, R 1a , R 1 , J, e, a and b is as defined herein.
- urea derivatives havingFormula (VIIa) , or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each R 1a , R 1 , J, e, a and b is as defined herein;
- R 00 is C 1-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl.
- urea derivatives havingFormula (IIIb) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- R 00 is C 1-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl
- each ring E, R 1 , R 1a , R 2 , e, a and n is as defined herein.
- composition comprising the compound disclosed herein.
- the pharmaceutical composition disclosed herein further comprises at least one of pharmaceutically acceptable carriers, excipients, diluents, adjuvants or vehicles.
- the pharmaceutical composition disclosed herein further comprisesother active agent used for treating a proliferative disease, an autoimmune disease or an inflammatory disease, wherein the other active agent is a chemotherapeutic agent, antiproliferative agent, immunosuppressive agent, immunostimulatory agent, antiinflammatory agent, an agent for treating atherosclerosis, an agent for treating pulmonary fibrosis, CDK4/6-kinase inhibitor, ABL inhibitor, ABL/Scr inhibitor, aurora kinase inhibitor, non-ATP-competitive inhibitor of BCR-ABL, c-KIT mutation inhibitor, RET inhibitor, PDGFR inhibitor, VEGFR inhibitor, FLT3 inhibitor, FLT3-ITD inhibitor or a combination thereof .
- the other active agent is a chemotherapeutic agent, antiproliferative agent, immunosuppressive agent, immunostimulatory agent, antiinflammatory agent, an agent for treating atherosclerosis, an agent for treating pulmonary fibrosis, CDK4/6-kinase inhibitor, ABL inhibitor, A
- the pharmaceutical composition disclosed herein wherein the other active agent is chlorambucil, melphalan, cyclophosphamide, ifosfamide, busulfan, carmustine, lomustine, streptozotocin, cisplatin, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbazine, methotrexate, fluorouracil, cytarabine, gemcitabine, mercaptopurine, fludarabine, vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel, topotecan, irinotecan, etoposide, trabectedin, dactinomycin, doxorubicin, epirubicin, daunorubicin, mitoxantrone, bleomycin, mitomycin C, ixabepilone, tamoxifen, flutamide, gonadorelin an
- provided herein is theuse of the compound or the pharmaceutical composition disclosed herein in the manufacture of a medicament for preventing, managing, treating or lessening a proliferative disease, an autoimmune disease or an inflammatory disease in a patient.
- the use disclosed herein, wherein the proliferative disease is chronic myelogenous leukemia, gastrointestinal stromal tumor, actute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, minimally differentiated acute myeloid leukemia, acute myelogenous leukemia (AML) , mutant chronic myelogenous leukemia (CML) , acute lymphocytic leukemia (ALL) , leukemia, chronic lymphocytic leukemia, primary macroglobulinemia, monocytic leukemia, leukemoid reaction, aplastic anemia, purpura, secondary benign monoclonal gammopathy, semi-molecular disease, colorectal cancer, stomach cancer, breast cancer, lung cancer, liver cancer, prostate cancer, pancreatic cancer, thyroid cancer, kidney cancer, brain tumor, neck cancer, central nervous system (
- the use disclosed herein, wherein the AML related complication is the symptom displayed by the patient, i.e., infection, bleeding, adult respiratory distress syndrome, sarcoidosis, pleural effusion, pulmonary fibrosis, pericardial effusion, cardiac arrhythmia, hypertension, heart failure, acute abdomen, portal hypertension, renal insufficiency, liver and spleen abscesses, anemia, thrombosis, diabetes, diabetes insipidus, electrolyte imbalance, neurological complications, intracranial hemorrhage, necrosis of the femoral head, bone and joint disease, skin lesions, retinal hemorrhage, optic disc edema, conjunctival hyperemia, edema, hypopyon, choroidal infiltration, iris infiltration, vitreous opacities, vision loss, hypopsia, orbital tumor, proptosis, acute glaucoma, chloroma, gingival hyperplasia, oral
- the use disclosed herein wherein the autoimmune disease is leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, acute myelogenous leukemia (AML) , mutant chronic myelogenous leukemia (CML) , acute lymphocytic leukemia (ALL) , rheumatoid arthritis, bone and joint pain, central nervous system involvement, lupus, multiple sclerosis, thyroiditis, type I diabetes, sarcoidosis, inflammatory bowel disease, Crohn's disease, systemic lupus or AML related complication.
- AML acute myelogenous leukemia
- CML mutant chronic myelogenous leukemia
- ALL acute lymphocytic leukemia
- the use disclosed herein, wherein the inflammatory disease is diverticulitis, colitis, pancreatitis, hepatitis, chronic hepatitis, cirrhosis, cholecystitis or chronic inflammation.
- the use disclosed herein, wherein the disease is a disease mediated by c-KIT mutation, RET, PDGFR, VEGFR, Bcr-ABL, FLT3 or induced by FLT3-ITD.
- a drug combination comprising the compound or the pharmaceutical composition disclosed herein and one or more other active agents used for the treatment of a proliferative disease, an autoimmune disease or an inflammatory disease.
- the drug combination disclosed herein wherein the other active agent is chemotherapeutic agent, antiproliferative agent, immunosuppressive agent, immunostimulatory agent, antiinflammatory agent, CDK4/6-kinase inhibitor, ABL inhibitor, ABL/Scr inhibitor, aurora kinase inhibitor, non-ATP-competitive inhibitor of BCR-ABL, c-KIT mutation inhibitor, RET inhibitor, PDGFR inhibitor, VEGFR inhibitor, FLT3 inhibitor, FLT3-ITD inhibitor or a combination thereof.
- the other active agent is chemotherapeutic agent, antiproliferative agent, immunosuppressive agent, immunostimulatory agent, antiinflammatory agent, CDK4/6-kinase inhibitor, ABL inhibitor, ABL/Scr inhibitor, aurora kinase inhibitor, non-ATP-competitive inhibitor of BCR-ABL, c-KIT mutation inhibitor, RET inhibitor, PDGFR inhibitor, VEGFR inhibitor, FLT3 inhibitor, FLT3-ITD inhibitor or a combination thereof.
- the drug combination disclosed herein, wherein the compound or the pharmaceutical composition disclosed herein is a FLT3 inhibitor or FLT3-ITD inhibitor.
- the drug combination disclosed herein, wherein the other active agent is a CDK4/6-kinase inhibitor.
- provided herein is a method of preventing, managing, treating or lessening a proliferative disease, an autoimmune disease or an inflammatory disease in a patient comprising administering to the patient a therapeutically effective amount of the compound or the pharmaceutical composition disclosed herein.
- the method disclosed herein wherein the proliferative disease is chronic myelogenous leukemia, gastrointestinal stromal tumor, acute myelogenous leukemia (AML) , mutant chronic myelogenous leukemia (CML) , acute lymphocytic leukemia (ALL) , leukemia, chronic lymphocytic leukemia, primary macroglobulinemia, monocytic leukemia, leukemoid reaction, aplastic anemia, purpura, secondary benign monoclonal gammopathy, semi-molecular disease, colorectal cancer, stomach cancer, breast cancer, lung cancer, liver cancer, prostate cancer, pancreatic cancer, thyroid cancer, kidney cancer, brain tumor, neck cancer, central nervous system (CNS) cancer, malignant glioma, bone marrow hyperplasia, infectious mononucleosis, malignant histiocytosis, lymphoma, non-lymphoreticular system tumor, multiple myeloma, granu
- AML acute
- the autoimmune disease is leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, acute myelogenous leukemia (AML) , mutant chronic myelogenous leukemia (CML) , acute lymphocytic leukemia (ALL) , rheumatoid arthritis, bone and joint pain, central nervous system involvement, lupus, multiple sclerosis, thyroiditis, type I diabetes, sarcoidosis, inflammatory bowel disease, Crohn's disease, systemic lupus or AML related complication; and
- the inflammatory disease is diverticulitis, colitis, pancreatitis, hepatitis, chronic hepatitis, cirrhosis, cholecystitis or chronic inflammation.
- the method disclosed herein wherein the disease is a disease mediated by c-KIT mutation, RET, PDGFR, VEGFR, Bcr-ABL, FLT3 or induced by FLT3-ITD.
- the compound or the pharmaceutical composition disclosed herein for use in preventing, managing, treating or lessening a proliferative disease, an autoimmune disease or an inflammatory disease in a patient.
- the compound or the pharmaceutical composition disclosedherein wherein the proliferative disease is chronic myelogenous leukemia, gastrointestinal stromal tumor, acute myelogenous leukemia (AML) , mutant chronic myelogenous leukemia (CML) , acute lymphocytic leukemia (ALL) , leukemia, chronic lymphocytic leukemia, primary macroglobulinemia, monocytic leukemia, leukemoid reaction, aplastic anemia, purpura, secondary benign monoclonal gammopathy, semi-molecular disease, colorectal cancer, stomach cancer, breast cancer, lung cancer, liver cancer, prostate cancer, pancreatic cancer, thyroid cancer, kidney cancer, brain tumor, neck cancer, central nervous system (CNS) cancer, malignant glioma, bone marrow hyperplasia, infectious mononucleosis, malignant histiocytosis, lymphoma, non-lymphoreticular system tumor, multiple myeloma
- AML acute
- the autoimmune disease is leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, acute myelogenous leukemia (AML) , mutant chronic myelogenous leukemia (CML) , acute lymphocytic leukemia (ALL) , rheumatoid arthritis, bone and joint pain, central nervous system involvement, lupus, multiple sclerosis, thyroiditis, type I diabetes, sarcoidosis, inflammatory bowel disease, Crohn's disease, systemic lupus or AML related complication; and
- the inflammatory disease is diverticulitis, colitis, pancreatitis, hepatitis, chronic hepatitis, cirrhosis, cholecystitis or chronic inflammation.
- the compound or the pharmaceutical composition disclosed herein, wherein the disease is a disease mediated by c-KIT mutation, RET, PDGFR, VEGFR, Bcr-ABL, FLT3 or induced by FLT3-ITD.
- Stereoisomer refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers) , geometric (cis/trans) isomers, atropisomers, and the like.
- Chiral refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
- Racemate or “racemic mixture” refers to an equimolar mixture of enantiomers which lacks optical activity.
- Enantiomer refers to two stereoisomers of a compound which are non-superimposable mirror images of one another.
- Diastereomer refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties or biological activities. Mixture of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography such as HPLC.
- d and l or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or l meaning that the compound is levorotatory.
- a compound prefixed with (+) or d is dextrorotatory.
- a specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
- a 50: 50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
- any asymmetric atom (e.g., carbon or the like) of the compound (s) disclosed herein can be present in racemic or enantiomerically enriched, for example the (R) -, (S) -or (R, S) -configuration.
- each asymmetric atom has at least 50 %enantiomeric excess, at least 60 %enantiomeric excess, at least 70 %enantiomeric excess, at least 80 %enantiomeric excess, at least 90 %enantiomeric excess, at least 95 %enantiomeric excess, or at least 99 %enantiomeric excess in the (R) -or (S) -configuration.
- the compounds can be present in the form of one of the possible stereoisomers or as mixtures thereof, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms.
- Optically active (R) -and (S) -isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis-or trans-configuration.
- Any resulting mixtures of stereoisomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric isomers, enantiomers, diastereomers, for example, by chromatography and/or fractional crystallization.
- racemates of final products or intermediates can be resolved into the optical antipodes by methods known to those skilled in the art, e.g., by separation of the diastereomeric salts thereof.
- Racemic products can also be resolved by chiral chromatography, e.g., high performance liquid chromatography (HPLC) using a chiral adsorbent.
- HPLC high performance liquid chromatography
- Preferred enantiomers can also be prepared by asymmetric syntheses. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981) ; Principles of Asymmetric Synthesis (2nd Ed. Robert E. Gawley, Jeffrey Aubé, Elsevier, Oxford, UK, 2012) ; Eliel, E.
- tautomer or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier. Where tautomerization is possible (e.g. in solution) , a chemical equilibrium of tautomers can be reached.
- proton tautomers also known as prototropic tautomers
- Valence tautomers include interconversions by reorganization of some of the bonding electrons.
- keto-enol tautomerization is the interconversion of pentane-2, 4-dione and 4-hydroxypent-3-en-2-one tautomers.
- tautomerization is phenol-keto tautomerization.
- a specific example of phenol-keto tautomerization is the interconversion of pyridin-4-ol and pyridin-4 (lH) -one tautomers. Unless otherwise stated, all tautomeric forms of the compounds disclosed herein are within the scope of the invention.
- “Pharmaceutically acceptable” refers to those compounds, materials, compositions and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or with reasonable the benefit/risk ratio relative to said other problems and complications, and effective for their intended use.
- compounds disclosed herein may optionally be substituted with one or more substituents, such as the compound (s) illustrated by general formula above, or as exemplified by particular classes, subclasses, and species of the invention.
- substituted refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent.
- an optionally substituted group may have a substituent at each substitutable position of the group. When more than one position in a given structure can be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at each position.
- substituents of compounds disclosed herein are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges.
- C 1-6 alkyl is specifically intended to individually disclose methyl, ethyl, C 3 alkyl, C 4 alkyl, C 5 alkyl and C 6 alkyl.
- linking substituents are described. Where the structure clearly requires a linking group, the Markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists “alkyl” or “aryl” then it is understood that the “alkyl” or “aryl” represents a linking alkylene group or arylene group, respectively.
- alkyl refers to a saturated linear or branched-chain monovalent hydrocarbon group of 1-20 carbon atoms, wherein the alkyl group is independently and optionally substituted with one or more substituents described herein.
- the alkyl group contains 1-10 carbon atoms.
- the alkyl group contains 1-8 carbon atoms.
- the alkyl group contains 1-6 carbon atoms.
- the alkyl group contains 1-4 carbon atoms, and in yet other embodiments, the alkyl group contains 1-3 carbon atoms.
- alkyl group examples include, but are not limited to, methyl (Me, -CH 3 ) , ethyl (Et, -CH 2 CH 3 ) , n-propyl (n-Pr, -CH 2 CH 2 CH 3 ) , isopropyl (i-Pr, -CH (CH 3 ) 2 ) , n-butyl (n-Bu, -CH 2 CH 2 CH 2 CH 3 ) , 2-methylpropyl or isobutyl (i-Bu, -CH 2 CH (CH 3 ) 2 ) , 1-methylpropyl or sec-butyl (s-Bu, -CH (CH 3 ) CH 2 CH 3 ) , tert-butyl (t-Bu, -C (CH 3 ) 3 ) , n-pentyl (-CH 2 CH 2 CH 2 CH 3 ) , 2-pentyl (-CH (CH 3 ) CH 2 CH 3 )
- alkynyl refers to a linear or branched-chain monovalent hydrocarbon group of 2-12 carbon atoms, with at least one site of unsaturation, i.e., a carbon-carbon sp triple bond, wherein the alkynyl group is optionally substituted with one or more substituents described herein.
- Some non-limiting examples of the alkynyl group include ethynyl (-C ⁇ CH, or ) , propargyl (-CH 2 C ⁇ CH, or ) , and the like.
- alkenyl refers to a linear or branched-chain monovalent hydrocarbon group of 2-12 carbon atoms, with at least one site of unsaturation, i.e., a carbon-carbon sp 2 double bond, wherein the alkenyl group is optionally substituted with one or more substituents described herein, and includes groups having “cis” and “trans” orientations, or alternatively, “E” and “Z” orientations.
- alkylene and alkylene chain refer to a straight or branched divalent hydrocarbon chain consisting solely of carbon and hydrogen, containing no unsaturation and having 1-8 carbon atoms.
- alkylene group include methylene, ethylene, propylene, n-butylene, and the like.
- the alkylene chain is attached to the rest of the molecule through any two carbons within the chain.
- alkenylene or “alkenylene chain” refers to a straight or branched divalent unsaturated hydrocarbon chain consisting solely of carbon and hydrogen and having 1-8 carbon atoms, wherein the unsaturated bond exists only as a double bond and the double bond may be located between any two carbon atoms of the chain.
- alkenylene group include ethenylene, 1, 3-propenylene, 2-butenylene, and the like.
- the alkenylene chain is attached to the rest of the molecule through any two carbons within the chain.
- alkynylene or “alkynylene chain” refers to a straight or branched divalent unsaturated hydrocarbon chain consisting solely of carbon and hydrogen and having 1-8 carbon atoms, wherein the unsaturated bond exists only as a triple bond and the triple bond may be located between any two carbon atoms of the chain.
- alkynylene group include ethynylene, 1-propynylene, 2-butynylene, 1-pentynylene 3-pentynylene, and the like.
- the alkynylene chain is attached to the rest of the molecule through any two carbons within the chain.
- halogen or “halogen atom” refers to fluoro (F) , chloro (Cl) , bromo (Br) or iodo (I) .
- alkoxy refers to an alkyl group, as previously defined, attached to the the rest of molecule via an oxygen atom. Unless otherwise specified, the alkoxy group contains 1-12 carbon atoms. In some embodiments, the alkoxy group contains 1-6 carbon atoms. In other embodiments, the alkoxy group contains 1-4 carbon atoms. In still other embodiments, the alkoxy group contains 1-3 carbon atoms. Some non-limiting examples of alkoxy group include, methoxy (MeO, -OCH 3 ) , ethoxy (EtO, -OCH 2 CH 3 ) , 1-propoxy (n-PrO, n-propoxy, -OCH 2 CH 2 CH 3 ) , and the like.
- amino refers to a group having the formula -NH 2 .
- aminoalkyl refers to a group having the formula R’ R” N-alkyl, wherein each of R’and R” is independently hydrogen, alkyl or haloalkyl.
- Alkyl and amino are as defined herein. Some examples include, but are not limited to, aminoethyl, aminomethyl, aminopropyl and the like.
- alkamino or “alkylamino” refers “N-alkylamino” , wherein amino group is substituted with one alkyl group, and wherein the alkyl group is as defined herein.
- the alkylamino group is a lower alkylamino group having one C 1-6 alkyl group attached to nitrogen atom.
- the alkylamino group is a lower alkylamino group having 1 to 3 carbon atoms.
- Some non-limiting examples of the alkylamino group include monoalkylamino such as N-methylamino, N-ethylamino, and the like.
- dialkamino or “di (alkyl) amino refers “N, N-dialkylamino” , wherein amino group is substituted with two alkyl groups, and wherein the alkyl group is as defined herein.
- the alkylamino group is a lower alkylamino group having two C 1-6 alkyl groups attached to nitrogen atom.
- the alkylamino group is a lower alkylamino group having two C 1-3 alkyl groups attached to nitrogen atom.
- dialkamino or di (alkyl) amino group include dialkylamino such as N, N-dimethylamino, N, N-diethylamino, and the like.
- alkoxyalkyl or “alkoxyalkoxy” refers to an alkyl group or alkoxy group substituted with one or more identical or different alkoxy groups, wherein the alkyl group and alkoxy group are as defined herein.
- alkoxyalkyl group and alkoxyalkoxy group include methoxymethyl, ethoxymethyl, methoxypropoxy, methoxymethoxy, and the like.
- haloalkyl or “haloalkoxy” refers to an alkyl group or alkoxy group substituted with one or more identical or different halogen atoms, wherein the alkyl group and alkoxy group are as defined herein.
- haloalkyl group and haloalkoxy group include 1, 1, 1-trifluoro-2-methylprop-2-yl (-C (CH 3 ) 2 CF 3 ) , 1, 1-difluoro-2-methylprop-2-yl (-C (CH 3 ) 2 CHF 2 ) , 1-fluoro-2-methylprop-2-yl (-C (CH 3 ) 2 CH 2 F) , difluoromethyl (-CHF 2 ) , trifluoromethyl (-CF 3 ) , trifluoromethoxy (-OCF 3 ) , 2, 2, 2-trifluoroethoxy (-OCH 2 CF 3 ) , 2, 2, 3, 3-tetrafluoropropoxy (-OCH 2 CF 2 CHF 2 ) , and the like.
- alkylaminohaloalkoxy refers to a haloalkoxy group substituted with one or more identical or different alkylamino groups, wherein the alkylamino group and haloalkoxy group are as defined herein.
- alkylaminohaloalkoxy group include methylaminodifluoromethoxy, and the like.
- hydroxyalkyl or “hydroxyalkoxy” refers to an alkyl group or alkoxy group substituted with one or more hydroxy groups, wherein the alkyl group and alkoxy group are as defined herein.
- Some non-limiting examples of the hydroxyalkyl group and hydroxyalkoxy group include hydroxymethyl, 1-hydroxy-n-butyl, 2-hydroxy-n-propyl, 1-hydroxyethyl, hydroxy-tert-butyl, hydroxypropyl, 1, 2-dihydroxypropyl, hydroxymethoxy, 1-hydroxyethoxy, and the like.
- aminoalkoxy or “alkylaminoalkoxy” refers to an alkoxy group substituted with one or more amino groups or alkylamino groups, wherein the alkylamino group and alkoxy group are as defined herein.
- aminoalkoxy group and alkylaminoalkoxy group include aminomethoxy, 1-aminoethoxy, methylaminomethoxy, ethylaminoethoxy, and the like.
- aryl used alone or as part of a larger moiety as in “arylalkyl” , “arylalkoxy” or “aryloxyalkyl” refers to monocyclic, bicyclic and tricyclic carbocyclic ring systems.
- term “aryl” can be replaced by or used as “arylene” . Wherein at least one ring in the “aryl” system is aromatic, and wherein each ring in the system contains 3 to 7 ring members.
- aryl may be used interchangeably with the term “aryl ring” or “aromatic ring” .
- Some non-limiting examples of the aryl group include phenyl, naphthyl and anthracene.
- heteroaryl or “heteroaryl ring” as used interchangeably herein, used alone or as part of a larger moiety as in “heteroarylalkyl” or “heteroarylalkoxy, ” which can be replaced by or used as “heteroarylene” in some embodiments, refers to a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein the bicyclic heteroaryl, tricyclic heteroaryl or tetracyclic heteroaryl ring system is fused to form a ring.
- the heteroaryl ring system is aromatic, in which optionally one or more ring atoms are independently selected from heteroatoms (heteroatoms are selected from N, O, P and S, wherein the S or P is optionally substituted with one or more oxo to provide the group SO, SO 2 , PO or PO 2 ) .
- the heteroaryl system may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound.
- the heteroaryl system group may be a 3-7 membered monocyclic ring, a 7-10 membered bicyclic ring or a 10-15 membered tricyclic ring.
- Bicyclic heteroaryl ring having 7-10 ring atoms can be arranged as a bicyclo [4, 5] , [5, 5] , [5, 6] or [6, 6] system, and tricyclic heteroaryl ring having 10-15 ring atoms can be arranged as a tricyclo [5, 5, 6] , [5, 6, 6] or [6, 5, 6] system.
- heteroaryl system (containing hetereoaryl group, hetereoaryl ring) include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 4-methylisoxazol-5-yl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl) , 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl)
- Carbocyclyl refers to a monovalent or multitivalent, non-aromatic, saturated or partially unsaturated ring consisting solely of carbon and hydrogen atoms and including 3-12 carbon atoms as a monocyclic ring or 7-12 carbon atoms as a bicyclic ring or tricyclic ring.
- Bicyclic carbocycles having 7-12 ring atoms can be arranged, for example, as a bicyclo [4, 5] , [5, 5] , [5, 6] or [6, 6] system, and bicyclic carbocycles having 9 or 10 ring atoms can be arranged as a bicyclo [5, 6] or [6, 6] system.
- the carbocyclyl, cycloaliphatic, carbocycle or cycloalkyl group can be a monoradical or a diradical, i.e., in some embodiments, the carbocyclyl, cycloaliphatic, carbocycle or cycloalkyl group can be replaced by or used as carbocyclylene or cycloalkylene.
- cycloaliphatic group examples include cycloalkyl, cycloalkenyl and cycloalkynyl. Further examples of the cycloaliphatic group include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, adamantly, and the like.
- heterocyclyl refers to a monocyclic, bicyclic, tricyclic or tetracyclic ring system in which one or more ring members are independently selected from heteroatoms and that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic.
- the heterocyclyl, heterocycle, heterocycloaliphatic or heterocyclic group can be a monoradical or a diradical, i.e., in some embodiments, the heterocyclyl, heterocycle, heterocycloaliphatic or heterocyclic group can be replaced by or used as heterocyclylene.
- the heterocyclyl system may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound.
- One or more hydrogen atoms on the heterocyclic ring are optionally substituted with one or more substituents described herein.
- the nitrogen atoms of nitrogen-containing heterocyclic group are oxidated to form nitrogen oxide.
- the heterocyclyl may be a carbon radical or heteroatom radical.
- the heterocyclyl group also includes a group in which the heterocyclyl group is fused with a saturated or partially unsaturated ring or a heterocyclic ring.
- Some non-limiting examples of the heterocyclyl group include pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, thioxanyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, epoxypropyl, azepanyl, oxepanyl, thiepanyl, N-morpholinyl, 2-morpholinyl, 3-morpholinyl, thiomorpholinyl, N-piperazinyl, 2-piperazinyl, 3-
- fused bicyclic refers to a saturated or unsaturated fused ring system, which refers to a bicyclic ring system that is not aromatic and includes at least one non-aromatic ring. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon) .
- Each cyclic ring in the fused bicyclyl can be either a carbocyclic ring or a heteroalicyclic ring.
- fused bicyclic ring system examples include hexahydro-furo [3, 2-b] furanyl, 2, 3, 3a, 4, 7, 7a-hexahydro-1H-indenyl, 7-azabicyclo [2.2.1] heptyl, fused bicyclo [3.3.0] octyl, fused bicyclo [3.1.0] hexyl, 1, 2, 3, 4, 4a, 5, 8, 8a-octahydronaphthyl, and the like.
- fused heterobicyclyl refers to saturated or unsaturated fused ring system, which refers to a bicyclic ring system that is not aromatic and includes at least one non-aromatic ring. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon) .
- the fused heterobicyclyl group can be a monoradical or a diradical, i.e., in some embodiments, the fused heterobicyclyl group can be replaced by or used as fused heterobicyclylene. And at least one ring in the fused ring system contains one or more heteroatoms.
- fused heterobicyclyl group examples include hexahydro-2H- [1, 4] dioxin [2, 3-c] pyrrolyl, 3-azabicyclo [3.3.0] octyl, 8-azabicyclo [4.3.0] nonyl, 8-azabicyclo [4.3.0] non-3-yl, 3-azabicyclo [4.3.0] non-3-yl, 1, 5-dioxa-8-azabicyclo [4.3.0] nonyl, (1R, 6S) -2, 5-dioxa-8-azabicyclo [4.3.0] nonyl, (1R, 6R) -2, 5-dioxa-8-azabicyclo [4.3.0] nonyl, isoindolinyl, 1, 2, 3, 4-tetrahydroquinolyl, 3-aza-7-oxabicyclo [3.3.0] octyl, 3, 7-diazabicyclo [3.3.0] octyl, 2,
- bridged bicyclyl refers to a saturated or unsaturated bridged ring system, which refers to a bicyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon) , in which each ring contains 3 to 7 ring members.
- Some non-limiting examples of the bridged bicyclyl group include bicyclo [2.2.1] heptyl, and the like.
- bridged heterobicyclyl refers to saturated or unsaturated bridged ring system, which refers to a bicyclic ring system that is not aromatic.
- the bridged heterobicyclyl group can be a monoradical or a diradical, i.e., in some embodiments, the bridged heterobicyclyl group can be replaced by or used as fused heterobicyclylene.
- Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon) . And at least one ring in the bridged ring system contains one or more heteroatoms.
- bridged heterobicyclyl group examples include 2-oxa-5-azabicyclo [2.2.1] heptyl, 2-thio-5-azabicyclo [2.2.1] heptyl, 2-oxo-5-azabicyclo [2.2.1] heptyl, 2, 5-diazabicyclo [2.2.1] heptyl, and the like.
- cycloalkylalkyl refers to an alkyl group substituted with one or more cycloalkyl groups, wherein the alkyl group and cycloalkyl group are as defined herein.
- Some non-limiting examples of the cycloalkylalkyl group include cyclopropylmethyl, cyclohexylmethyl, cyclohexylethyl, and the like.
- heterocyclylalkyl refers to an alkyl group substituted with one or more heterocyclyl groups, wherein the alkyl and heterocyclyl group are as defined herein.
- Some non-limiting examples of the heterocyclylalkyl group include oxiranylmethyl, morpholinylmethyl, piperidylethyl, and the like.
- cycloalkyloxy refers to an optionally substituted cycloalkyl or carbocyclyl group, as defined herein, attached to an oxygen atom, wherein the oxygen atom serves as the attaching point to the rest of the molecule.
- cycloalkyloxy group include cyclopropyloxy, cyclopentyloxy, cyclohexyloxy, hydroxy-substituted cyclopropyloxy, and the like.
- heterocyclylalkylaryl refers to an aryl group substituted with one or more heterocyclylalkyl groups, wherein the aryl and heterocyclylalkyl are as defined herein.
- heterocyclylalkylaryl group include, but are not limited to, N- (4-methylpiperazinyl) -methyl- (3-trifluoromethyl) phenyl, piperazinyl-methyl-phenyl, and the like.
- heterocyclylalkylheteroaryl refers to a hereoaryl group substituted with one or more heterocyclylalkyl groups, wherein the heteroaryl and heterocyclylalkyl are as defined herein.
- heterocyclylalkylheteroaryl group include, but are not limited to, N- (4-methylpiperazinyl) -methyl- (3-trifluoromethyl) pyridyl, piperazinyl-methyl-pyridyl, and the like.
- cycloalkylamino refers to an amino group substituted with one or two cycloalkyl groups, wherein the cycloalkyl group is as defined herein.
- Some non-limiting examples of the cycloalkylamino group include cyclopropylamino, cyclopentylamino, cyclohexylamino, hydroxy-substituted cyclopropylamino, dicyclohexylamino, dicyclopropylamino, and the like.
- arylalkoxy refers to an alkoxy group substituted with one or more aryl groups, wherein the aryl group and alkoxy group are as defined herein.
- arylalkoxy group include phenylmethoxy, phenylethoxy, (p-tolyl) methoxy, phenylpropoxy, and the like.
- arylalkylamino refers to an alkylamino group substituted with one or more aryl groups, wherein the aryl group and alkylamino group are as defined herein.
- arylalkylamino group include phenylmethylamino, phenylethylamino, phenylpropylamino, (p-tolyl) methylamino, and the like.
- heteroarylalkoxy refers to an alkoxy group substituted with one or more heteroaryl groups, wherein the heteroaryl group and alkoxy group are as defined herein.
- Some non-limiting examples of the heteroarylalkoxy group include pyridin-2-ylmethoxy, thiazol-2-yl-ethoxy, imidazol-2-ylethoxy, pyrimidin-2-ylpropoxy, pyrimidin-2-ylmethoxy, and the like.
- heteroarylalkylamino refers to a heteroarylalkyl group which contains a nitrogen atom attached to other groups via the nitrogen atom, wherein the heteroarylalkyl group is as defined herein.
- the heteroarylalkylamino group include pyridin-2-ylmethylamino, thiazol-2-ylethylamino, imidazol-2-ylethylamino, pyrimidin-2-ylpropylamino, pyrimidin-2-ylmethylamino, and the like.
- heterocyclylalkoxy refers to a heterocyclyl-substituted alkoxy group, wherein the oxygen atom serves as the attaching point to the rest of the molecule
- heterocyclylalkylamino refers to a heterocyclyl-substituted alkylamino group, wherein the nitrogen atom serves as the attaching point to the rest of the molecule.
- heterocyclyl, alkoxy and alkylamino group are as defined herein.
- heterocyclylalkoxy group and heterocyclylalkylamino group include morpholin-4-ylethoxy, piperazin-4-ylethoxy, piperidin-4-ylethylamino, and the like.
- cycloalkylalkoxy or “carbocyclylalkoxy” refers to an alkoxy group substituted with one or more cycloalkyl or carbocyclyl groups, wherein the cycloalkyl or carbocyclyl group and alkoxy group are as defined herein.
- Some non-limiting examples of the cycloalkylalkoxy group or carbocyclylalkoxy group include cyclopropylmethoxy, cyclopropylethoxy, cyclopentylethoxy, cyclohexylethoxy, cyclohexylmethoxy, cyclopropylpropoxy, and the like.
- cycloalkylalkylamino or “carbocyclylalkylamino” refers to an alkylamino group substituted with one or more cycloalkyl or carbocyclyl groups, wherein the cycloalkyl or carbocyclyl group and alkylamino group are as defined herein.
- cycloalkylalkylamino group or carbocyclylalkylamino examples include cyclopropylmethylamino, cyclopropylethylamino, cyclopentylethylamino, cyclohexylethylamino, cyclohexylmethylamino, cyclopropylpropylamino, and the like.
- aryloxyalkoxy refers to an alkoxy group substituted with one or more aryloxy groups, wherein the alkoxy group and aryloxy group are as defined herein.
- aryloxyalkoxy group include phenyloxymethoxy, phenyloxyethoxy, phenyloxypropoxy, and the like.
- heteroaryloxyalkoxy refers to an alkoxy group substituted with one or more heteroaryloxy groups, wherein the alkoxy group and heteroaryloxy group are as defined herein.
- Some non-limiting examples of the heteroaryloxyalkoxy group include pyridinyloxymethoxy, pyrimidinyloxyethoxy, thiazolyloxypropoxy, and the like.
- aromaticity refers to an optionally substituted aryl group, as defined herein, attached to an oxygen atom, wherein the oxygen atom serves as the attaching point to the rest of the molecule.
- aryloxy group include phenyloxy, methylphenyloxy, ethylphenyloxy, and the like.
- heteroaryloxy refers to an optionally substituted heteroaryl group, as defined herein, attached to an oxygen atom, wherein the oxygen atom serves as the attaching point to the rest of the molecule.
- the heteroaryloxy group include pyrid-2-yloxy, thiazol-2-yloxy, imidazol-2-yloxy, pyrimidin-2-yloxy, and the like.
- heterocyclyloxyalkoxy refers to an alkoxy group substituted with one or more heterocyclyloxy groups, wherein the alkoxy group and heterocyclyloxy group are as defined herein.
- Some non-limiting examples of the heterocyclyloxyalkoxy group include pyrrol-2-yloxymethoxy, pyrrol-3-yloxyethoxy, piperidin-2-yloxyethoxy, piperidin-3-yloxyethoxy, piperazin-2-yloxymethoxy, piperidin-4-yloxyethoxy, and the like.
- carbocyclyloxyalkoxy refers to an alkoxy group substituted with one or more carbocyclyloxy groups, wherein the alkoxy group and carbocyclyloxy group are as defined herein.
- carbocyclyloxyalkoxy group include cyclopropyloxymethoxy, cyclopropyloxyethoxy, cyclopentyloxyethoxy, cyclohexyloxyethoxy, cyclohexen-3-yloxyethoxy, and the like.
- heterocyclyloxy refers to an optionally substituted heterocyclyl group, as defined herein, attached to an oxygen atom, wherein the oxygen atom serves as the attaching point to the rest of the molecule.
- the heterocyclyloxy group include pyrrol-2-yloxy, pyrrol-3-yloxy, piperidin-2-yloxy, piperidin-3-yloxy, piperazin-2-yloxy, piperidin-4-yloxy, and the like.
- fused bicyclyloxy refers to an optionally substituted fused bicyclyl group, as defined herein, attached to an oxygen atom, wherein the oxygen atom serves as the attaching point to the rest of the molecule.
- fused bicyclyloxy group include 1, 2, 3, 4, 4a, 5, 8, 8a-octahydronaphthyloxy, fused bicyclo [3.3.0] oct-2-yloxy, fused bicyclo [3.1.0] hex-2-yloxy, and the like.
- fused heterobicyclyloxy refers to an optionally substituted fused heterobicyclyl group, as defined herein, attached to an oxygen atom, wherein the oxygen atom serves as the attaching point to the rest of the molecule.
- fused heterobicyclyloxy group include hexahydro-furo [3, 2-b] furan-2-yloxy, 7-azabicyclo [2.3.0] hept-2-yloxy, 7-azabicyclo [2.3.0] hept-4-yloxy, and the like.
- fused bicyclylamino refers to an amino group substituted with one or two fused bicyclyl groups, wherein the fused bicyclyl group is as defined herein.
- fused bicyclylamino group include 1, 2, 3, 4, 4a, 5, 8, 8a-octahydronaphthylamino, di (1, 2, 3, 4, 4a, 5, 8, 8a-octahydronaphthyl) amino, fused bicyclo [3.3.0] octylamino, fused bicyclo [3.1.0] hexylamino, and the like.
- fused heterobicyclylamino refers to an amino group substituted with one or two fused heterobicyclyl groups, wherein the fused heterobicyclyl group is as defined herein.
- fused heterobicyclylamino group include hexahydro-furo [3, 2-b] furan-2-ylamino, 7-azabicyclo [2.3.0] hept-2-ylamino, 7-azabicyclo [2.3.0] hept-4-ylamino, and the like.
- fused bicyclylalkylamino refers to an alkylamino group substituted with one or two fused bicyclyl groups, wherein the fused bicyclyl group is as defined herein.
- fused bicyclylalkylamino group include 1, 2, 3, 4, 4a, 5, 8, 8a-octahydronaphthylmethylamino, di (1, 2, 3, 4, 4a, 5, 8, 8a-octahydronaphthyl) methylamino, fused bicyclo [3.3.0] octylmethylamino, fused bicyclo [3.1.0] hexylmethylamino, and the like.
- fused heterobicyclylalkylamino refers to an alkylamino group substituted with one or two fused heterobicyclyl groups, wherein the fused heterobicyclyl group is as defined herein.
- fused heterobicyclylalkylamino group include hexahydro-furo [3, 2-b] furan-2-ylmethylamino, 7-azabicyclo [2.3.0] hept-2-ylmethylamino, 7-azabicyclo [2.3.0] hept-4-ylmethylamino, and the like.
- fused bicyclylalkoxy refers to an alkoxy group substituted with one or more fused bicyclyl groups, wherein the alkoxy group and fused bicyclyl group are as defined herein.
- fused bicyclylalkoxy include 1, 2, 3, 4, 4a, 5, 8, 8a-octahydronaphthylmethoxy, 1, 2, 3, 4, 4a, 5, 8, 8a-octahydronaphthylethoxy, fused bicyclo [3.3.0] octylethoxy, fused bicyclo [3.1.0] hexylpropoxy, and the like.
- fused heterobicyclylalkoxy refers to an alkoxy group substituted with one or more fused heterobicyclyl groups, wherein the alkoxy group and fused heterobicyclyl group are as defined herein.
- fused heterobicyclylalkoxy group include hexahydro-furo [3, 2-b] furan-2-ylpropoxy, 7-azabicyclo [2.2.1] hept-2-ylethoxy, 7-azabicyclo [2.3.0] hept-4-ylpropoxy, hexahydro-furo [3, 2-b] furan-2-ylethoxy, 7-azabicyclo [2.3.0] hept-2-ylpropoxy, 7-azabicyclo [2.3.0] hept-4-ylethoxy, and the like.
- fused bicyclylalkyl refers to an alkyl group substituted with one or more fused bicyclyl groups, wherein the alkyl group and fused bicyclyl group are as defined herein.
- fused bicyclylalkyl group include 1, 2, 3, 4, 4a, 5, 8, 8a-octahydronaphthylmethyl, 1, 2, 3, 4, 4a, 5, 8, 8a-octahydronaphthylethyl, fused bicyclo [3.3.0] octylethyl, fused bicyclo [3.1.0] hexylpropyl, and the like.
- fused heterobicyclylalkyl refers to an alkyl group substituted with one or more fused heterobicyclyl groups, wherein the alkyl group and fused heterobicyclyl group are as defined herein.
- fused heterobicyclylalkyl group include hexahydro-furo [3, 2-b] furan-2-ylpropyl, 7-azabicyclo [2.2.1] hept-2-ylethyl, 7-azabicyclo [2.3.0] hept-4-ylpropyl, hexahydro-furo [3, 2-b] furan-2-ylethyl, 7-azabicyclo [2.3.0] hept-2-ylpropyl, 7-azabicyclo [2.3.0] hept-4-ylethyl, and the like.
- fused heterobicyclyloxyalkoxy refers to an alkoxy group substituted with one or more fused heterobicyclyloxy groups, wherein the alkoxy group and fused heterobicyclyloxy group are as defined herein.
- fused heterobicyclyloxyalkoxy group examples include hexahydro-furo [3, 2-b] furan-2-yloxypropoxy, 7-azabicyclo [2.2.1] hept-2-yloxyethoxy, 7-azabicyclo [2.3.0] hept-4-yloxypropoxy, hexahydro-furo [3, 2-b] furan-2-yloxyethoxy, 7-azabicyclo [2.3.0] hept-2-yloxypropoxy, 7-azabicyclo [2.3.0] hept-4-yloxyethoxy, and the like.
- fused heterobicyclyloxyalkylamino refers to an alkylamino group substituted with one or more fused heterobicyclyloxy groups, wherein the alkylamino group and fused heterobicyclyloxy group are as defined herein.
- fused heterobicyclyloxyalkylamino group examples include hexahydro-furo [3, 2-b] furan-2-yloxypropylamino, 7-azabicyclo [2.2.1] hept-2-yloxyethylamino, 7-azabicyclo [2.3.0] hept-4-yloxypropylamino, hexahydro-furo [3, 2-b] furan-2-yloxyethylamino, 7-azabicyclo [2.3.0] hept-2-yloxypropylamino, 7-azabicyclo [2.3.0] hept-4-yloxyethylamino, and the like.
- bridged heterobicyclylalkoxy refers to an alkoxy group substituted with one or more bridged heterobicyclyl groups, wherein the bridged heterobicyclyl group and alkoxy group are as defined herein.
- Some non-limiting examples of the bridged heterobicyclylalkoxy group include 2-oxa-5-azabicyclo [2.2.1] heptylmethoxy, 2, 5-diazabicyclo [2.2.1] heptylethoxy, 2-methyl-2, 5-diazabicyclo [2.2.1] heptylpropoxy, and the like.
- bridged heterobicyclylalkyl refers to an alkyl group substituted with one or more bridged heterobicyclyl groups, wherein the bridged heterobicyclyl group and alkyl group are as defined herein.
- Some non-limiting examples of the bridged heterobicyclylalkyl group include 2-oxa-5-azabicyclo [2.2.1] heptylmethyl, 2, 5-diazabicyclo [2.2.1] heptylethyl, 2-methyl-2, 5-diazabicyclo [2.2.1] heptylpropyl, and the like.
- bridged heterobicyclylalkylamino refers to an alkylamino group substituted with one or more bridged heterobicyclyl groups, wherein the bridged heterobicyclyl group and alkylamino group are as defined herein.
- Some non-limiting examples of the bridged heterobicyclylalkylamino group include 2-oxa-5-azabicyclo [2.2.1] heptylmethylamino, 2, 5-diazabicyclo [2.2.1] heptylethylamino, 2-methyl-2, 5-diazabicyclo [2.2.1] heptylpropylamino, and the like.
- bridged heterobicyclyloxy refers to an optionally substituted bridged heterobicyclyl group, as defined herein, attached to an oxygen atom, wherein the oxygen atom serves as the attaching point to the rest of the molecule.
- Some non-limiting examples of the bridged heterobicyclyloxy group include 2-methyl-2, 5-diazabicyclo [2.2.1] heptyloxy, 2, 5-diazabicyclo [2.2.1] heptyloxy, and the like.
- arylalkyl refers to an alkyl group substituted with one or more aryl groups, wherein the alkyl group and aryl group are as defined herein.
- arylalkyl group include phenylethyl, phenylmethyl, (p-tolyl) ethyl, and the like.
- heteroarylalkyl refers to an alkyl group substituted with one or more heteroaryl groups, wherein the alkyl group and heteroaryl group are as defined herein.
- heteroarylalkyl group include pyrid-2-ylethyl, thiazol-2-ylmethyl, imidazol-2-ylethyl, pyrimidin-2-ylpropyl, and the like.
- alkylthio refers to a group in which a linear or branched alkyl group of one to ten carbon atoms is attached to a divalent sulfur atom, wherein the alkyl group is as defined herein.
- the alkylthio group is lower alkylthio group having one to three carbon atoms.
- Some non-limiting examples of the alkylthio group include methylthio (CH 3 S-) , ethylthio, and the like.
- spirocyclyl refers to a ring originating from a particular annular carbon of another ring.
- a saturated bridged ring system (ring B and B’ ) is termed as “fused bicyclic”
- ring A’and ring B share an atom between the two saturated ring system, which terms as a “spirocyclyl” or “spiro bicyclyl” .
- Each cyclic ring in a spirocyclyl can be either a carbocyclic or a heteroalicyclic.
- the spirocyclyl, spirocyclic, spiro bicyclyl or spiro bicyclic group may be a monoradical or a diradical. i.e., in some embodiments, the spirocyclyl, spirocyclic, spiro bicyclyl or spiro bicyclic group can be replaced by or used as spirocyclylene.
- the spiro bicyclyl group include spiro [2.4] hept-5-yl, spiro [4.4] nonyl, and the like.
- spiro heterobicyclyl refers to a ring originating from a particular annular carbon of another ring.
- a saturated bridged ring system (ring B and B’ ) is termed as “fused bicyclic”
- ring A’and ring B share an atom between the two saturated ring system, which terms as a “spirocyclyl” or “spiro bicyclyl” .
- the spiro heterobicyclyl group may be a monoradical or a diradical.
- the spiro heterobicyclyl group can be replaced by or used as spiro heterobicyclylene.
- spiro heterobicyclyl group examples include 4-aza-spiro [2.4] hept-5-yl, 4-oxa-spiro [2.4] hept-5-yl, 5-aza-spiro [2.4] hept-5-yl, 7-hydroxy-5-azaspiro [2.4] hept-5-yl, 2-aza-spiro [4.5] decyl, 2-aza-spiro [3.3] heptyl, 2-aza-spiro [4.4] nonyl, 2-methyl-2, 6-diaza-spiro [4.5] decyl, 3-aza-spiro [5.4] decyl, and the like.
- spiro heterobicyclylalkoxy refers to an alkoxy group substituted with one or more spiro heterobicyclyl groups, wherein the spiro heterobicyclyl group and alkoxy group are as defined herein.
- Some non-limiting examples of the spiro heterobicyclylalkoxy group include 4-aza-spiro [2.4] hept-5-yl-methoxy, 4-aza-spiro [2.4] heptan-2-yl-ethoxy, 4-oxa-spiro [2.4] hept-5-yl-ethoxy, 5-aza-spiro [2.4] hept-5-yl-propoxy, and the like.
- spiro heterobicyclylalkyl refers to an alkyl group substituted with one or more spiro heterobicyclyl groups, wherein the spiro heterobicyclyl group and alkyl group are as defined herein.
- Some non-limiting examples of the spiro heterobicyclylalkyl group include 4-aza-spiro [2.4] hept-5-yl-methyl, 4-aza-spiro [2.4] heptan-2-yl-ethyl, 4-oxa-spiro [2.4] hept-5-yl-ethyl, 5-aza-spiro [2.4] hept-5-yl-propyl, and the like.
- Anti-proliferative agent refers to anti-metabolites (e.g., 5-fluoro-uracil, methotrexate and fludarabine) , antimicrotubule agents (e.g., vinca alkaloids such as vincristine and vinblastine, taxanes such as paclitaxel and docetaxel) , alkylating agents (e.g., cyclophosphamide, melphalan, carmustine and nitrosoureas such as bischloroethylnitrosourea and hydroxyurea) , platinum agents (e.g., cisplatin, carboplatin, oxaliplatin, JM-216 and Cl-973) , anthracyclines (e.g., doxorubicin and daunorubicin) , antitumor antibiotics (e.g., mitomycin, idarubicin, doxorubicin and daunorubicin) , topo
- a bond drawn from a substituent R to the center of one ring within a ring system represents substitution of the substituent R at any substitutable or reasonable position on the ring.
- Formula a represents possible substitution of the substituent R in any of the position on ring D or ring B, as shown in Formula b, Formula c, Formula d, Formula e, Formula f, Formula g and Formula h.
- a bond drawn from a substituent (R) n to the center of one ring within a ring system represents substitution of n substituents R at any substitutable position on the rings.
- Formula i represents possible substitution of n substituents R in any of the position on ring D or ring B.
- two attachment points within a ring system C can attach to the rest of the molecule, for example, either E” or E’ on ring C as shown in Formula j, can attach to the rest of the molecule and can be used interchangeably with each other.
- the attachment point can attach to the rest of the molecule at any attachable position on the rings.
- Formula k represents attaching at any attachable position on ring D or ring B.
- the attachment points can attach to the rest of the molecule at any attachable position on the rings, meanwhile, the two attachment points can be used interchangeably with each other.
- Formula m represents attaching at any attachable position on the rings, and the two attachment points can be used interchangeably with each other.
- a specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
- a 50: 50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
- the term “racemic mixture” or “racemate” refers to an equimolar mixture of two enantiomeric species, devoid of optical activity.
- a “hydrate” refers to a compound disclosed herein or a salt thereof, which further includes a stoichiometric or non-stoichiometeric amount of water bound by non-covalent intermolecular forces, and also refers to the complex where the solvent molecule is water.
- a “solvate” refers to an association or complex of one or more solvent molecules and a compound disclosed herein.
- Some non-limiting examples of the solvent that form solvates include water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid and ethanolamine.
- hydrate can be used when said solvent is water.
- one solvent molecule is associated with one molecule of the compounds disclosed herein, such as a hydrate.
- more than one solvent molecule may be associated with one molecule of the compounds disclosed herein, such as a dihydrate.
- less than one solvent molecule may be associated with one molecule of the compounds disclosed herein, such as a hemihydrate.
- all the solvates of the invention retain the biological effectiveness of the non-hydrate form of the compounds disclosed herein.
- esters refers to an in vivo hydrolysable ester of a compound of the Formula (I) to (VIII) containing hydroxy group, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent alcohol.
- in vivo hydrolysable ester forming from a compound of the Formula (I) to (VIII) containing hydroxy group include, phosphate, acetoxymethoxy, 2, 2-dimethylpropionyloxymethoxy, alkanoyl, benzoyl, phenylacetyl, alkoxycarbonyl, dialkylcarbamoyl, N- (dialkylaminoethyl) -N-alkylcarbamoyl, and the like.
- N-oxide refers to one or more than one nitrogen atoms oxidized to form an N-oxide, where a compound contains several amine functional groups.
- Particular examples of N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle.
- N-oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a per-acid (e.g. a peroxycarboxylic acid, peroxosulfuric acid) (See, Advanced Organic Chemistiy, by Jerry March, 4th Edition, Wiley Interscience, pages) . More particularly, N-oxides can be made by the procedure of L. W.
- the amine compound of the present invention can be N-oxidized to form the correspounding N-oxide, such as the synthsis of 4- (3- (4- ( (4- (3- (5- (1-hydroxy-2-methylpropan-2-yl) isoxazol-3-yl) ureido) phenyl) ethynyl) phenoxy) propyl) morpholine 4-oxide as described in example 88.
- prodrug refers to a compound that is transformed in vivo into a compound of Formula (I) to (VIII) . Such a transformation can be affected, for example, by hydrolysis of the prodrug form in blood or enzymatic transformation of the prodrug form in blood or tissue to the parent form.
- Prodrugs of the compounds disclosed herein may be, for example, esters. Some common esters which have been utilized as prodrugs are phenyl esters, aliphatic (C 1 -C 24 ) esters, acyloxymethyl esters, carbonates, carbamates and amino acid esters. For example, a compound disclosed herein that contains a hydroxy group may be acylated at this position in its prodrug form.
- prodrug forms include phosphates such as those phosphate compounds derived from the phosphonation of a hydroxy group on the parent compound.
- phosphates such as those phosphate compounds derived from the phosphonation of a hydroxy group on the parent compound.
- a thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A. C. S. Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, J. Rautio et al., Prodrugs: Design and Clinical Applications, Nature Review Drug Discovery, 2008, 7, 255-270, and S. J. Hecker et al., Prodrugs of Phosphates and Phosphonates, Journal of Medicinal Chemistry, 2008, 51, 2328-2345, all of which are incorporated herein by reference in their entireties.
- a “metabolite” is a product produced through metabolism in the body of a specified compound or salt thereof.
- the metabolite of a compound may be identified using routine techniques known in the art and their activities determined using tests such as those described herein. Such products may result for example from the oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound.
- the invention includes metabolites of compounds disclosed herein, including metabolites produced by contacting a compound disclosed herein with a mammal for a sufficient time period.
- compositions may be prepared from the active ingredients in combination with pharmaceutically acceptable carriers.
- a “pharmaceutically acceptable salts” refers to organic or inorganic salts of a compound disclosed herein.
- Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmacol Sci, 1977, 66: 1-19, which is incorporated herein by reference.
- Some non-limiting examples of pharmaceutically acceptable and nontoxic salts include salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid and malonic acid or by using other methods used in the art such as ion exchange.
- salts include adipate, 2-hydroxy propionate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, laurylsulfate, malate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, palmitate, pamoate, pectinate, persulfate, 3-
- Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts.
- This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oilsoluble or dispersable products may be obtained by such quaternization.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, C 1-8 sulfonate or aryl sulfonate.
- Amine salts include, but are not limited to, N, N’ -dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamine, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1-para-chlorobenzyl-2-pyrrolidin-1’ -ylmethylbenzimidazole, diethylamine and other alkylamine, piperazine and tris (hydroxymethyl) aminomethane.
- Alkali earth metal salts include, but are not limited to, barium, calcium and magnesium. Transition metal salts include, but are not limited to, zinc.
- protecting group refers to a substituent that is commonly employed to block or protect a particular functionality while reacting with other functional groups on the compound.
- an “amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound.
- suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (Boc) , benzyloxycarbonyl (Cbz) and 9-fluorenylmethyloxycarbonyl (Fmoc) .
- a “hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality.
- suitable hydroxy-protecting groups include acetyl and silyl.
- a “carboxy-protecting group” refers to a substituent of the carboxy group that blocks or protects the carboxy functionality.
- Some non-limiting examples of the carboxy-protecting group include -CH 2 CH 2 SO 2 Ph, cyanoethyl, 2- (trimethylsilyl) ethyl, 2- (trimethylsilyl) ethoxymethyl, 2- (p-toluenesulfonyl) ethyl, 2- (p-nitrophenylsulfonyl) ethyl, 2- (diphenylphosphino) ethyl, nitroethyl, and the like.
- the structure preferably controls.
- treatment refers to the disease or disorder (i.e., slowing or arresting the development of or alleviate the disease or at least one of the clinical symptoms) .
- “treating” refers to alleviation or amelioration of at least one physical parameter, including physical parameters of the patient may not be perceived.
- “treating” means from the body (e.g., stabilization of a discernible symptom) or physiologically (e.g., stabilization of a physical parameter) or both said modulating the disease or disorder.
- “treating” refers to preventing or delaying the onset of the disease or disorder, the onset or worsening.
- prevent refers to a reduction in risk of acquiring a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop in a subject that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease) .
- substituted urea derivatives and pharmaceutical compositions thereof used for drug therapy and a series of substituted urea compounds used for modulating the activities of Abl and FLT3 kinases and for inhibiting FLT3-ITD, and the uses thereof as therapeutic agents for the treatment of diseases mediated by Abl, FLT3 or induced by FLT3-ITD.
- the novel substituted urea derivatives may be used for preventing or treating the diseases induced by abnormal cell proliferation.
- the disorders induced by the abnormal cell proliferation are selected from the group consisting of stomach cancer, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, tuberous sclerosis, uterine cancer, cervical cancer , head and neck cancer, esophageal cancer, thyroid cancer, parathyroid cancer, renal cell carcinoma, osteosarcoma, prostate cancer, urinary tract cancer, bladder cancer, blood cancer, lymphoma, psoriasis and fibroadenoma.
- Blood cancer is selected from the group consisting of leukemia, multiple myeloma and myelodysplastic syndrome.
- Lymphoma is Hodgkin's disease or non-Hodgkin's lymphoma.
- substituted urea derivatives having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each of ring A and ring E is independently C 6-10 aryl or C 1-12 heteroaryl;
- each J is -G- (CH 2 ) n -R 2 ;
- each R 3 and R 3a is independently C 1-4 alkyl, C 3-10 cycloalkyl, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl;
- each R 4 is independently H, C 1-4 alkyl, C 3-10 cycloalkyl, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl;
- ring K is 5-to 6-membered heteroaryl
- each a and e is independently 0, 1, 2, 3 or 4;
- each n, d and b is independently 1, 2, 3 or 4;
- each t is independently 0, 1 or 2;
- each R 3b and R 3c is independently H, F, Cl, Br, cyano, nitro, hydroxy, mercapto, amino, carboxy, C 1-4 alkyl, C 1-4 haloalkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl.
- ring A is C 6-10 aryl or C 1-12 heteroaryl.
- ring Eis C 6-10 aryl or C 1-12 heteroaryl.
- each J is -G- (CH 2 ) n -R 2 .
- each R 3 and R 3a is independently C 1-4 alkyl, C 3-10 cycloalkyl, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl;
- each R 4 , t and n is as defined herein.
- eachR 4 is independently H, C 1-4 alkyl, C 3-10 cycloalkyl, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl.
- ring K is 5-to 6-membered heteroaryl.
- each a is independently 0, 1, 2, 3 or 4.
- each e is independently 0, 1, 2, 3 or 4.
- each n is independently 1, 2, 3 or 4.
- each d is independently 1, 2, 3 or 4.
- each b is independently 1, 2, 3 or 4.
- each t is independently 0, 1 or 2.
- each R 3b and R 3c is independently H, F, Cl, Br, cyano, nitro, hydroxy, mercapto, amino, carboxy, C 1-4 alkyl, C 1-4 haloalkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl.
- each R 3b and R 3c is as defined herein.
- urea derivatives having Formula (IIa) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- R 0 is C 2-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl
- each ring A, ring E, R 1 , R 1a , e, b, a and J is as defined herein.
- R 0 is C 2-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl.
- urea derivatives having Formula (II) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each ring A, ring E, R 1 , R 1a , e, b, a and J is as defined herein.
- ring A is one of the following sub-formulae:
- each X, Y, Z, Z 1 , Z 2 , Z 3 and Z 4 is independently N or CH;
- each T, T 1 and T 2 is independently -O-, -S-, -N (R 4 ) -or -CH 2 -;
- each R 4 is as defined herein.
- ring E is one of the following sub-formulae:
- each X, Y, Z, Z 1 , Z 2 , Z 3 and Z 4 is independently N or CH;
- each T, T 1 and T 2 is independently -O-, -S-, -N (R 4 ) -or -CH 2 -;
- each R 4 is as defined herein.
- each R 1 and R 1a is independently H, F, Cl, Br, cyano, nitro, hydroxy, mercapto, amino, carboxy, C 1-4 alkyl, C 1-4 haloalkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 1-4 alkylamino, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl.
- ring A is one of the following sub-formulae:
- ring E is one of the following sub-formulae:
- each R 1 and R 1a is independently H, F, Cl, Br, trifluoromethyl, chloroethyl, trifluoroethyl, methyl, ethyl, propyl, isopropyl, dimethylamino, methylamino, diethylamino, ethylamino, hydroxy, cyano, nitro, methoxy, ethoxy, propoxy, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl.
- each R 3 , R 3a and R 2a is as defined herein.
- each R 3b and R 3c is independently H, F, Cl, Br, cyano, nitro, hydroxy, mercapto, amino, carboxy, C 1-4 alkyl, C 1-4 haloalkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 2-10 heterocyclyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl.
- each R 3 and R 3a is independently C 1-4 alkyl, C 3-10 cycloalkyl, C 2-10 heterocycloalkyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl.
- each R 2 is independently -NR 3 R 3a , C 1-4 alkoxy-C 1-4 -alkyl, C 1-4 alkyl or C 1-4 hydroxyalkyl, or each R 2 is independently one of the following sub-formulae:
- each X 6 , X 7 , X 8 and X 9 is independently N or CH;
- each q, m, p and r is independently 0, 1, 2, 3 or 4;
- each t is independently 0, 1 or 2;
- each R 2 is independently substituted with one or more R 2a which are the same or different;
- each R 4b , R 4a , R 3 , R 3a , R 3b , R 3c and R 2a is as defined herein.
- each R 4a is independently H, C 1-4 alkyl, C 3-10 cycloalkyl, C 2-10 heterocycloalkyl, C 1-6 alkoxy-C 1-6 -alkyl, or C 1-4 hydroxyalkyl.
- each R 3b and R 3c is as defined herein.
- each R 2 is independently one of the following sub-formulae:
- each sub-formula represented by R 2 is independently substituted with one or more R 2a which are the same or different;
- each n and R 2a is as defined herein.
- each R 3 and R 3a is independently methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, C 2-10 heterocycloalkyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl.
- each R 4 and R 4a is independently H, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, C 2-10 heterocycloalkyl, C 1-6 alkoxy-C 1-6 -alkyl or C 1-4 hydroxyalkyl.
- each R 3b , R 3c , n and R 2a is as defined herein.
- t is as defined herein.
- ring K is
- substituted urea derivatives having Formula (IIIa) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- R 0 is C 2-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl
- each ring E, R 1a , R 1 , J, e, a and b is as defined herein.
- substituted urea derivatives having Formula (III) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each ring E, R 1a , R 1 , J, e, a and b is as defined herein.
- substituted urea derivatives having Formula (IIIb) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- R 00 is methyl, C 2-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl
- each ring E, R 1a , R 1 , R 2 , e, a and n is as defined herein.
- substituted urea derivatives having Formula Formula (IV) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each R 1a , R 1 , J, e, a and b is as defined herein.
- substituted urea derivatives having Formula (V) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each R 1a , R 1 , J, e, a and b is as defined herein;
- each of X, Y, Z, Z 1 , Z 3 and Z 4 is independently N or CH.
- substituted urea derivatives having Formula (VI) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each ring A, R 1a , R 1 , J, e, a and b is as defined herein.
- urea derivatives havingFormula (VIIa) , or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- each R 1a , R 1 , J, e, a and b is as defined herein;
- R 00 is methyl, C 2-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl.
- substituted urea derivative having one of the following structures, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- substituted urea derivative having one of the following structures, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- provided herein is theuse of the compound or the pharmaceutical composition disclosed herein in the manufacture of a medicament for preventing, managing, treating or lessening a cancer, a tumor, an inflammatory disease, an autoimmune disease or an immune-mediated disease in a patient.
- the use disclosed herein, wherein the cancer, tumour, inflammatory disease, autoimmune disease, or immune-mediated disease is mediated by abnormal activation of B lymphocytes, T lymphocytes, or both.
- the inflammatory disease, autoimmune disease, or immune-mediated disease is arthritis, rheumatoid arthritis, spondyloarthropathy, gouty arthritis, osteoarthritis, juvenile arthritis, other arthritic condition, lupus, systemic lupus erythematosus (SLE) , skin-related disease, psoriasis, eczema, dermatitis, atopic dermatitis, pain, lung disease, lung inflammation, adult respiratory distress syndrome (ARDS) , pulmonary sarcoidosis, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (COPD) , cardiovascular disease, atherosclerosis, myocardial infarction, congestive heart failure, cardiac reperfusion injury, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, asthma, Sjogren's syndrome, autoimmune thyroid disease, urticaria (rubella) , multiple sclerosis, sclero
- the disease is an autoimmune disease or an transplantation-induced inflammation, including but not limited to, homograft, graft-versus-host disease, or autoimmune diabetes.
- the use disclosed herein, wherein the AML related complication is the symptom displayed by the patient, i.e., infection, bleeding, adult respiratory distress syndrome, sarcoidosis, pleural effusion, pulmonary fibrosis, pericardial effusion, cardiac arrhythmia, hypertension, heart failure, acute abdomen, portal hypertension, renal insufficiency, liver and spleen abscesses, anemia, thrombosis, diabetes, diabetes insipidus, electrolyte imbalance, neurological complications, intracranial hemorrhage, necrosis of the femoral head, bone and joint disease, skin lesions, retinal hemorrhage, optic disc edema, conjunctival hyperemia, edema, hypopyon, choroidal infiltration, iris infiltration, vitreous opacities, vision loss, hypopsia, orbital tumor, proptosis, acute glaucoma, chloroma, gingival hyperplasia, oral
- provided herein is use of the compound disclosed herein in the manufacture of a medicament for preventing, managing, treating or lessening a proliferative disease, an autoimmune disease or an inflammatory disease in a patient.
- provided herein is use of the compound of Formula (I) to (VIII) or the pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment of FLT3 mediated diseases, wherein the use comprises administering a therapeutically effective amount of the compound of Formula (I) to (VIII) , or a pharmaceutically acceptable salt, a isomer, a solvate, a hydrate or a prodrug thereof.
- the compounds and the compositions provided herein are effective to modulate the activity of the Ab1 protein tyrosine family.
- the compounds and the compositions provided herein are effective to modulate the activity of the fms-like tyrosine kinase 3 receptor kinase (FLT-3 kinase) .
- FLT-3 kinase fms-like tyrosine kinase 3 receptor kinase
- the compounds and the compositions provided herein are effective to inhibit the activity of the fms-like tyrosine kinase 3 receptor kinase mutation (FLT-3-ITD kinase) .
- FLT-3-ITD kinase fms-like tyrosine kinase 3 receptor kinase mutation
- the compounds and the compositions provided herein are effective to modulate the activity of the Src subfamily, which includes Src, Yes, Fyn, Lyn, Lck, BIk, Hck, Fgr and Yrk.
- the compounds and the compositions provided herein are effective to modulate the activity of one or more kinases selected from the group consisting of sterile 20, sterile 11, sterile, the camk subfamily (calmodulin regulated kinases and related kinases) , the AGC subfamily (protein kinase A, protein kinase G and protein kinase C) , the CMGC subfamily (CDK, map kinase, glycogen synthetase kinase and clk) , the sterile 20 subfamily, Frk, Btk, Csk, AbI, Zap70, Fes, Fps, Fak, Jak and Ack (and their respective subfamilies) .
- the camk subfamily calmodulin regulated kinases and related kinases
- AGC subfamily protein kinase A, protein kinase G and protein kinase C
- CDK map kinase, glycogen
- provided herein are methods of using the disclosed compounds and compositions, or pharmaceutically acceptable salts, solvates, hydrates or prodrugs thereof, for the local or systemic treatment or prophylaxis of human and veterinary diseases, disorders and conditions modulated or otherwise affected via kinase activity.
- the salt is a pharmaceutically acceptable salt.
- pharmaceutically acceptable refers to that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
- the compounds disclosed herein also include salts of the compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula (I) to (VIII) , and/or for separating enantiomers of compounds of Formula (I) to (VIII) .
- the desired salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, malic acid, 2-hydroxypropionic acid, citric acid, oxalic acid, glycolic acid and salicylic acid; a pyranosidyl acid, such as glucuronic acid and galacturonic acid; an alpha-hydroxy acid, such as citric acid and tartaric acid; an amino acid, such as aspartic acid and glutamic acid; an aromatic acid, such as benzoic acid and cinnamic acid; a sulfonic acid, such as p-toluenesulfonic acid, benzenes
- an inorganic acid such as hydro
- the desired salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary) , an alkali metal hydroxide, ammonium, N + (R 14 ) 4 salt or alkaline earth metal hydroxide, and the like.
- an inorganic or organic base such as an amine (primary, secondary or tertiary) , an alkali metal hydroxide, ammonium, N + (R 14 ) 4 salt or alkaline earth metal hydroxide, and the like.
- suitable salts include organic salts derived from amino acids, such as glycine and arginine; ammonia, such as primary, secondary and tertiary amine, N + (R 14 ) 4 salt, wherein R 14 is H, C 1-4 alkyl, C 6-10 aryl, C 6-10 aryl-C 1-4 -alkyl, and the like; and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, lithium, and the like, and further include, when appropriate, nontoxic ammonium, quaternary ammonium and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, C 1-8 sulfonate or aryl sulfonate.
- the invention features pharmaceutical compositions that include a compound of Formula (I) to (VIII) , a hydrate, a solvate, an isomer, a physiologically/pharmaceutically acceptable salt or a prodrug thereof, a compound listed herein, or a compound named in examples 1-90, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
- the compositions disclosed herein can be used in the manufacture of a medicament for preventing, managing, treating or lessening a disease mediated by protein kinase.
- the compositions disclosed herein acting as c-KIT mutation, RET, PDGFR, Bcr-ABL and FLT3 kinase or FLT3-ITD kinase inhibitors are used for preparation of medicaments.
- compositions disclosed herein may include a compound of Formula (I) to (VIII) , and a pharmaceutically acceptable carrier.
- the compounds of Formula (I) to (VIII) can also be included in pharmaceutical compositions in combination with the second therapeutically active compound.
- the second therapeutically active compound disclosed herein may be a chemical therapeutic agent, an anti-proliferative agent, an immunosuppressive agent, an immunostimulatory agent, an anti-inflammatory agent, a CDK4/6 kinase inhibitor, an ABL inhibitors, an ABL/Scr inhibitor, an Aurora kinase inhibitor, a non-ATP-competitive inhibitor of BCR-ABL, a c-KIT mutation inhibitor, a RET inhibitor, a PDGFR inhibitor, a VEGFR inhibitor, a FLT3 inhibitor, a flt3-ITD inhibitor or a combination thereof.
- the pharmaceutical carrier employed can be, for example, a solid, liquid or gas.
- solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, and the like.
- liquid carriers are sugar syrup, peanut oil, olive oil, water, and the like.
- gaseous carriers include carbon dioxide, nitrogen, and the like.
- the carrier or diluent may include any time delay material well known to the art, such as glyceryl monostearate or glyceryl stearate, alone or mixed with a wax.
- some non-limiting examples of materials which can serve as pharmaceutically acceptable carriers include ion exchanger; aluminum; alumina; aluminum stearate; lecithin; serum protein such as human serum albumin; buffer substance such as phosphate; glycine; sorbic acid; potassium sorbate; partial glyceride mixture of saturated vegetable fatty acid; water; electrolyte such as protamine sulfate, disodium hydrogen phosphate and potassium hydrogen phosphate; salt such as sodium chloride and zinc salt; colloidal silica; magnesium trisilicate; polyvinyl pyrrolidone; polyacrylate; wax; polyethylene-polyoxypropylene-block polymer; wool fat; sugar such as lactose, glucose and sucrose; starch such as corn starch and potato starch; cellulose and its derivative such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as coco
- compositions of the invention disclosed herein can be prepared and packaged in bulk form, wherein the pharmaceutical compositionscontain a safe and effective amount of extractable compounds of the present invention, and then can be administered to the patient in the form of powder or syrup.
- the pharmaceutical compositions of the present invention disclosed herein can be prepared and packaged in unit dosage form, wherein each physically discrete unit contains a safe and effective amount of a compound of the present invention.
- the pharmaceutical compositions of the present invention disclosed herein generally contain, for example, 0.5 mg to 1 g, or 1 mg to 700 mg, or 5 mg to 100 mg of the compounds disclosed herein.
- a “pharmaceutically acceptable excipient” means a pharmaceutically acceptable material, a composition, or a vehicle involved in giving form or consistency to the dosage form or pharmaceutical composition.
- Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically acceptable are avoided.
- each excipient must of course be pharmaceutically-acceptable eg of sufficiently high purity.
- Suitable pharmaceutically acceptable excipients will vary depending upon the particular dosage form chosen.
- suitable pharmaceutically acceptable excipients may be chosen for a particular function that they may serve in the composition.
- certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms.
- Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms.
- Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the carrying or transporting of the compound of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body.
- Certain pharmaceutically acceptable excipients may be chosen for their ability to enhance patient compliance.
- Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrating agents, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifying agents, sweetening agents, flavoring agents, taste masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, adhesion promoters, antioxidants, preservatives, stabilizers, surfactants and buffers.
- excipients include the following types of excipients: diluents, fillers, binders, disintegrating agents, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifying agents, sweetening agents, flavoring agents, taste masking agents, coloring agents, anti-caking agents, humectants, chel
- Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically-acceptable excipients in appropriate amounts for use in the invention.
- resources that are available to the skilled artisan which describe pharmaceutically acceptable excipients and may be useful in selecting suitable pharmaceutically acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company) , The Handbook of Pharmaceutical Additives (Gower Publishing Limited) , and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press) .
- FLT3 activity increase includes, but is not limited to, enhanced FLT3 activity resulting from increased or denovo expression of FLT3 in cells, increased FLT3 expression or activity, and FLT3 mutations resulting in constitutive activation.
- the existence of inappropriate or abnormal FLT3 ligand and FLT3 levels or activity can be determined using well-known methods in the art. For example, abnormally high FLT3 levels can be determined using commercially available ELISA kits. FLT3 levels can also be determined using flow cytometric analysis, immunohistochemical analysis and in situ hybridization techniques.
- An inappropriate activation of FLT3 can be determined by an increase in one or more of the activities occurring subsequent to FLT3 binding: (1) phosphorylation or autophosphorylation of FLT3; (2) phosphorylation of FLT3 substrates such as Stat5 and Ras; (3) activation of related complexes such as PI3K; (4) activation of adaptor molecules; and (5) cell proliferation. These activities can be readily measured by well-known methods in the art.
- the compound of Formula (I) to (VIII) , or the pharmaceutical composition disclosed herein is useful in, but not limited to, preventing or treating proliferative diseases, conditions, or disorders in a patient by administering to the patient the compound of Formula (I) to (VIII) , or the pharmaceutical composition disclosed herein in an effective amount.
- diseases, conditions, or disorders include cancer, particularly hematopoietic system cancer, metastatic cancer, atherosclerosis, and lung fibrosis.
- neoplasia including cancer and metastatic cancer, including, but not limited to: carcinoma such as cancer of bladder, breast, colon, kidney, liver, lung (including small cell lung cancer) , esophageal, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin (including squamous cell carcinoma) ; hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, hairy cell leukemia and Burkett’s lymphoma; hematopoietic tumors of myeloid lineage including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of
- the compounds or the pharmaceutical compositions disclosed herein are also useful in themanufacture of the medicaments for the treatment of EGFR, EGFR (T790M) , BLK, BMX/ETK, BTK, JAK1, JAK2, JAK3, TEC, TXK, FLT3 and FLT3 (D835Y) protein kinase mediated, c-KIT mutation mediated and/or FLT3-ITD mediated diseases like proliferative diseases, autoimmune diseases, kidney diseases, tissue transplant rejection, lupus erythematosis, multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, AML, arthritis, asthma, and the like.
- the compounds or the pharmaceutical compositions disclosed herein are also useful in themanufacture of the medicaments for the treatment of complicationsof the diseases mediated by EGFR, EGFR (T790M) , BLK, BMX/ETK, BTK, JAK1, JAK2, JAK3, TEC, TXK, FLT3 and FLT3 (D835Y) protein kinase mediated, c-KIT mutation and/or FLT3-ITD.
- the compounds or the pharmaceutical compositions disclosed herein are also useful in the treatment of diabetic conditions such as diabetic retinopathy and microangiopathy.
- the compounds or the pharmaceutical compositions disclosed herein are also useful in the reduction of blood flow in a tumor.
- the compounds or the pharmaceutical compositions disclosed herein are also useful in the reduction of metastasis of a tumor.
- these compounds or the pharmaceutical compositions are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like.
- animals include horses, dogs and cats.
- the compounds of Formula (I) to (VIII) disclosed herein include the pharmaceutically acceptable derivatives thereof.
- the compounds or the pharmaceutical compositions disclosed herein also are useful in themanufacture of the medicament for inhibiting the growth of a cell that expresses VEGFR or c-Met, which includes contacting the cell with a compound or composition disclosed herein.
- a cell whose growth can be inhibited include: a breast cancer cell, a colorectal cancer cell, a lung cancer cell, a papillary carcinoma cell, a prostate cancer cell, a lymphoma cell, a colon cancer cell, a pancreatic cancer cell, an ovarian cancer cell, a cervical cancer cell, a central nervous system cancer cell, an osteogenic sarcoma cell, a renal carcinoma cell, a hepatocellular carcinoma cell, a bladder cancer cell, a gastric carcinoma cell, a head and neck squamous carcinoma cell, a melanoma cell or a leukemia cell.
- the compounds or the pharmaceutical compositions disclosed herein also are useful in themanufacture of the medicament for inhibiting VEGFR and/or c-Met kinase activity in a biological sample, which includes contacting the biological sample with a compound or composition disclosed herein.
- biological sample means a external living organism sample including but not limited to, cell cultures or extracts thereof; biopsied materials obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body liquids or extracts thereof.
- Inhibition of kinase activity, particularly VEGFR or c-Met kinase activity, in a biological sample is useful for a variety of purposes known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ-transplantation, biological specimen storage and biological assays.
- the treatment method that includes administering a compound or composition disclosed herein can further include administering to the patient an additional therapeutic agent (combination therapy) selected from: a chemotherapeutic or anti-proliferative agent, or an anti-inflammatory agent, wherein the additional therapeutic agent is appropriate for the disease being treated and the additional therapeutic agent is administered together with a compound or composition disclosed herein as a single dosage form or separately from the compound or composition as part of a multiple dosage form.
- the additional therapeutic agent may be administered in combination with the compound disclosed herein simultaneously or sequentially. In the latter case, administration may be staggered by, for example, 6 hours, 12 hours, 1 day, 2 days, 3 days, 1 week, 2 weeks, 3 weeks, 1 month or 2 months.
- a therapeutically effective dosage should produce a serum concentration of active ingredient of from about 0.1 ng/ml to about 50-100 ⁇ g/ml.
- the pharmaceutical compositions disclosed herein should provide a dosage of from about 0.001 mg to about 2000 mg of compound per kilogram of body weight per day.
- Pharmaceutical dosage unit forms are prepared to provide from about 1 mg to about 1000 mg, and in some embodiments, from about 10 mg to about 500 mg, from about 20 mg to about 250 mg or from about 25 mg to about 100 mg of the essential active ingredient or a combination of essential ingredients per dosage unit form. In some embodiments, pharmaceutical dosage unit forms are prepared to provide about 1 mg, 20 mg, 25 mg, 50 mg, 100 mg, 250 mg, 500 mg, 1000 mg or 2000 mg of the essential active ingredient. In some embodiments, pharmaceutical dosage unit forms are prepared to provide about 50 mg of the essential active ingredient.
- the active ingredient of the pharmaceutical compostion may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is also to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
- an “effective amount” or “effective dose” is that amount effective for treating or lessening the severity of one or more of the aforementioned disorders.
- the compounds and compositions, according to the method disclosed herein, may be administered using any amount and any route of administration effective for treating or lessening the severity of the disorder or disease. The exact amount required will vary from subject to subject, depending on the species, age, and the general condition of the subject, the severity of the infection, the particular agent, the mode of administration, and the like.
- a compound or composition can also be administered with one or more other therapeutic agents, as discussed above.
- the compounds or the pharmaceutical compositions thereof disclosed herein may also be used for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters.
- vascular stents for example, have been used to overcome restenosis (re-narrowing of the vessel wall after injury) .
- patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted effects may be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a compound disclosed herein.
- the dosage used can be varied depending upon the type of cancer, the age and general condition of the patient, the particular compound administered, the presence or level of toxicity or adverse effects experienced with the drug, and other factors.
- a representative example of a suitable dosage range is from as low as about 0.01 mg/kg to as high as about 100 mg/kg. However, the dosage administered is generally left to the discretion of the physician.
- the methods of treatment are preferably carried out by delivering the compounds of Formula (I) to (VIII) disclosed herein orally or parenterally.
- parenteral as used herein includes intravenous, intramuscular or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred.
- the invention can also be carried out by delivering the compounds of Formula Formula (I) to (VIII) disclosed herein subcutaneously, intranasally, intrarectally, transdermally or intravaginally.
- the compounds of Formula (I) to (VIII) , or the pharmaceutical compositions disclosed herein may also be administered by inhalation.
- “Inhalation” is meant intranasal and oral inhalation administration.
- Appropriate dosage forms for such administration such as an aerosol formulation or a metered dose inhaler, may be prepared by convention techniques.
- the compounds of Formula (I) to (VIII) , or the pharmaceutical compositions disclosed herein can be employed to prepare a wide variety of pharmaceutical dosage forms.
- a solid dosage is used for oral administration, the preparation can be in the form of a tablet, hard gelatin capsule, lozenge, troche, drop, lotion, and the like.
- the amount of solid carrier will vary widely, but generally will be from about 0.025 mg to about 1 g.
- the preparation is typically in the form of a syrup, emulsion, soft gelatin capsule, suspension or solution.
- the drug may be in solid or liquid form, and may be formulated for administration directly or may be suitable for reconstitution. Topical dosage forms are also included.
- topical dosage forms are solids, liquids and semi-solids.
- Solids would include dusting powders, poultices, and the like.
- Liquids include solutions, suspensions and emulsions.
- Semi-solids include creams, ointments, gels, and the like.
- a representative, topical dose of a compound of Formula (I) to (VIII) is from as low as about 0.01 mg to as high as about 2.0 g, administered one to four, preferably one to two times daily.
- the active ingredient may comprise, for topical administration, from about 0.001 %to about 10%w/w.
- Drops according to the invention may comprise sterile or non-sterile aqueous or oil solutions or suspensions, and may be prepared by dissolving the active ingredient in a suitable aqueous solution, optionally including a bactericidal and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent.
- a suitable aqueous solution optionally including a bactericidal and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent.
- the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98 °C -100 °C for half an hour.
- the solution may be sterilized by filtration and transferred to the container aseptically.
- bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%) , benzalkonium chloride (0.01%) and chlorhexidine (0.01%) .
- Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
- Lotions according to the invention include those suitable for application to the skin or eye.
- An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.
- Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or oil such as castor oil or arachis oil.
- Creams, ointments or pastes according to the invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous liquid, with a greasy or non-greasy base.
- the base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, coenzyme M, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol or macrogel.
- the formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof.
- suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof.
- Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicas, and other ingredients such as lanolin may also be included.
- the compounds or the pharmaceutical compositions disclosed herein can also be administered in the form of coating, and suitable coated implantable devices are known in the art.
- the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid and mixtures thereof.
- the coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccharides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
- the compounds may also be coated on implantable medical devices, such as beads, or co-formulated with a polymer or other molecule, to provide a “drug depot” thus permitting the drug to be released over a longer time period than administration of an aqueous solution of the drug.
- the present invention provides the combination of one or more compounds or compositions, or a pharmaceutically acceptable derivative thereof with other active drug for the treatment of diseases and conditions described herein.
- effective amounts of the compounds or compositions containing therapeutically effective concentrations of the compounds which are formulated for oral, systemic, including parenteral or intravenous delivery, or for local or topical application are administered to an individual exhibiting the symptoms of the disease or disorder to be treated.
- the amounts are effective to treat, manage or ameliorate the disease or ameliorate or eliminate one or more symptoms of the disease or disorder.
- the compounds, isomers, prodrugs and pharmaceutically acceptable derivatives thereof disclosed herein can be widely used in combination therapy for the treatment of the present discomforts and diseases herein. Accordingly, the compounds, isomers, prodrugs and pharmaceutically acceptable derivatives thereof provided herein are intended for use in combination with other active agents to treat the before mentioned diseases/discomforts of the present invention.
- the compounds, compositions or pharmaceutically acceptable derivatives thereof provided herein may be administered simultaneously with, prior to, or after administration of one or more of the other pharmaceutical active drugs.
- Other active drugs are particularly useful for the treatment of a proliferative disorder or cancer which plagues subject.
- one or more other active drugs are selected from anticancer agents (such as cell signaling inhibitors, mitotic inhibitors, alkylating agents, anti-metabolites, chimeric (intercalating) anticancer agents, topoisomerase inhibitors, immunotherapeutic agents, or anti-hormonal agents) , steroids, methotrexate, leflunomide, anti-TNF- ⁇ agents, calcineurin phosphatase (calcineurin) inhibitors, antihistamines, chemotherapeutic agents, antiproliferative agents, immunosuppressive agents, immunostimulatory agents, anti-inflammatory agent, CDK4/6 kinase inhibitor, ABL inhibitors, ABL/Scr inhibitors, aurora kinase inhibitors, non-ATP-competitive inhibitor of BCR-ABL, c-KIT mutation inhibitors, RET inhibitors, PDGFR inhibitors, VEGFR inhibitors, FLT3 inhibitor, FLT3-ITD inhibitor or a combination thereof
- anticancer agents such as cell signaling
- one or more other active drugs may be: streptozotocin, oxaliplatin, temozolomide, methotrexate, fluorouracil, gemcitabine, mercaptopurine, vinorelbine, docetaxel, topotecan, irinotecan, trabectedin, dactinomycin, mitomycin C, ixabepilone, gonadorelin analogues, megestrol, prednisone, methylprednisolone, thalidomide, interferon- ⁇ , leucovorin, sirolimus, temsirolimus, everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, bortezomib, bosutinib, brivanib, cabozantinib, cediranib, crenolanib, crizotinib, da
- the compound or the pharmaceutical compostition of the present invention and other active drug with which can be combined are made as separate formulations, which may be the same or different, and can be administered sequentially or simultaneously; when administered sequentially, the second drug is administered at the time when the first drug has not lost the active effect in vivo; 2) the compound or the pharmaceutical compostition of the present invention and other active drug with which can be combined can be made as a single formulation for administering simultaneously.
- a combination therapy used for treating or preventing the symptoms or complications associated with cancer or related diseases, comprising administering to a subject in need of such treatment a compound or a compostion of the invention, or a pharmaceutically acceptable derivative thereof, and one or more other active drugs.
- a drug combination comprising a FLT3 inhibitor or FLT3-ITD inhibitor and CDK4/6 kinase inhibitor.
- the compound of the invention, or a composition, or a pharmaceutically acceptable derivative thereof, as FLT3 inhibitor or FLT3-ITD inhibitor may be administered simultaneously with, prior to, or after administration of one or more of other active therapeutic agents.
- other active therapeutic agent is a CDK4/6 kinase inhibitor.
- CDK4/6 kinase inhibitor is deferasirox, palbociclib, abemaciclib, ribociclib, rigosertib sodium, selinexor, roniciclib, AT-7519, seliciclib, alvocidib etc.
- the compounds disclosed herein may be prepared by methods described herein, wherein the substituents are as defined for Formula (I) to (VIII) above, except where further noted.
- the following non-limiting schemes and examples are presented to further exemplify the invention.
- temperatures are set forth in degrees Celsius (°C) .
- Reagents were purchased from commercial suppliers such as Aldrich Chemical Company, Arco Chemical Company and Alfa Chemical Company, and were used without further purification unless otherwise indicated.
- Common solvents were purchased from commercial suppliers such as Shantou XiLong Chemical Factory, Guangdong Guanghua Reagent Chemical Factory Co. Ltd., Guangzhou Reagent Chemical Factory, Tianjin YuYu Fine Chemical Ltd., Qingdao Tenglong Reagent Chemical Ltd., and Qingdao Ocean Chemical Factory.
- Anhydrous THF, dioxane, toluene, and ether were obtained by refluxing the solvent with sodium.
- Anhydrous CH 2 Cl 2 and CHCl 3 were obtained by refluxing the solvent with CaH 2 .
- EtOAc, PE, n-hexane, N, N-dimethylacetamide and N, N-dimethylformamide were treated with anhydrous Na 2 SO 4 prior to use.
- reaction flasks were typically fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried.
- MS data were determined by an Agilent 6120 Series Quadrupole HPLC-M (Zorbax SB-C18, 2.1 x 30 mm, 3.5 ⁇ m, 6 min, flow rate: 0.6 mL/min, mobile phase: 5%-95% (1%formic acid in CH 3 CN) in (1%formic acid in H 2 O) , ESI) with UV detection at 210 nm and 254 nm.
- Compound (9a) and (12a) can be prepared from compound (6a) by the following steps.
- Compound (6a) can react with benzyl alcohol and sodium hydride to form compound (7a) andcompound (10a) under a N 2 atmosphere in an ice-water bath.
- compound (7a) andcompound (10a) can respectively be converted to compound (8a) andcompound (11a) by catalytic hydrogenation in the presence of 10%Pd/C under a H 2 atmosphere, and then compound (8a) andcompound (11a) can respectivelyreact with NIS to form compound (9a) andcompound (12a) by iodination.
- Compound (14a) can be prepared from compound (13a) by the following step.
- Compound (13a) can react with NIS to form compound (14a) .
- Compound (6b) can be prepared from compound (15a) by the following steps, and wherein each R 0 is as defined herein.
- Compound (15a) can be converted to compound (16a) in acetonitrile in the presence of a strong base.
- Compound (16a) can react with hydroxylamine hydrochloride to form compound (17a) by ring closing.
- Compound (17a) can react with phenyl chloroformate to form compound (6b) .
- Compound (5) can be prepared by the process illustrated in Scheme 1 of synthesis of intermediate (5) , and wherein, each a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (1) can react withcompound (2) to form compound (3) in the presence of a base.
- Compound (3) can react withcompound (4) to form compound (5) in the presence of a catalyst.
- Compound (5) can be prepared by the process illustrated in Scheme 2 ofsynthesis of intermediate (5) , and wherein, each a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (1) can react withcompound (4) to form compound (19) in the presence of a catalyst.
- Compound (19) can react withcompound (2) to form compound (5) in the presence of a base.
- Compound (5) can be prepared by the process illustrated in Scheme 3of synthesis of intermediate (5) , and wherein, each a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (1) can react withcompound (10) to form compound (3) by Mitsunobu reaction.
- Compound (3) can react withcompound (14) to form compound (33) in the presence of a catalyst. Then compound (33) can be reduced to form compound (5) .
- Compound (11) can be prepared by the process illustrated in Scheme of synthesis of intermediate (11) , and wherein, each a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (8) can react withcompound (4) to form compound (9) .
- Compound (9) can react withcompound (10) to form compound (11) in the presence of a base.
- Compound (17) can be prepared by the process illustrated in Scheme of synthesis of intermediate (17) , and wherein, each a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (13) can react with compound (14) to form Compound (15) in the presence of a palladium catalyst.
- Compound (15) can react with compound (10) to form compound (16) in the presence of a base, and compound (16) can be reduced to form compound (17) .
- Compound (23) can be prepared by the process illustrated in Scheme of synthesis of intermediate (23) , and wherein, each a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (20) can react withcompound (14) to form compound (21) in the presence of a catalyst.
- Compound (21) can react withcompound (10) to form compound (22) in the presence of a base, and compound (22) can be reduced to form compound (23) .
- Compound (27) can be prepared by the process illustrated in Scheme of synthesis of intermediate (27) , and wherein, each a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (25) can react with compound (10) to form Compound (26) in the presence of a base.
- Compound (26) can react withcompound (4) to form compound (27) in the presence of a catalyst.
- Compound (31) can be prepared by the process illustrated in Scheme of synthesis of intermediate (31) , and wherein, each a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (29) can react withcompound (2) to form compound (30) in the presence of a base.
- Compound (30) can react withcompound (4) to form compound (31) in the presence of a catalyst.
- Compound (5b) can be prepared by the process illustrated in Scheme 1 of synthesis of intermediate (5b) , and wherein, each ring E, ring A, a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (1b) can react withcompound (2) to form Compound (3b) in the presence of a base.
- Compound (3b) can react withcompound (4b) to form compound (5b) in the presence of a catalyst.
- Compound (5b) can be prepared by the process illustrated in Scheme 2 of synthesis of intermediate (5b) , and wherein, each ring E, ring A, a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (1b) can react withcompound (4b) to form compound (19b) in the presence of a catalyst.
- Compound (19b) can react withcompound (2) to form compound (5b) in the presence of a base.
- Compound (5b) can be prepared by the process illustrated in Scheme 3 of synthesis of intermediate (5b) , and wherein, each ring E, ring A, a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (1b) can react with compound (10) to form compound (3b) by Mitsunobu reaction.
- Compound (3b) can react with compound (14b) to form compound (33b) in the presence of a catalyst, and compound (33b) can be reduced to form compound (5b) .
- Compound (5b) can be prepared by the process illustrated in Scheme 4 of synthesis of intermediate (5b) , and wherein, each ring E, ring A, a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (1b) can react withcompound (14b) to form compound (15b) in the presence of a palladium catalyst.
- Compound (15b) can react withcompound (10) to form compound (33b) in the presence of a base.
- Compound (33b) can be reduced to form compound (5b) .
- Compound (5b) can be prepared by the process illustrated in Scheme 5 of synthesis of intermediate (5b) , and wherein, each ring E, ring A, a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (1b) can react withcompound (10) to form compound (3b) in the presence of a base.
- Compound (3b) can react withcompound (4b) to form compound (5b) in the presence of a catalyst.
- Compound (5b) can be prepared by the process illustrated in Scheme 6 of synthesis of intermediate (5b) , and wherein, each ring E, ring A, a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (1b) can react withcompound (4b) to form compound (15b) in the presence of a catalyst.
- Compound (15b) can react withcompound (10) to form compound (5b) in the presence of a base.
- Compound (7b) can be prepared by the process illustrated in Scheme 1, and wherein, each R 00 is independently methyl or R 0 , and each ring E, ring A, a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (5b) can react withcompound (6c) to form the objective compound (7b) in the presence of a base.
- Compound (7c) can be prepared by the process illustrated in Scheme 2, and wherein, each L, n, ring K, ring E, ring A, a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (5b) can react withcompound (6d) to form the objective compound (7c) in the presence of a base.
- Compound (18) can be prepared by the process illustrated in Scheme 3, and wherein, each R 00 is independently methyl or R 0 , and each R 0 , a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (17) can react withcompound (6c) to form the objective compound (18) in the presence of a base.
- Compound (7) can be prepared by the process illustrated in Scheme 4, and wherein, each R 00 is independently methyl or R 0 , and each R 0 , a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (5) can react withcompound (6c) to form the objective compound (7) in the presence of a base.
- Compound (24) can be prepared by the process illustrated in Scheme 5, and wherein, each R 00 is independently methyl or R 0 , and each R 0 , a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (23) can react withcompound (6c) to form the objective compound (24) in the presence of a base.
- Compound (28) can be prepared by the process illustrated in Scheme 6, and wherein, each R 00 is independenlty methyl or R 0 , and each R 0 , a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (27) can react withcompound (6c) to form the objective compound (28) in the presence of a base.
- Compound (32) can be prepared by the process illustrated in Scheme 7, and wherein, each R 00 is independenlty methyl or R 0 , and each R 0 , a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (31) can react withcompound (6c) to form the objective compound (32) in the presence of a base.
- Compound (12) can be prepared by the process illustrated in Scheme 8, and wherein, each R 00 is independently methyl or R 0 , and each R 0 , a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (11) can react withcompound (6c) to form the objective compound (12) in the presence of a base.
- Compound (7) can be prepared by the process illustrated in Scheme 9, and wherein, each a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (3) can react with acetonitrile in the presence of a catalyst to form compound (35) .
- Compound (34) can react with compound (35) and compound (6) to form the objective compound (7) by one-pot reaction.
- Compound (7a) can be prepared by the process illustrated in Scheme 10, and wherein, each R 00 is independently methyl or R 0 , and each a, e, R 0 , R 1 , R 1a , R 2 and n is as defined herein.
- Compound (5) can react withcompound (6c) to form the the objective compound (7a) in the presence of a base.
- Compound (7b) can be prepared by the process illustrated in Scheme 11, and wherein, each R 00 is independently methyl or R 0 , and each R 0 , ring E, ring A, a, e, R 1 , R 1a , R 2 and n is as defined herein.
- Compound (11b) can react withcompound (8b) to form compound (12b) in the presence of a base.
- Compound (12b) can react withcompound (14b) to form compound (9b) in the presence of a catalyst.
- Compound (9b) can be reduced to form compound (10b) .
- Compound (10b) can react withcompound (6c) to form compound (11b) in the presence of a base.
- Compound (11b) can react with acetonitrile to form the the objective compound (7a) by ring closing in the presence of a base (the base can be but not limited to potassium carbonate) .
- Step 1) 4- (3- (2-fluoro-4-iodophenoxy) propyl) morpholine
- Step 2) 4- ( (3-fluoro-4- (3-morpholinopropoxy) phenyl) ethynyl) aniline
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (3-fluoro-4- (3-morpholinopropoxy) phenyl) ethynyl) phenyl) urea
- Step 1) 4- (3- (2-chloro-4-iodophenoxy) propyl) morpholine
- the title compound was prepared as an off-white solid (2.46 g, 82%) by the procedure described in step 1 of example 1, using 2-chloro-4-iodophenol (2.0 g, 7.88 mmol) , 3-chloropropyl morpholine (1.41 g, 8.65 mmol) and potassium carbonate (1.63 g, 11.81 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 382.0 [M+1] + .
- Step 2) 4- ( (3-chloro-4- (3-morpholinopropoxy) phenyl) ethynyl) aniline
- the title compound was prepared as a light yellow solid (1.49 g, 76.8%) by the procedure described in step 2 of example 1, using 4- (3- (2-chloro-4-iodophenoxy) propyl) morpholine (2.0 g, 5.25 mmol) , 4-ethynylaniline (1.23 g, 10.51 mmol) , triethylamine (3.5 mL) , PdCl 2 (PPh 3 ) 2 (0.15 g, 0.22 mmol) and CuI (0.04 g, 0.21 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 371.2 [M+1] + .
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (3-chloro-4- (3-morpholinopropoxy) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a light yellow solid (146 mg, 14.5%) by the procedure described in step 3 of example 1, using 4- ( (3-chloro-4- (3-morpholinopropoxy) phenyl) ethynyl) aniline (0.7 g, 1.89 mmol) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (1.23 g, 4.73 mmol) , DMAP (30 mg, 0.25 mmol) and triethylamine (0.1 mL, 0.72 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) 4- (3- (4-iodo-2- (trifluoromethyl) phenoxy) propyl) morpholine
- the title compound was prepared as brown oil (3.1g, 71.76%) by the procedure described in step 1 of example 1, using 2-trifluoromethyl-4-iodophenol (3.0 g, 10.41 mmol) , 3-chloropropyl morpholine (1.64 g, 10.02 mmol) and potassium carbonate (2.15 g, 15.55 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 416.1 [M+1] + .
- Step 2) 4- ( (4- (3-morpholinopropoxy) -3- (trifluoromethyl) phenyl) ethynyl) aniline
- the title compound was prepared as a yellow solid (1.9 g, 75.04%) by the procedure described in step 2 of example 1, using 4- (3- (2-trifluoromethyl-4-iodophenoxy) propyl) morpholine (2.6 g, 6.26 mmol) , 4-ethynylaniline (1.47 g, 12.55 mmol) , triethylamine (50 mL) , PdCl 2 (PPh 3 ) 2 (0.18 g, 0.26 mmol) and CuI (48 mg, 0.25 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 405.2 [M+1] + .
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (4- (3-morpholinopropoxy) -3- (trifluoromethyl) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a light yellow solid (302 mg, 22.5%) by the procedure described in step 3 of example 1, using 4- ( (3-trifluoromethyl-4- (3-morpholinopropoxy) phenyl) ethynyl) aniline (0.95 g, 2.35 mmol) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (1.53 g, 5.88 mmol) , DMAP (0.29 g, 2.37 mmol) and triethylamine (0.33 mL, 2.37 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) 4- (3- (3-fluoro-4-iodophenoxy) propyl) morpholine
- the title compound was prepared as brown oil (4.0 g, 65.19%) by the procedure described in step 1 of example 1, using 3-fluoro-4-iodophenol (4.0 g, 16.80 mmol) , 3-chloropropyl morpholine (2.74 g, 16.81 mmol) and potassium carbonate (3.48 g, 25.21 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 366.0 [M+1] + .
- Step 2) 4- ( (2-fluoro-4- (3-morpholinopropoxy) phenyl) ethynyl) aniline
- the title compound was prepared as a yellow solid (2.56 g, 77.57%) by the procedure described in step 2 of example 1, using 4- (3- (3-fluoro-4-iodophenoxy) propyl) morpholine (3.4 g, 9.31 mmol) , 4-ethynylaniline (2.18 g, 18.63 mmol) , triethylamine (40 mL) , PdCl 2 (PPh 3 ) 2 (0.26 g, 0.37mmol) and CuI (71 mg, 0.37 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 355.2 [M+1] + .
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (2-fluoro-4- (3-morpholinopropoxy) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a white solid (210 mg, 17.87%) by the procedure described in step 3 of example 1, using 4- ( (2-fluoro-4- (3-morpholinopropoxy) phenyl) ethynyl) aniline (800 mg, 2.26 mmol) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (1.46 g, 5.61 mmol) , DMAP (0.27 g, 2.21 mmol) and triethylamine (0.23 g, 2.27 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) 4- (3- (3-chloro-4-iodophenoxy) propyl) morpholine
- the title compound was prepared as a light yellow solid (3.6 g, 89 %) by the procedure described in step 1 of example 1, using 3-chloro-4-iodophenol (2.7 g, 10.63 mmol) , 3-chloropropyl morpholine (1.73 g, 10.61 mmol) and potassium carbonate (2.20 g, 15.94 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 382.0 [M+1] + .
- Step 2) 4- ( (2-chloro-4- (3-morpholinopropoxy) phenyl) ethynyl) aniline
- the title compound was prepared as a brown solid (700 mg, 27%) by the procedure described in step 2 of example 1, using 4- (3- (3-chloro-4-iodophenoxy) propyl) morpholine (2.65 g, 6.95 mmol) , 4-ethynylaniline (1.62 g, 13.84 mmol) , triethylamine (40 mL) , PdCl 2 (PPh 3 ) 2 (0.20 g, 0.285mmol) and CuI (53 mg, 0.28 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 371.2 [M+1] + .
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (2-chloro-4- (3-morpholinopropoxy) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a light yellow solid (369 mg, 36.9%) by the procedure described in step 3 of example 1, using 4- ( (2-chloro-4- (3-morpholinopropoxy) phenyl) ethynyl) aniline (690 mg, 1.86 mmol) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (1.21 g, 4.65 mmol) , DMAP (0.23 g, 1.88 mmol) and triethylamine (0.26 mL, 1.87 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) 4- ( (5-chloropyrazolo [1, 5-a] pyrimidin-3-yl) ethynyl) aniline
- Step 2) 4- ( (5- (3-morpholinopropoxy) pyrazolo [1, 5-a] pyrimidin-3-yl) ethynyl) aniline
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (5- (3-morpholinopropoxy) pyrazolo [1, 5-a] pyrimidin -3-yl) ethynyl) phenyl) urea
- the title compound was prepared as an off-white solid (90 mg, 30%) by the procedure described in step 3 of example 1, using 4- ( (5- (3-morpholinopropoxy) pyrazolo [1, 5-a] pyrimidin-3-yl) ethynyl) aniline (0.21 g, 0.56 mmol) and phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (0.43 g, 1.6 mmol) , DMAP (30 mg, 0.2 mmol) and triethylamine (83 mg, 0.77 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 2) 4- (3- ( (3- ( (4-nitrophenyl) ethynyl) imidazo [1, 2-b] pyridazin-6-yl) oxy) propyl) morpholine
- Step 3) 4- ( (6- (3-morpholinopropoxy) imidazo [1, 2-b] pyridazin-3-yl) ethynyl) aniline
- Step 4) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (6- (3-morpholinopropoxy) imidazo [1, 2-b] pyridazin -3-yl) ethynyl) phenyl) urea
- the title compound was prepared as a light yellow solid (385 mg, 33%) by the procedure described in step 3 of example 1, using 4- ( (6- (3-morpholinopropoxy) imidazo [1, 2-b] pyridazin-3-yl) ethynyl) aniline (0.80 g, 2.1 mmol) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (1.15 g, 4.23 mmol) , DMAP (0.27 g, 2.1 mmol) and triethylamine (0.3 mL, 2.2 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) 4- ( (4-aminophenyl) ethynyl) -3-fluorophenol
- the title compound was prepared as a yellow solid (1.63 g, 57 %) by the procedure described in step 1 of example 6, using 3-fluoro-4-iodophenol (3.0 g, 13 mmol) , 4-ethynylaniline (2.95 g, 25.2 mmol) , triethylamine (40 mL) , PdCl 2 (PPh 3 ) 2 (0.36 g, 0.51 mmol) and CuI (0.1 g, 0.51 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 228.1 [M+1] + .
- Step 2) 4- ( (4- (3- (2-oxa-6-azaspiro [3.4] octan-6-yl) propoxy) -2-fluorophenyl) ethynyl) aniline
- Step 3) 1- (4- ( (4- (3- (2-oxa-6-azaspiro [3.4] octan-6-yl) propoxy) -2-fluorophenyl) ethynyl) phenyl) -3- (5- (tert-butyl) isoxazol-3-yl) urea
- the title compound was prepared as a light yellow solid (140 mg, 31%) by the procedure described in step 3 of example 1, using 4- ( (4- (3- (2-oxa-6-azaspiro [3.4] octan-6-yl) propoxy) -2-fluorophenyl) ethynyl) aniline (0.31 g, 0.81 mmol) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (0.42 g, 1.6 mmol) , DMAP (50 mg, 0.41 mmol) and triethylamine (0.12 mL, 0.82 mmol) in acetonitrile (2 mL) .
- Step 5 4- (2- ( (3- ( (4-nitrophenyl) ethynyl) imidazo [1, 2-b] pyridazin-8-yl) oxy) ethyl) morpholine
- Step 6) 4- ( (8- (2-morpholinoethoxy) imidazo [1, 2-b] pyridazin-3-yl) ethynyl) aniline
- Step 7) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (8- (2-morpholinoethoxy) imidazo [1, 2-b] pyridazin -3-yl) ethynyl) phenyl) urea
- the title compound was prepared as a white solid (30 mg, 51%) by the procedure described in step 3 of example 1, using 4- ( (8- (2-morpholinoethoxy) imidazo [1, 2-b] pyridazin-3-yl) ethynyl) aniline (40 mg, 0.11 mmol) , acetonitrile (30 mL) , Et 3 N (0.3 mL, 2.2 mmol) and phenyl N- (5- (tert-butyl) isoxazol-3-yl) carbamate (0.29 g, 1.1 mmol) in acetonitrile.
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- the title compound was prepared as oil (0.45 g, 78%) by the procedure described in step 3 of example 9, using 6-hydroxyimidazo [1, 2-b] pyridazine (300 mg, 2.22 mmol) and NIS (0.55 g, 2.4 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 261.9 [M+1] + .
- Step 2) 3- ( (4-nitrophenyl) ethynyl) imidazo [1, 2-b] pyridazin-6-ol
- the title compound was prepared as oil (160 mg, 75%) by the procedure described in step 4 of example 9, using 3-iodoimidazo [1, 2-b] pyridazin-6-ol (200 mg, 0.77 mmol) , 4-nitrophenylacetylene (0.23 g, 1.53 mmol) , CuI (58 mg, 0.31 mmol) , Pd (PPh 3 ) 2 Cl 2 (108 mg, 0.15 mmol) , PPh 3 (80 mg, 0.31 mmol) , THF (50 mL) and Et 3 N (0.32 mL, 2.3 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 281.1 [M+1] + .
- Step 3) 4- (2- ( (3- ( (4-nitrophenyl) ethynyl) imidazo [1, 2-b] pyridazin-6-yl) oxy) ethyl) morpholine
- the title compound was prepared as oil (0.15 g, 75%) by the procedure described in step 5 of example 9, using 3- ( (4-nitrophenyl) ethynyl) imidazo [1, 2-b] pyridazin-6-ol (141 mg, 0.5 mmol) , 4- (2-chloroethyl) morpholine hydrochloride (0.19 g, 1.0 mmol) and potassium carbonate (0.7 g, 5.0 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 394.1 [M+1] + .
- Step 4) 4- ( (6- (2-morpholinoethoxy) imidazo [1, 2-b] pyridazin-3-yl) ethynyl) aniline
- the title compound was prepared as oil (75 mg, 90%) by the procedure described in step 6 of example 9, using 4- (2- ( (3- ( (4-nitrophenyl) ethynyl) imidazo [1, 2-b] pyridazin-6-yl) oxy) ethyl) morpholine (89 mg, 0.23 mmol) , ammonium chloride (0.24 g, 4.5 mmol) and reduced iron power (0.13 g, 2.3 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 364.2 [M+1] + .
- Step 5 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (6- (2-morpholinoethoxy) imidazo [1, 2-b] pyridazin -3-yl) ethynyl) phenyl) urea
- the title compound was prepared as a white solid (30 mg, 50%) by the procedure described in step 3 of example 1, using 4- ( (6- (2-morpholinoethoxy) imidazo [1, 2-b] pyridazin-3-yl) ethynyl) aniline (40 mg, 0.11 mmol) , acetonitrile (30 mL) , Et 3 N (0.3 mL, 2.2 mmol) and phenyl N- (5- (tert-butyl) isoxazol-3-yl) carbamate (0.29 g, 1.1 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) 4- ( (4-aminophenyl) ethynyl) phenol
- the title compound was prepared as oil (5.4 g, 57%) by the procedure described in step 1 of example 6, using 4-iodophenol (10.0 g, 45.0 mmol) , 4-ethynylaniline (10.6 g, 90 mmol) , bis (triphenylphosphine) palladium (II) chloride (3.2 g, 4.5 mmol) , cuprous iodide (0.86 g, 4.5 mmol) , THF (60mL) and TEA (60 mL) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 210.2 [M+1] + .
- Step 2) 4- ( (4- (3- ( (4aR, 7aS) -tetrahydro-2H- [1, 4] dioxino [2, 3-c] pyrrol-6 (3H) -yl) propoxy) phenyl) ethynyl) aniline
- the title compound was prepared as a claybank solid (325 mg, 61.7%) by the procedure described in step 2 of example 8, using 4- ( (4-aminophenyl) ethynyl) phenol (200.0 mg, 0.96 mmol) , (4aR, 7aS) -6- (3-chloropropyl) hexahydro-2H- [1, 4] dioxino [2, 3-c] pyrrole (233.7 mg, 1.14 mmol) , potassium carbonate (397.4 mg, 2.88 mmol) and potassium iodide (20 mg) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 379.5 [M+1] + .
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (4- (3- ( (4aR, 7aS) -tetrahydro-2H- [1, 4] dioxino [2, 3-c] pyrrol-6 (3H) -yl) propoxy) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a white solid (25 mg, 18%) by the procedure described in step 3 of example 1, using 4- ( (4- (3- ( (4aR, 7aS) -tetrahydro-2H- [1, 4] dioxino [2, 3-c] pyrrol-6 (3H) -yl) propoxy) phenyl) ethynyl) aniline (100 mg, 0.60 mmol) , dichloromethane (20 mL) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (232.8 mg, 0.90 mmol) , DMAP (10 mg) and triethylamine (35.1 mg, 0.30 mmol) .
- Step 1) 4- ( (4- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) ethynyl) aniline
- the title compound was prepared as a claybank solid (296 mg, 63.1%) by the procedure described in step 2 of example 8, using 4- ( (4-aminophenyl) ethynyl) phenol (300.0 mg, 1.4 mmol) , 1- (2-chloroethyl) -4-methylpiperazine (275.4 mg, 1.7 mmol) , potassium carbonate (594.3 mg, 4.3 mmol) and potassium iodide (20 mg) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 336.3 [M+1] + .
- Step 2) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (4- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a white solid (25 mg, 42 %) by the procedure described in step 3 of example 1, using 4- ( (4- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) ethynyl) aniline (200 mg, 0.26 mmol) , dichloromethane (20 mL) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (103.1 mg, 0.40 mmol) , DMAP (20 mg) and triethylamine (13.1 mg, 0.13 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) 4- ( (4- (3- (4-methylpiperazin-1-yl) propoxy) phenyl) ethynyl) aniline
- the title compound was prepared as a claybank solid (275 mg, 55 %) by the procedure described in step 2 of example 8, using 4- ( (4-aminophenyl) ethynyl) phenol (300.0 mg, 1.4 mmol) , 1- (3-chloropropyl) -4-methylpiperazine (303.2 mg, 1.7 mmol) , potassium carbonate (594.3 mg, 4.3 mmol) and potassium iodide (20 mg) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 350.3 [M+1] + .
- Step 2) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (4- (3- (4-methylpiperazin-1-yl) propoxy) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a white solid (140 mg, 47 %) by the procedure described in step 3 of example 1, using 4- ( (4- (3- (4-methylpiperazin-1-yl) propoxy) phenyl) ethynyl) aniline (200 mg, 0.57 mmol) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (223.5 mg, 0.86 mmol) , DMAP (20 mg) and triethylamine (28.8 mg, 0.28 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) 4- ( (4- (2- (4-dimethylaminopiperidin-1-yl) ethoxy) phenyl) ethynyl) aniline
- the title compound was prepared as a claybank solid (263 mg, 52 %) by the procedure described in step 2 of example 8, using 4- ( (4-aminophenyl) ethynyl) phenol (300.0 mg, 1.4 mmol) , 1- (2-chloroethyl) -4-dimethylaminopiperidine (323.0 mg, 1.7 mmol) , potassium carbonate (594.3 mg, 4.3 mmol) and potassium iodide (20 mg) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 364.2 [M+1] + .
- Step 2) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (4- (2- (4- (dimethylamino) piperidin-1-yl) ethoxy) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a white solid (27 mg, 18.6 %) by the procedure described in step 3 of example 1, using 4- ( (4- (2- (4-dimethylaminopiperidin-1-yl) ethoxy) phenyl) ethynyl) aniline (100 mg, 0.28 mmol) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (107.4 mg, 0.4 mmol) , DMAP (10 mg) and triethylamine (14.4 mg, 0.14 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 2) 4- (3- ( (3-iodopyrazolo [1, 5-a] pyrimidin-7-yl) oxy) propyl) morpholine
- Step 3) 4- ( (7- (3-morpholinopropoxy) pyrazolo [1, 5-a] pyrimidin-3-yl) ethynyl) aniline
- the title compound was prepared as oil (0.31 g, 60 %) by the procedure described in step 2 of example 1, using 4- (3- ( (3-iodopyrazolo [1, 5-a] pyrimidin-7-yl) oxy) propyl) morpholine (0.5 g, 1.0 mmol) , triethylamine (0.26 g, 2.6 mmol) , 4-ethynylaniline (0.27 g, 2.3 mmol) , CuI (0.019 g, 0.10 mmol) and PdCl 2 (PPh 3 ) 2 (0.07 g, 0.1 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 378.2 [M+1] + .
- Step 4) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (7- (3-morpholinopropoxy) pyrazolo [1, 5-a] pyrimidin -3-yl) ethynyl) phenyl) urea
- Step 1) 4- (2- ( (3-iodopyrazolo [1, 5-a] pyrimidin-7-yl) oxy) ethyl) morpholine
- the title compound was prepared as a light yellow solid (0.98 g, 73%) by the procedure described in step 2 of example 15, using t-BuOK (0.6 g, 5.0 mmol) , N- (2-hydroxyethyl) morpholine (0.71 g, 5.4 mmol) and 7-chloro-3-iodopyrazolo [1, 5-a] pyrimidine (1.0 g, 3.6 mmol) , which was used directly for the next step without further purification.
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 375.0 [M+1] + .
- Step 2) 4- ( (7- (2-morpholinoethoxy) pyrazolo [1, 5-a] pyrimidin-3-yl) ethynyl) aniline
- the title compound was prepared as oil (0.22 g, 61 %) by the procedure described in step 2 of example 1, using 4- (2- ( (3-iodopyrazolo [1, 5-a] pyrimidin-7-yl) oxy) ethyl) morpholine (3.70 g, 1.0 mmol) , triethylamine (0.26 g, 2.6 mmol) , 4-ethynylaniline (0.27 g, 2.3 mmol) , CuI (0.019 g, 0.10 mmol) and PdCl 2 (PPh 3 ) 2 (0.07 g, 0.1 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 364.2 [M+1] + .
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (7- (2-morpholinoethoxy) pyrazolo [1, 5-a] pyrimidin -3-yl) ethynyl) phenyl) urea
- the title compound was prepared as a light yellow solid (85 mg, 27 %) by the procedure described in step 4 of example 15, using 4- ( (7- (2-morpholinoethoxy) pyrazolo [1, 5-a] pyrimidin-3-yl) ethynyl) aniline (0.22 g, 0.6 mmol) , triethylamine (0.16 g, 1.6 mmol) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (0.26 g, 0.98 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) 4- (3- ( (5-iodopyridin-2-yl) oxy) propyl) morpholine
- Step 2) 4- ( (6- (3-morpholinopropoxy) pyridin-3-yl) ethynyl) aniline
- the title compound was prepared as a brown ropy solid (0.35 g, 38%) by the procedure described in step 2 of example 1, using 4- (3- ( (5-iodopyridin-2-yl) oxy) propyl) morpholine (1.0 g, 2.87 mmol) , 4-ethynylaniline (0.4 g, 3.44 mmol) , CuI (0.05 g) , PdCl 2 (PPh 3 ) 2 (0.2 g) and triethylamine (0.35 g) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 338.2 [M+1] + .
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (6- (3-morpholinopropoxy) pyridin-3-yl) ethynyl) phenyl) urea
- Step 2) 4- ( (4-chloro-3- (3-morpholinopropoxy) phenyl) ethynyl) aniline
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (4-chloro-3- (3-morpholinopropoxy) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a white solid (100 mg, 35%) by the procedure described in step 3 of example 1, using 4- ( (4-chloro-3- (3-morpholinopropoxy) phenyl) ethynyl) aniline (200 mg, 0.54 mmol) , dichloromethane (20 mL) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (210.6 mg, 0.81 mmol) , DMAP (20 mg) and triethylamine (5 mL) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) 4- ( (4- (3- (2-oxa-6-azaspiro [3.4] octan-6-yl) propoxy) phenyl) ethynyl) aniline
- Step 2) 1- (4- ( (4- (3- (2-oxa-6-azaspiro [3.4] octan-6-yl) propoxy) phenyl) ethynyl) phenyl) -3- (5- (tert-butyl) isoxazol-3-yl) urea
- the title compound was prepared as a white solid (80 mg, 52.3%) by the procedure described in step 3 of example 1, using 4- ( (4- (3- (2-oxa-6-azaspiro [3.4] octan-6-yl) propoxy) phenyl) ethynyl) aniline (108 mg, 0.30 mmol) , dichloromethane (20 mL) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (116.4 mg, 0.45 mmol) , DMAP (20 mg) and triethylamine (5 mL) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) 4- ( (4-aminophenyl) ethynyl) -2-methoxyphenol
- the title compound was prepared as a brown solid (1.63 g, 69.1%) by the procedure described in step 1 of example 18, using 2-methoxy-4-iodophenol (2.50 g, 10.0 mmol) , 4-ethynylaniline (2.34 g, 20.0 mmol) , bis (triphenylphosphine) palladium (II) chloride (700 mg, 1.0 mmol) , CuI (190 mg, 1.0 mmol) , THF (60 mL) and triethylamine (6 mL) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 241.2 [M+1] + .
- Step 2) 4- ( (3-methoxy-4- (3-morpholinopropoxy) phenyl) ethynyl) aniline
- the title compound was prepared as a claybank solid (215 mg, 47.0%) by the procedure described in step 2 of example 18, using 4- ( (4-aminophenyl) ethynyl) -2-methoxyphenol (0.3 g, 1.26 mmol) , 1- (3-chloropropyl) morpholine (414.0 mg, 2.52 mmol) , potassium carbonate (529.9 mg, 3.84 mmol) and potassium iodide (30 mg) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 367.4 [M+1] + .
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (3-methoxy-4- (3-morpholinopropoxy) phenyl) ethynyl) phenyl) urea
- the title compound was preparedas a white solid (50 mg, 16%) by the procedure described in step 3 of example 1, using 4- ( (3-methoxy-4- (3-morpholinopropoxy) phenyl) ethynyl) aniline (215 mg, 0.59 mmol) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (231.4 mg, 0.89 mmol) , DMAP (20 mg) and triethylamine (5 mL) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) 4- ( (4-nitrophenyl) ethynyl) phenol
- Step 2) 4- (3- (4- ( (4-nitrophenyl) ethynyl) phenoxy) propyl) morpholine
- Step 4) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (4- (3-morpholinopropoxy) phenyl) ethynyl) phenyl) urea
- Step 1) 4- ( (4- (3- (2-oxa-5-azabicyclo [2.2.1] heptan-5-yl) propoxy) phenyl) ethynyl) aniline
- the title compound was prepared as a claybank solid (90 mg, 56%) by the procedure described in step 2 of example 8, using 4- ( (4-aminophenyl) ethynyl) phenol (100.0 mg, 0.47 mmol) , 5- (3-chloropropyl) -2-oxa-5-azabicyclo [2.2.2] heptane (99.8 mg, 0.57 mmol) , acetonitrile (40 mL) , potassium carbonate (194.6 mg, 1.41 mmol) and potassium iodide (30 mg) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 349.5 [M+1] + .
- Step 2) 1- (4- ( (4- (3- (2-oxa-5-azabicyclo [2.2.1] heptan-5-yl) propoxy) phenyl) ethynyl) phenyl) -3- (5-(tert-butyl) isoxazol-3-yl) urea
- the title compound was prepared as a white solid (22 mg, 17%) by the procedure described in step 3 of example 1, using 4- ( (4- (3- (2-oxa-5-azabicyclo [2.2.1] heptan-5-yl) propoxy) phenyl) ethynyl) aniline (90 mg, 0.26 mmol) , dichloromethane (20 mL) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (103.1 mg, 0.40 mmol) , DMAP (20 mg) and triethylamine (5 mL) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 2) 6- (3- (2-fluoro-4-iodophenoxy) propyl) -2-oxa-6-azaspiro [3.3] heptane
- Step 4) 4- ( (4- (3- (2-oxa-6-azaspiro [3.3] heptan-6-yl) propoxy) -3-fluorophenyl) ethynyl) aniline
- Step 5 1- (4- ( (4- (3- (2-oxa-6-azaspiro [3.3] heptan-6-yl) propoxy) -3-fluorophenyl) ethynyl) phenyl) -3- (5- (tert-butyl) isoxazol-3-yl) urea
- the title compound was prepared as a light yellow solid (200 mg, 40%) by the procedure described in step 3 of example 1, using 4- ( (4- (3- (2-oxa-6-azaspiro [3.3] heptan-6-yl) propoxy) -3-fluorophenyl) ethynyl) aniline (330 mg, 0.9 mmol) , acetonitrile (50 mL) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (1.2 g, 4.5 mmol) and DIPEA (1.5 mL, 9 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 1) (4aR, 7aS) -6- (2- (4- ( (4-nitrophenyl) ethynyl) phenoxy) ethyl) hexahydro-2H- [1, 4] dioxino [2, 3-c] pyrrole
- the title compound was prepared as a claybank solid (0.43 g, 55%) by the procedure described in step 2 of example 18, using 4- ( (4-nitrophenyl) ethynyl) phenol (0.48 g, 2.0 mmol) , (4aR, 7aS) -6- (2-chloroethyl) -hexahydro-2H- [1, 4] dioxino [2, 3-c] pyrrole (0.57 g, 3.0 mmol) , acetonitrile (40 mL) , potassium carbonate (0.69 g, 5.0 mmol) and potassium iodide (50 mg) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 395.2 [M+1] + .
- Step 2) 4- ( (4- (2- ( (4aR, 7aS) -tetrahydro-2H- [1, 4] dioxino [2, 3-c] pyrrol-6 (3H) -yl) ethoxy) phenyl) ethynyl) aniline
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 365.2 [M+1] + .
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (4- (2- ( (4aR, 7aS) -tetrahydro-2H- [1, 4] dioxino [2, 3-c] pyrrol-6 (3H) -yl) ethoxy) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a white solid (0.22 g, 50%) by the procedure described in step 3 of example 1, using 4- ( (4- (2- ( (4aR, 7aS) -tetrahydro-2H- [1, 4] dioxino [2, 3-c] pyrrol-6 (3H) -yl) ethoxy) phenyl) ethynyl) an iline (300 mg, 0.82 mmol) , acetonitrile (30 mL) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (1.2 g, 4.5 mmol) , DIPEA (1.5 mL, 9 mmol) .
- Step 1) 4- (2- (4- ( (4-nitrophenyl) ethynyl) phenoxy) ethyl) morpholine
- Step 2) 4- ( (4- (2-morpholinoethoxy) phenyl) ethynyl) aniline
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (4- (2-morpholinoethoxy) phenyl) ethynyl) phenyl) urea
- Step 1) 4- (2- (4-iodo-2- (trifluoromethyl) phenoxy) ethyl) morpholine
- the title compound was prepared as an oil (681 mg, 85%) by the procedure described in step 1 of example 1, using 2-trifluoromethyl-4-iodophenol (576 mg, 2.00 mmol) , acetonitrile (70 mL) , chloroethylmorpholine (360 mg, 2.40 mmol) and potassium carbonate (552 mg, 4.00 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 402.8 [M+1] + .
- Step 2) 4- (2- (4- ( (4-nitrophenyl) ethynyl) -2- (trifluoromethyl) phenoxy) ethyl) morpholine
- the title compound was preparedby the procedure described in step 2 of example 1, using 4- (2- (4-iodo-2- (trifluoromethyl) phenoxy) ethyl) morpholine (400 mg, 0.99 mmol) , 4-nitrophenylacetylene (294 mg, 1.99 mmol) , CuI (58 mg, 0.31 mmol) , Pd (PPh 3 ) 2 Cl 2 (108 mg, 0.15 mmol) , THF (50 mL) and Et 3 N (0.32 mL, 2.3 mmol) .
- Step 3) 4- ( (4- (2-morpholinoethoxy) -3- (trifluoromethyl) phenyl) ethynyl) aniline
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 391.3 [M+1] + .
- Step 4) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (4- (2-morpholinoethoxy) -3- (trifluoromethyl) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a light yellow solid (100 mg, 38.9%) by the procedure described in step 3 of example 1, using 4- ( (4- (2-morpholinoethoxy) -3- (trifluoromethyl) phenyl) ethynyl) aniline (180 mg, 0.35 mmol) , acetonitrile (30 mL) , triethylamine (0.3 mL, 2.2 mmol) and phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (0.29 g, 1.1 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- Step 2) 1- (3-chloropropoxy) -4- ( (4-nitrophenyl) ethynyl) -2- (trifluoromethyl) benzene
- the title compound was prepared as a light yellow solid (635 mg, 82.8%) by the procedure described in step 3 of example 23, using 1- (3-chloropropoxy) -4-iodo-2- (trifluoromethyl) benzene (730 mg, 2.0 mmol) , 4-nitrophenylacetylene (590 mg, 4.0 mmol) , CuI (58 mg, 0.31 mmol) , Pd (PPh 3 ) 2 Cl 2 (108 mg, 0.15 mmol) , THF (100 mL) and Et 3 N (0.32 mL, 2.3 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 384.3 [M+1] + .
- Step 3 4- ( (4- (3-chloropropoxy) -3- (trifluoromethyl) phenyl) ethynyl) aniline
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 354.1 [M+1] + .
- Step 4) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (4- (3-chloropropoxy) -3- (trifluoromethyl) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as oil (262 mg, 50.6%) by the procedure described in step 3 of example 1, using 4- ( (4- (3-chloropropoxy) -3- (trifluoromethyl) phenyl) ethynyl) aniline (350 mg, 0.99 mmol) , acetonitrile (70 mL) , Et 3 N (0.3 mL, 2.2 mmol) and phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (0.55 g, 2.1 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 520.5 [M+1] + .
- Step 5) 1- (4- ( (4- (3- (2-oxa-6-azaspiro [3.3] heptan-6-yl) propoxy) -3- (trifluoromethyl) phenyl) ethynyl) phenyl) -3- (5- (tert-butyl) isoxazol-3-yl) urea
- Step 1) 1- (3- (4-iodo-2- (trifluoromethyl) phenoxy) propyl) -4-methylpiperazine
- the title compound was prepared as an oil (320 mg, 71.7%) by the procedure described in step 1 of example 1, using 2-trifluoromethyl-4-iodophenol (300 mg, 1.04 mmol) , acetonitrile (30 mL) , 1- (3-chloropropyl) -4-methylpiperazine (200 mg, 1.14 mmol) and potassium carbonate (430 mg, 3.12 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 428.9 [M+1] + .
- Step 2) 1-methyl-4- (3- (4- ( (4-nitrophenyl) ethynyl) -2- (trifluoromethyl) phenoxy) propyl) piperazine
- the title compound was prepared as a light yellow solid (650 mg, 88.8%) by the procedure described in step 2 of example 1, using 1- (3- (4-iodo-2- (trifluoromethyl) phenoxy) propyl) -4-methylpiperazine (700 mg, 1.63 mmol) , nitrophenylacetylene (480 mg, 3.27 mmol) , CuI (58 mg, 0.31 mmol) , Pd (PPh 3 ) 2 Cl 2 (108 mg, 0.15 mmol) , THF (70 mL) and Et 3 N (0.32 mL, 2.3 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 449.3 [M+1] + .
- Step 3 4- ( (4- (3- (4-methylpiperazin-1-yl) propoxy) -3- (trifluoromethyl) phenyl) ethynyl) aniline
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos. ion) m/z: 418.3 [M+1] + .
- Step 4) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4- ( (4- (3- (4-methylpiperazin-1-yl) propoxy) -3-(trifluoromethyl) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a light yellow solid (40 mg, 28.6%) by the procedure described in step 3 of example 1, using 4- ( (4- (3- (4-methylpiperazin-1-yl) propoxy) -3- (trifluoromethyl) phenyl) ethynyl) aniline (100 mg, 0.35 mmol) , acetonitrile (30 mL) , triethylamine (0.3 mL, 2.2 mmol) and phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (0.29 g, 1.1 mmol) .
- the compound was characterized by the following spectroscopic data: MS-ESI: (ESI, pos.
- the title compound was prepared by the procedure described in step 1 of example 1, using 4-iodophenol (20 g, 91 mmol) , DMF (100 mL) , potassium carbonate (42 g, 300 mmol) and 4- (3-chloropropyl) morpholine (14.9 g, 91 mmol) , and the reaction mixture was concentrated in vacuo to give the title compound (30 g, 95%) which was used directly for the next step.
- Step 2) 4- (3- (4-ethynylphenoxy) propyl) morpholine
- Step 3) 1- (5- (tert-butyl) isoxazol-3-yl) -3- (2-methoxy-4- ( (4- (3-morpholinopropoxy) phenyl) ethynyl) phenyl) urea
- the title compound was prepared as a white solid (90 mg, 70%) by the procedure described in step 3 of example 79, using 2-amino-5-iodo-benzonitrile (59.2 mg, 0.24 mmol) , CuI (9 mg, 0.047 mmol) , Pd (PPh 3 ) 2 Cl 2 (17 mg, 0.024 mmol) , 4- (3- (4-ethynylphenoxy) propyl) morpholine (0.12 g, 0.49 mmol) , THF (20 mL) , triethylamine (0.2 mL) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (0.13 g, 0.5 mmol) and DMAP (14 mg, 0.11 mmol) .
- the title compound was prepared as a white solid (130 mg, 59%) by the procedure described in step 3 of example 79, using 2-fluoro-4-iodoaniline (100 mg, 0.42 mmol) , 4- (3- (4-ethynylphenoxy) propyl) morpholine (210 mg, 0.86 mmol) , CuI (0.02 g, 0.1 mmol, 100 mass%) , Pd (PPh 3 ) 2 Cl 2 (38 mg, 0.054 mmol) , THF (20 mL) , triethylamine (0.4 mL) , phenyl (5- (tert-butyl) isoxazol-3-yl) carbamate (220 mg, 0.85 mmol) and DMAP (25 mg, 0.20 mmol) .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
Example No. | FLT3 (IC50, nM) | Example No. | FLT3 (IC50, nM) |
1 | 115 | 12 | 28 |
2 | 75 | 13 | 23 |
3 | 62 | 14 | 72 |
4 | 39 | 15 | 102 |
5 | 189 | 20 | 110 |
6 | 94 | 21 | 41 |
8 | 61 | 24 | 160 |
11 | 169 | 25 | 84 |
Cell name | Cells/per well | Incubation time (h) | Complete medium |
MV-4-11 | 15000 | 72 | IMDM+10%FBS |
Claims (28)
- A compound having Formula (I) , or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,whereineach of ring A and ring E is independently C6-10 aryl or C1-12 heteroaryl;each J is -G- (CH2) n-R2;each G is independently -O-, -S (=O) t-, -S-, -C (=O) -, -OC (=O) -, -C (=S) -, -C (=S) -N (R4) -or -(CH2) n-C (=O) -;each R1 and R1a is independently H, F, Cl, Br, cyano, nitro, hydroxy, mercapto, amino, carboxy, C1-4 alkyl, C1-4 haloalkyl, C1-6 alkoxy, C1-4 alkylamino, C1-4 alkyl-C (=O) -NH-, C1-4 alkylthio, C3-10 cycloalkyl, C2-10 heterocyclyl, C1-6 alkoxy-C1-6-alkyl or C1-4 hydroxyalkyl;each R2 is independently -NR3R3a, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, heterocyclyl, alkyl-S (=O) t-, hydroxyalkyl, hydroxyalkoxy, aminoalkoxy, haloalkoxy, alkoxyalkyl, alkyl, alkoxy, alkylaminohaloalkoxy, alkylaminoalkoxy, arylalkoxy, arylalkylamino, heteroarylalkoxy, heteroarylalkylamino, heterocyclylalkylamino, heterocyclylalkylaryl, heterocylylalkylheteroaryl, cycloalkyloxy, cycloalkylamino, heterocyclylalkoxy, carbocyclylalkoxy, carbocyclylalkylamino, aryloxyalkoxy, aryloxy, heteroaryloxy, heteroaryloxyalkoxy, heterocyclyloxyalkoxy, carbocyclyloxyalkoxy, heterocyclyloxy, fused bicyclyloxy, fused bicyclylalkyl, fused heterobicyclylalkyl, fused heterobicyclyloxy, fused heterobicyclylamino, fused heterobicyclylalkoxy, fused heterobicyclylalkylamino, fused heterobicyclyloxyalkoxy, fused heterobicyclyloxyalkylamino, spiro heterobicyclylalkyl, spiro heterobicyclylalkoxy, bridged heterobicyclylalkyl, bridged heterobicyclyloxy, bridged heterobicyclylalkoxy, bridged heterobicyclylalkylamino, aryl, arylalkyl, heteroarylalkyl, heteroaryl, bridged heterobicyclyl, spiro heterobicyclyl or fused heterobicyclyl;each R3 and R3a is independently C1-4 alkyl, C3-10 cycloalkyl, C2-10 heterocyclyl, C1-6 alkoxy-C1-6-alkyl or C1-4 hydroxyalkyl;each R4 is independently H, C1-4 alkyl, C3-10 cycloalkyl, C2-10 heterocyclyl, C1-6 alkoxy-C1-6-alkyl or C1-4 hydroxyalkyl;ring K is 5-to 6-membered heteroaryl;each L is independently amino, nitro, C1-4 alkylthio, C1-6 alkyl, C3-10 cycloalkyl, C2-10 heterocyclyl, C1-4 haloalkyl, C1-4 alkylamino, hydroxy, F, Cl, Br, I, C1-4 alkyl-C (=O) -NH-, C1-4 alkoxy, C1-4 hydroxyalkyl or cyano;each a and e is independently 0, 1, 2, 3 or 4;each n, d and b is independently 1, 2, 3 or 4; andeach t is independently 0, 1 or 2;wherein optionally each aryl, - (CH2) n-C (=O) -, alkyl-S (=O) t-, hydroxyalkyl, arylalkyl, heteroarylalkyl, heteroaryl, heterocyclyl, bridged heterobicyclyl, spiro heterobicyclyl, fused heterobicyclyl, alkyl, alkoxy, alkoxyalkyl, haloalkyl, alkylamino, hydroxyalkoxy, aminoalkoxy, haloalkoxy, cycloalkylalkyl, heterocyclylalkyl, alkylaminohaloalkoxy, alkylaminoalkoxy, arylalkoxy, arylalkylamino, heteroarylalkoxy, heteroarylalkylamino, heterocyclylalkylamino, heterocyclylalkylaryl, heterocyclylalkylheteroaryl, cycloalkyloxy, cycloalkylamino, heterocyclylalkoxy, carbocyclylalkoxy, carbocyclylalkylamino, aryloxyalkoxy, aryloxy, heteroaryloxy, heteroaryloxyalkoxy, heterocyclyloxyalkoxy, carbocyclyloxyalkoxy, heterocyclyloxy, fused bicyclyloxy, fused bicyclylalkyl, fused heterobicyclylalkyl, fused heterobicyclyloxy, fused heterobicyclylamino, fused heterobicyclylalkoxy, fused heterobicyclylalkylamino, fused heterobicyclyloxyalkoxy, fused heterobicyclyloxyalkylamino, spiro heterobicyclylalkyl, spiro heterobicyclylalkoxy, bridged heterobicyclylalkyl, bridged heterobicyclyloxy, bridged heterobicyclylalkoxy, bridged heterobicyclylalkylamino, alkyl-C (=O) -NH-, alkylthio and cycloalkyl described in R1, R1a, R2, R3, R3a, A, E, J, G, L and/or K is independently substituted with one or more R2a which are the same or different, and whereineach R2a is independently H, F, Cl, Br, I, C1-4 haloalkyl, C1-4 alkyl, C1-4 alkylamino, di-C1-4 alkylamino, di (C1-4 alkyl) amino, hydroxy, cyano, nitro, -C (=O) -NH2, carboxy, -S(=O) tO-H, -OS (=O) t-H, -S (=O) tNH2, triazolyl, tetrazolyl, - (CR3bR3c) n-NH2, amino, oxo (=O) , C1-4 alkyl-C (=O) -, benzyl, phenyl, C1-6 alkyl-S (=O) t-, C1-6 alkoxy-C1-6-alkyl, C1-4 alkyl-C (=O) -NH-, C1-4 alkoxy, C1-4 hydroxyalkyl or C1-4 alkylthio; andeach R3b and R3c is independently H, F, Cl, Br, cyano, nitro, hydroxy, mercapto, amino, carboxy, C1-4 alkyl, C1-4 haloalkyl, C1-6 alkoxy, C3-10 cycloalkyl, C2-10 heterocyclyl, C1-6 alkoxy-C1-6-alkyl or C1-4 hydroxyalkyl.
- The compound according to claim 1 having Formula (II) or Formula (IIa) , or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,wherein R0 is C2-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl.
- The compound according to claim 1 or 2, wherein each ring A and ring E is independently one of the following sub-formulae:whereineach X, Y, Z, Z1, Z2, Z3 and Z4 is independently N or CH;each T, T1 and T2 is independently -O-, -S-, -N (R4) -or -CH2-; andeach R1 and R1a is independently H, F, Cl, Br, cyano, nitro, hydroxy, mercapto, amino, carboxy, C1-4 alkyl, C1-4 haloalkyl, C1-6 alkoxy, C3-10 cycloalkyl, C1-4 alkylamino, C2-10 heterocyclyl, C1-6 alkoxy-C1-6-alkyl or C1-4 hydroxyalkyl.
- The compound according to claim 1 or 2, wherein,each ring A and ring E is independently one of the following sub-formulae:each R1 and R1a is independently H, F, Cl, Br, trifluoromethyl, chloroethyl, trifluoroethyl, methyl, ethyl, propyl, isopropyl, dimethylamino, methylamino, diethylamino, ethylamino, hydroxy, cyano, nitro, methoxy, ethoxy, propoxy, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, C2-10 heterocyclyl, C1-6 alkoxy-C1-6-alkyl or C1-4 hydroxyalkyl.
- The compound according to claim 1 or 2, wherein,each R2 is independently -NR3R3a, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4-alkyl, C2-10 heterocyclyl-C1-4-alkyl, C1-6 alkyl-S (=O) t-, C1-4 hydroxyalkyl, C1-4 hydroxyalkoxy, C1-4 aminoalkoxy, C1-4 haloalkoxy, C1-4 alkylamino-C1-4-haloalkoxy, C1-4 alkylamino-C1-4-alkoxy, C1-6 alkoxy-C1-6-alkyl, C1-6 alkyl, C1-6 alkoxy, C6-10 aryl-C1-4-alkoxy, C6-10 aryl-C1-4-alkylamino, C1-9 heteroaryl-C1-4-alkoxy, C1-9 heteroaryl-C1-4-alkylamino, C2-10 heterocyclyl-C1-4-alkylamino, C2-10 heterocyclyl-C1-4-alkyl-C6-10-aryl, C2-10 heterocyclyl-C1-4-alkyl-C1-9-heteroaryl, C3-10 cycloalkyloxy, C3-10 cycloalkylamino, C2-10 heterocyclyl-C1-4-alkoxy, C3-10 carbocyclyl-C1-4-alkoxy, C3-10 carbocyclyl-C1-4-alkylamino, C6-10 aryloxy-C1-4-alkoxy, C6-10 aryloxy, C1-9 heteroaryloxy, C1-9 heteroaryloxy-C1-4-alkoxy, C2-10 heterocyclyloxy-C1-4-alkoxy, C3-10 carbocyclyloxy-C1-4-alkoxy, C2-10 heterocyclyloxy, C6-10 aryl, C6-10 aryl-C1-6-alkyl, C1-9 heteroaryl-C1-6-alkyl, C1-9 heteroaryl, C2-10 heterocyclyl, C6-12 fused bicyclyloxy, C6-12 fused bicyclyl-C1-6-alkyl, C5-12 fused heterobicyclyl-C1-6-alkyl, C5-12 fused heterobicyclyloxy, C5-12 fused heterobicyclylamino, C5-12 fused heterobicyclyl-C1-6-alkoxy, C5-12 fused heterobicyclyl-C1-6-alkylamino, C5-12 fused heterobicyclyloxy-C1-6-alkoxy, C5-12 fused heterobicyclyloxy-C1-6-alkylamino, C5-12 spiro heterobicyclyl-C1-6-alkyl, C5-12 spiro heterobicyclyl-C1-6-alkoxy, C5-12 bridged heterobicyclyl-C1-6-alkyl, C5-12 bridged heterobicyclyloxy, C5-12 bridged heterobicyclyl-C1-6-alkoxy, C5-12 bridgedheterobicyclyl-C1-6-alkylamino, C5-12 bridged heterobicyclyl, C5-12 spiro heterobicyclyl or C5-12 fused heterobicyclyl; and wherein each R2 is independently substituted with one or more R2a which are the same or different; andeach R3 and R3a is independently C1-4 alkyl, C3-10 cycloalkyl, C2-10 heterocycloalkyl, C1-6 alkoxy-C1-6-alkyl or C1-4 hydroxyalkyl.
- The compound according to claim 1 or 2, wherein,each R2 is independently -NR3R3a, C1-4 alkoxy-C1-4-alkyl, C1-4 alkyl or C1-4 hydroxyalkyl, or each R2 is independently one of the following sub-formulae:wherein each X6, X7, X8 and X9 is independently N or CH;each X1, X2, X3, X4 and X5 is independently - (C (R4b) 2) m-, -C (=O) -, -O-, -N (R4a) -or -S(=O) t-;each q, m, p and r is independently 0, 1, 2, 3 or 4;each t is independently 0, 1 or 2;wherein each R2 is independently substituted with one or more R2a which are the same or different;each R4a is independently H, C1-4 alkyl, C3-10 cycloalkyl, C2-10 heterocycloalkyl, C1-6 alkoxy-C1-6-alkyl, or C1-4 hydroxyalkyl; andeach R4b is independently H, F, Cl, Br, cyano, nitro, hydroxy, mercapto, amino, carboxy, C1-4 alkyl, C3-10 cycloalkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkylamino, - (CR3bR3c) n-NH2, -C(=O) -NH2, C2-10 heterocycloalkyl, C1-6 alkoxy-C1-6-alkyl or C1-4 hydroxyalkyl.
- The compound according to claim 1 or 2, wherein,each R2 is independently one of the following sub-formulae:each R3 and R3a is independently methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, C2-10 heterocycloalkyl, C1-6 alkoxy-C1-6-alkyl or C1-4 hydroxyalkyl;each R4 and R4a is independently H, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, C2-10 heterocycloalkyl, C1-6 alkoxy-C1-6-alkyl or C1-4 hydroxyalkyl;each R4b is independently H, F, Cl, Br, cyano, nitro, hydroxy, mercapto, amino, carboxy, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, trifluoromethyl, methoxy, C1-4 alkylamino, - (CR3bR3c) n-NH2, -C (=O) -NH2, C2-10 heterocycloalkyl, C1-6 alkoxy-C1-6-alkyl or C1-4 hydroxyalkyl;wherein each sub-formula represented by R2 is independently substituted with one or more R2a which are the same or different; andeach R2a is independently H, F, Cl, Br, I, trifluoromethyl, chloroethyl, trifluoroethyl, methyl, ethyl, propyl, isopropyl, dimethylamino, methylamino, diethylamino, ethylamino, hydroxy, cyano, nitro, -C (=O) -NH2, carboxy, -S (=O) tO-H, -OS (=O) t-H, -S (=O) tNH2, triazolyl, tetrazolyl, -(CH2) -NH2, - (CH2) 3-NH2, - (CH (CF3) ) -NH2, - (CH2) 2-NH2, oxo (=O) , methyl-C (=O) -, ethyl-C (=O) -, propyl-C (=O) -, benzyl or phenyl.
- The compound according to claim 1, wherein,ring K iseach L is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C3-6 heterocycloalkyl, amino, cyano, nitro, F, Cl, Br, I, trifluoromethyl, 1,1, 1-trifluoro-2-methylprop-2-yl, methyl, ethyl, butyl, propyl, isopropyl, tert-butyl, C1-4 alkylamino, hydroxy, cyano, nitro, C1-4 alkyl-C (=O) -NH-, C1-4 alkoxy, hydroxymethyl, hydroxyethyl, 1-hydroxy-n-butyl, 2-hydroxy-n-propyl, hydroxy-tert-butyl or C1-4 alkylthio.
- The compound according to claim 1 having Formula (III) or (IIIa) , or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,wherein R0 is C2-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl.
- The compound according to claim 1 having Formula (VIIa) , or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,wherein R00 is C1-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl.
- The compound according to claim 1 having Formula (IIIb) , or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,wherein R00 is C1-3 alkyl, trifluoromethyl, fluoromethyl, difluoromethyl or hydroxymethyl.
- A pharmaceutical composition comprising the compound according to any one of claims 1 to 14.
- The pharmaceutical composition further comprisingat least one of pharmaceutically acceptable carriers, excipients, diluents, adjuvants or vehicles.
- A pharmaceutical composition according to claim 15or 16 further comprising other active agent used for treating a proliferative disease, an autoimmune disease or an inflammatory disease, wherein the other active agent is a chemotherapeutic agent, antiproliferative agent, immunosuppressive agent, immunostimulatory agent, antiinflammatory agent, an agent for treating atherosclerosis, an agent for treating pulmonary fibrosis, CDK4/6-kinase inhibitor, ABL inhibitor, ABL/Scr inhibitor, aurora kinase inhibitor, non-ATP-competitive inhibitor of BCR-ABL, c-KIT mutation inhibitor, RET inhibitor, PDGFR inhibitor, VEGFR inhibitor, FLT3 inhibitor, FLT3-ITD inhibitor or a combination thereof .
- The pharmaceutical composition according to claim 17, wherein the other active agent is chlorambucil, melphalan, cyclophosphamide, ifosfamide, busulfan, carmustine, lomustine, streptozotocin, cisplatin, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbazine, methotrexate, fluorouracil, cytarabine, gemcitabine, mercaptopurine, fludarabine, vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel, topotecan, irinotecan, etoposide, trabectedin, dactinomycin, doxorubicin, epirubicin, daunorubicin, mitoxantrone, bleomycin, mitomycin C, ixabepilone, tamoxifen, flutamide, gonadorelin analogue, megestrol, prednisone, dexamethasone, methylprednisolone, thalidomide, interferon-α, leucovorin calcium, sirolimus, temsirolimus, everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, bortezomib, bosutinib, brivanib, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, danusertib, dasatinib, dovitinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, icotinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motesanib, neratinib, nilotinib, niraparib, oprozomib, olaparib, pazopanib, pictilisib, ponatinib, quizartinib, regorafenib, rigosertib, rucaparib, ruxolitinib, saracatinib, saridegib, sorafenib, sunitinib, tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, veliparib, vemurafenib, vismodegib, volasertib, alemtuzumab, bevacizumab, brentuximab vedotin, catumaxomab, cetuximab, denosumab, gemtuzumab, ipilimumab, nimotuzumab, ofatumumab, panitumumab, rituximab, tositumomab, trastuzumab, cabozantinib, ponatinib, midostaurin, pacritinib, quizartinib, gilteritinib, AKN-028, AT-9283, crenolanib, ENMD-2076, famitinib, dovitinib, PLX-3397, palbociclib, abemaciclib, ribociclib, rigosertib sodium, selinexor, roniciclib, AT-7519, seliciclib, alvocidib or a combination thereof.
- Use of the compound according to any one of claims 1 to 14 or the pharmaceutical composition according to any one of claims 15 to 18 in the manufacture of a medicament for preventing, managing, treating or lessening a proliferative disease, an autoimmune disease or an inflammatory disease in a patient.
- The use according to claim 19, wherein the proliferative disease is chronic myelogenous leukemia, gastrointestinal stromal tumor, acute myelogenous leukemia (AML) , mutant chronic myelogenous leukemia (CML) , acute lymphocytic leukemia (ALL) , leukemia, chronic lymphocytic leukemia, primary macroglobulinemia, monocytic leukemia, leukemoid reaction, aplastic anemia, purpura, secondary benign monoclonal gammopathy, semi-molecular disease, colorectal cancer, stomach cancer, breast cancer, lung cancer, liver cancer, prostate cancer, pancreatic cancer, thyroid cancer, kidney cancer, brain tumor, neck cancer, central nervous system (CNS) cancer, malignant glioma, bone marrow hyperplasia, infectious mononucleosis, malignant histiocytosis, lymphoma, non-lymphoreticular system tumor, multiple myeloma, granulocytic sarcoma, solitary plasmacytoma, malignant lymphoma, osteolytic lesions, lymphoblastoma, non-Hodgkin's lymphoma, infectious mononucleosis syndrome, acute histiocytosis, Hodgkin's lymphoma, colon cancer, colorectal cancer, small-cell lung cancer, neuroblastoma, neuroendocrine cell tumor, islet cell tumor, medullary thyroid carcinoma, melanoma, retinoblastoma, uterine cancer, ovarian cancer, head and neck squamous cell carcinoma, digestive malignant tumor, non-small cell lung cancer, cervical cancer, testicular tumor, bladder cancer, myeloma or AML related complication;the autoimmune disease is leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, acute myelogenous leukemia (AML) , mutant chronic myelogenous leukemia (CML) , acute lymphocytic leukemia (ALL) , rheumatoid arthritis, bone and joint pain, central nervous system involvement, lupus, multiple sclerosis, thyroiditis, type I diabetes, sarcoidosis, inflammatory bowel disease, Crohn's disease, systemic lupus or AML related complication; andthe inflammatory disease is diverticulitis, colitis, pancreatitis, hepatitis, chronic hepatitis, cirrhosis, cholecystitis or chronic inflammation.
- The use according to claim 19, wherein the disease is a disease mediated by c-KIT mutation, RET, PDGFR, VEGFR, Bcr-ABL, FLT3 or induced by FLT3-ITD.
- A method of preventing, managing, treating or lessening a proliferative disease, an autoimmune disease or an inflammatory disease in a patient comprising administering to the patient a therapeutically effective amount of the compound according to any one of claims 1 to 14 or the pharmaceutical composition according to any one of claims 15 to 18.
- The method according to claim 22, wherein the proliferative disease is chronic myelogenous leukemia, gastrointestinal stromal tumor, acute myelogenous leukemia (AML) , mutant chronic myelogenous leukemia (CML) , acute lymphocytic leukemia (ALL) , leukemia, chronic lymphocytic leukemia, primary macroglobulinemia, monocytic leukemia, leukemoid reaction, aplastic anemia, purpura, secondary benign monoclonal gammopathy, semi-molecular disease, colorectal cancer, stomach cancer, breast cancer, lung cancer, liver cancer, prostate cancer, pancreatic cancer, thyroid cancer, kidney cancer, brain tumor, neck cancer, central nervous system (CNS) cancer, malignant glioma, bone marrow hyperplasia, infectious mononucleosis, malignant histiocytosis, lymphoma, non-lymphoreticular system tumor, multiple myeloma, granulocytic sarcoma, solitary plasmacytoma, malignant lymphoma, osteolytic lesions, lymphoblastoma, non-Hodgkin's lymphoma, infectious mononucleosis syndrome, acute histiocytosis, Hodgkin's lymphoma, colon cancer, colorectal cancer, small-cell lung cancer, neuroblastoma, neuroendocrine cell tumor, islet cell tumor, medullary thyroid carcinoma, melanoma, retinoblastoma, uterine cancer, ovarian cancer, head and neck squamous cell carcinoma, digestive malignant tumor, non-small cell lung cancer, cervical cancer, testicular tumor, bladder cancer, myeloma or AML related complication;the autoimmune disease is leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, acute myelogenous leukemia (AML) , mutant chronic myelogenous leukemia (CML) , acute lymphocytic leukemia (ALL) , rheumatoid arthritis, bone and joint pain, central nervous system involvement, lupus, multiple sclerosis, thyroiditis, type I diabetes, sarcoidosis, inflammatory bowel disease, Crohn's disease, systemic lupus or AML related complication; andthe inflammatory disease is diverticulitis, colitis, pancreatitis, hepatitis, chronic hepatitis, cirrhosis, cholecystitis or chronic inflammation.
- The method according to claim 22, wherein the disease is a disease mediated by c-KIT mutation, RET, PDGFR, VEGFR, Bcr-ABL, FLT3 or induced by FLT3-ITD.
- The compound according to any one of claims 1 to 14 or the pharmaceutical composition according to any one of claims 15 to 18 for use in preventing, managing, treating or lessening a proliferative disease, an autoimmune disease or an inflammatory disease in a patient.
- The compound or the pharmaceutical composition according to claim 25, wherein the proliferative disease is chronic myelogenous leukemia, gastrointestinal stromal tumor, acute myelogenous leukemia (AML) , mutant chronic myelogenous leukemia (CML) , acute lymphocytic leukemia (ALL) , leukemia, chronic lymphocytic leukemia, primary macroglobulinemia, monocytic leukemia, leukemoid reaction, aplastic anemia, purpura, secondary benign monoclonal gammopathy, semi-molecular disease, colorectal cancer, stomach cancer, breast cancer, lung cancer, liver cancer, prostate cancer, pancreatic cancer, thyroid cancer, kidney cancer, brain tumor, neck cancer, central nervous system (CNS) cancer, malignant glioma, bone marrow hyperplasia, infectious mononucleosis, malignant histiocytosis, lymphoma, non-lymphoreticular system tumor, multiple myeloma, granulocytic sarcoma, solitary plasmacytoma, malignant lymphoma, osteolytic lesions, lymphoblastoma, non-Hodgkin's lymphoma, infectious mononucleosis syndrome, acute histiocytosis, Hodgkin's lymphoma, colon cancer, colorectal cancer, small-cell lung cancer, neuroblastoma, neuroendocrine cell tumor, islet cell tumor, medullary thyroid carcinoma, melanoma, retinoblastoma, uterine cancer, ovarian cancer, head and neck squamous cell carcinoma, digestive malignant tumor, non-small cell lung cancer, cervical cancer, testicular tumor, bladder cancer, myeloma or AML related complication;the autoimmune disease is leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, acute myelogenous leukemia (AML) , mutant chronic myelogenous leukemia (CML) , acute lymphocytic leukemia (ALL) , rheumatoid arthritis, bone and joint pain, central nervous system involvement, lupus, multiple sclerosis, thyroiditis, type I diabetes, sarcoidosis, inflammatory bowel disease, Crohn's disease, systemic lupus or AML related complication; andthe inflammatory disease is diverticulitis, colitis, pancreatitis, hepatitis, chronic hepatitis, cirrhosis, cholecystitis or chronic inflammation.
- The compound or the pharmaceutical composition according to claim 25, wherein the disease is a disease mediated by c-KIT mutation, RET, PDGFR, VEGFR, Bcr-ABL, FLT3 or induced by FLT3-ITD.
- A drug combination comprising the compound according to any one of claims 1 to 14 or the pharmaceutical composition according to any one of claims 15 to 18 and one or more other active agents used for the treatment of a proliferative disease, an autoimmune disease or an inflammatory disease; wherein the other active agent is chemotherapeutic agent, antiproliferative agent, immunosuppressive agent, immunostimulatory agent, antiinflammatory agent, CDK4/6-kinase inhibitor, ABL inhibitor, ABL/Scr inhibitor, aurora kinase inhibitor, non-ATP-competitive inhibitor of BCR-ABL, c-KIT mutation inhibitor, RET inhibitor, PDGFR inhibitor, VEGFR inhibitor, FLT3 inhibitor, FLT3-ITD inhibitor or a combination thereof.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15822879.1A EP3169671B1 (en) | 2014-07-17 | 2015-07-16 | 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)urea derivatives and related compounds as flt3 inhibitors for treating cancer |
KR1020167036774A KR102485100B1 (en) | 2014-07-17 | 2015-07-16 | Substituted urea derivatives and pharmaceutical uses thereof |
ES15822879T ES2747249T3 (en) | 2014-07-17 | 2015-07-16 | Derivatives of 1- (5- (tert-butyl) isoxazol-3-yl) -3- (4 - ((phenyl) ethynyl) phenyl) urea and related compounds as FLT3 inhibitors for the treatment of cancer |
CA2952083A CA2952083C (en) | 2014-07-17 | 2015-07-16 | Substituted urea derivatives and pharmaceutical uses thereof |
DK15822879.1T DK3169671T3 (en) | 2014-07-17 | 2015-07-16 | 1- (5- (TERT.-BUTYL) ISOXAZOL-3-YL) -3- (4 - ((PHENYL) ETHYNYL) PHENYL) URE ADDITIVES AND RELATED COMPOUNDS AS FLT3 INHIBITORS FOR TREATMENT OF CANCER |
US15/314,938 US10065934B2 (en) | 2014-07-17 | 2015-07-16 | Substituted urea derivatives and pharmaceutical uses thereof |
JP2017502247A JP6665154B2 (en) | 2014-07-17 | 2015-07-16 | Substituted urea derivatives and their pharmaceutical use |
AU2015291522A AU2015291522B2 (en) | 2014-07-17 | 2015-07-16 | Substituted urea derivatives and pharmaceutical uses thereof |
HK17105889.4A HK1232224A1 (en) | 2014-07-17 | 2017-06-14 | Substituted urea derivatives and pharmaceutical uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410342509.4 | 2014-07-17 | ||
CN201410342509 | 2014-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016008433A1 true WO2016008433A1 (en) | 2016-01-21 |
Family
ID=55077927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/084253 WO2016008433A1 (en) | 2014-07-17 | 2015-07-16 | Substituted urea derivatives and pharmaceutical uses thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US10065934B2 (en) |
EP (1) | EP3169671B1 (en) |
JP (1) | JP6665154B2 (en) |
KR (1) | KR102485100B1 (en) |
CN (1) | CN105272930B (en) |
AU (1) | AU2015291522B2 (en) |
CA (1) | CA2952083C (en) |
DK (1) | DK3169671T3 (en) |
ES (1) | ES2747249T3 (en) |
HK (1) | HK1232224A1 (en) |
HU (1) | HUE046008T2 (en) |
WO (1) | WO2016008433A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106883235A (en) * | 2016-12-29 | 2017-06-23 | 天津国际生物医药联合研究院 | The preparation and application of furodiazole compound |
WO2018050801A1 (en) * | 2016-09-16 | 2018-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
WO2019011264A1 (en) * | 2017-07-13 | 2019-01-17 | Sunshine Lake Pharma Co., Ltd. | Salt of substituted urea derivative and use thereof in medicine |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
US11426412B2 (en) | 2017-10-18 | 2022-08-30 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
US11459338B2 (en) | 2017-11-24 | 2022-10-04 | Jubilant Episcribe Llc | Heterocyclic compounds as PRMT5 inhibitors |
US11529341B2 (en) | 2018-03-13 | 2022-12-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
US11833156B2 (en) | 2017-09-22 | 2023-12-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
US11958846B2 (en) | 2018-08-17 | 2024-04-16 | Novartis Ag | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101852169B1 (en) | 2010-05-20 | 2018-04-26 | 어레이 바이오파마 인크. | Macrocyclic compounds as trk kinase inhibitors |
SI3322706T1 (en) | 2015-07-16 | 2021-04-30 | Array Biopharma, Inc. | Substituted pyrazolo(1,5-a)pyridine compounds as ret kinase inhibitors |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
ES2948194T3 (en) | 2017-01-18 | 2023-09-01 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrazine compounds as RET kinase inhibitors |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
CN109251183A (en) * | 2017-07-13 | 2019-01-22 | 广东东阳光药业有限公司 | The crystal form of substituted urea derivative and its application in drug |
CN109251182A (en) * | 2017-07-13 | 2019-01-22 | 广东东阳光药业有限公司 | The salt of substituted urea derivative and its application in drug |
TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
JOP20180094A1 (en) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | Heterocyclic compound as a protein kinase inhibito |
CN111971286B (en) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors |
WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
CN111630054B (en) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors |
CN108947982A (en) * | 2018-08-16 | 2018-12-07 | 刘璐 | The pyrazines derivatives, composition and application for treating non-alcoholic fatty liver disease |
US11964988B2 (en) | 2018-09-10 | 2024-04-23 | Array Biopharma Inc. | Fused heterocyclic compounds as RET kinase inhibitors |
KR102163889B1 (en) * | 2019-01-11 | 2020-10-12 | 동의대학교 산학협력단 | Composition for preventing and treating of neuropathic pain containing nypa fruticans wurmb extract |
KR102217261B1 (en) * | 2019-06-27 | 2021-02-17 | 한국생명공학연구원 | Composition for preventing or treating spinal muscular atrophy |
CN112341378A (en) * | 2019-08-06 | 2021-02-09 | 北京赛特明强医药科技有限公司 | Urea substituted alkynyl pyrimidine or urea substituted alkynyl pyridine compound, and composition and application thereof |
CN114981298B (en) | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | Compositions and methods for preventing and treating hearing loss |
KR102318032B1 (en) * | 2020-02-20 | 2021-10-26 | 동의대학교 산학협력단 | Composition for prevention and alleviation of inflammation and neuropathic pain |
US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005060970A1 (en) * | 2003-12-24 | 2005-07-07 | Astrazeneca Ab | Pyrimidines with tie2 (tek) activity |
WO2005060969A1 (en) * | 2003-12-24 | 2005-07-07 | Astrazeneca Ab | Pyrimidines with tie2 (tek) activity |
WO2006082404A1 (en) * | 2005-02-05 | 2006-08-10 | Astrazeneca Ab | Compounds having tie2 (tek) inhibitory activity |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
WO2000055152A1 (en) | 1999-03-12 | 2000-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
WO2003029209A2 (en) | 2001-10-02 | 2003-04-10 | Smithkline Beecham Corporation | Chemical compounds |
AU2004291147A1 (en) * | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Urea derivatives as kinase modulators |
BRPI0512891A (en) * | 2004-07-02 | 2008-04-15 | Icos Corp | compound and a pharmaceutically acceptable salt or prodrug or solvate thereof, composition, methods of inhibiting checkpoint kinase 1 in a cell, of sensitizing cells in an individual undergoing chemotherapeutic or radiotherapeutic treatment for a medical condition and of inhibiting aberrant cell proliferation, use of a compound, and article of manufacture for pharmaceutical use in human |
DOP2006000051A (en) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | VEGF-R2 INHIBITORS AND METHODS |
JP5249776B2 (en) | 2005-12-02 | 2013-07-31 | バイエル・ヘルスケア・エルエルシー | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyperproliferative diseases and diseases associated with angiogenesis |
PL2495016T3 (en) | 2005-12-23 | 2020-06-01 | Ariad Pharmaceuticals, Inc. | Bicyclic Heteroaryl Compounds |
CN101448843B (en) * | 2006-03-17 | 2012-05-09 | 埃姆比特生物科学公司 | Imidazolothiazole compounds for the treatment of disease |
MX2008014289A (en) | 2006-05-08 | 2008-11-26 | Ariad Pharma Inc | Acetylenic heteroaryl compounds. |
WO2007133562A2 (en) | 2006-05-08 | 2007-11-22 | Ariad Pharmaceuticals, Inc. | Monocyclic heteroaryl compounds |
EP2070929A1 (en) * | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
WO2009100536A1 (en) | 2008-02-15 | 2009-08-20 | Methylgene Inc. | Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures |
WO2011150198A1 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl urea compounds and methods of use thereof |
CN103172648B (en) | 2011-12-20 | 2016-05-25 | 上海迪诺医药科技有限公司 | Three Hete rocyclic derivatives, preparation method and application |
EP2828259B1 (en) * | 2012-03-22 | 2018-08-08 | Oscotec, Inc. | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
WO2013170770A1 (en) | 2012-05-16 | 2013-11-21 | 上海医药集团股份有限公司 | Acetylene derivatives having antitumor activity |
WO2015165085A1 (en) | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
-
2015
- 2015-07-16 EP EP15822879.1A patent/EP3169671B1/en active Active
- 2015-07-16 DK DK15822879.1T patent/DK3169671T3/en active
- 2015-07-16 HU HUE15822879A patent/HUE046008T2/en unknown
- 2015-07-16 ES ES15822879T patent/ES2747249T3/en active Active
- 2015-07-16 AU AU2015291522A patent/AU2015291522B2/en active Active
- 2015-07-16 CA CA2952083A patent/CA2952083C/en active Active
- 2015-07-16 CN CN201510422604.XA patent/CN105272930B/en active Active
- 2015-07-16 US US15/314,938 patent/US10065934B2/en active Active
- 2015-07-16 WO PCT/CN2015/084253 patent/WO2016008433A1/en active Application Filing
- 2015-07-16 KR KR1020167036774A patent/KR102485100B1/en active IP Right Grant
- 2015-07-16 JP JP2017502247A patent/JP6665154B2/en active Active
-
2017
- 2017-06-14 HK HK17105889.4A patent/HK1232224A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005060970A1 (en) * | 2003-12-24 | 2005-07-07 | Astrazeneca Ab | Pyrimidines with tie2 (tek) activity |
WO2005060969A1 (en) * | 2003-12-24 | 2005-07-07 | Astrazeneca Ab | Pyrimidines with tie2 (tek) activity |
WO2006082404A1 (en) * | 2005-02-05 | 2006-08-10 | Astrazeneca Ab | Compounds having tie2 (tek) inhibitory activity |
Non-Patent Citations (1)
Title |
---|
See also references of EP3169671A4 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018050801A1 (en) * | 2016-09-16 | 2018-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
US11065230B2 (en) | 2016-09-16 | 2021-07-20 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
CN106883235A (en) * | 2016-12-29 | 2017-06-23 | 天津国际生物医药联合研究院 | The preparation and application of furodiazole compound |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
US11213529B2 (en) * | 2017-07-13 | 2022-01-04 | Sunshine Lake Pharma Co., Ltd. | Salt of substituted urea derivative and use thereof in medicine |
JP2020526550A (en) * | 2017-07-13 | 2020-08-31 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | Substituted urea derivatives in salts and their use in drugs |
WO2019011264A1 (en) * | 2017-07-13 | 2019-01-17 | Sunshine Lake Pharma Co., Ltd. | Salt of substituted urea derivative and use thereof in medicine |
AU2018299536B2 (en) * | 2017-07-13 | 2022-06-02 | Sunshine Lake Pharma Co., Ltd. | Salt of substituted urea derivative and use thereof in medicine |
JP7202350B2 (en) | 2017-07-13 | 2023-01-11 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | Salts of substituted urea derivatives and their use in medicine |
US11833156B2 (en) | 2017-09-22 | 2023-12-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
US11426412B2 (en) | 2017-10-18 | 2022-08-30 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
US11459338B2 (en) | 2017-11-24 | 2022-10-04 | Jubilant Episcribe Llc | Heterocyclic compounds as PRMT5 inhibitors |
US11529341B2 (en) | 2018-03-13 | 2022-12-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
US11958846B2 (en) | 2018-08-17 | 2024-04-16 | Novartis Ag | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
US20170114032A1 (en) | 2017-04-27 |
CN105272930A (en) | 2016-01-27 |
US10065934B2 (en) | 2018-09-04 |
ES2747249T3 (en) | 2020-03-10 |
AU2015291522A1 (en) | 2016-12-22 |
JP2017520607A (en) | 2017-07-27 |
HK1232224A1 (en) | 2018-01-05 |
AU2015291522B2 (en) | 2018-12-06 |
EP3169671A1 (en) | 2017-05-24 |
EP3169671A4 (en) | 2018-02-28 |
EP3169671B1 (en) | 2019-08-21 |
CN105272930B (en) | 2018-07-13 |
CA2952083C (en) | 2023-01-24 |
DK3169671T3 (en) | 2019-09-23 |
JP6665154B2 (en) | 2020-03-13 |
CA2952083A1 (en) | 2016-01-21 |
HUE046008T2 (en) | 2020-02-28 |
KR102485100B1 (en) | 2023-01-04 |
KR20170031669A (en) | 2017-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3169671B1 (en) | 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)urea derivatives and related compounds as flt3 inhibitors for treating cancer | |
EP3172214B1 (en) | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof | |
CN104513252B (en) | Substituted urea derivative and its application in medicine | |
WO2016015604A1 (en) | Compounds as cdk small-molecule inhibitors and uses thereof | |
US9181277B2 (en) | Aminoquinazoline derivatives and their salts and methods of use | |
WO2018183964A1 (en) | Isoquinolines as inhibitors of hpk1 | |
WO2018081091A1 (en) | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors | |
JP6389829B2 (en) | Heteroaromatic compounds as PI3 kinase modulators and methods of use thereof | |
JP6268183B2 (en) | Heteroaromatic compounds as PI3 kinase modulators and methods of use thereof | |
BRPI1012159B1 (en) | Compounds derived from n-(hetero)aryl-pyrrolidine of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors, compositions pharmaceuticals comprising said compounds and uses thereof | |
TWI684591B (en) | Substituted urea derivatives and pharmaceutical uses thereof | |
TWI690533B (en) | Compounds as cdk small-molecule inhibitors and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15822879 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2015822879 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015822879 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15314938 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2952083 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015291522 Country of ref document: AU Date of ref document: 20150716 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167036774 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017502247 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |